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I. Introduction 
Experimental carcinogenesis, histological and cytogenetic studies and epidemiological 
observations indicate that the development of tumors is a multistep process The 
number and the nature of the steps is unknown But the general idea is that each step 
creates a subclone of cells with a new phenotype that replaces its predecessors as the 
result of a selection process (1-5) In separate steps, cells might acquire the power for 
uninhibited proliferation, invasiveness, and ultimately full metastatic potential But how 
many alterations are necessary on a molecular level to create such spectrum of newly 
acquired properties and what is their nature9 That changes on the DNA level should be 
responsible for tumongenesis is based on the following observations 
a) In many cancer cells chromosomes are damaged and often the damage increases 
during tumor development (6, 7), 
b) The carcinogenicity of substances is closely related to their mutagenic potential (8), 
c) An inherited predisposition for some cancers has been observed (9, 10) 
Moreover, xeroderma pigmentosa patients show a clear connection between 
susceptibility to cancer and impaired ability to repair damaged DNA (11) 
Each step in the tumor progression is thought to be the result of the mutation, 
activation or deletion of particular genes Since about 10 years, molecular biological 
cancer research is focused on a restricted number of genes, the so called (proto-) 
oncogenes In general, understanding oncogenesis on a molecular level is 
understanding the consequences of genetic alterations for the expression and the 
biochemical functions of these genes Definition of the oncogenes originated from tumor 
virus research 
II. Molecular genetic analysis: Activation of (proto-)oncogenes 
A Animal cancer RNA tumor viruses 
Mammalian tumor viruses belong taxonomically to diverse families They are divided 
in two groups the DNA - and RNA tumor viruses Among them the DNA viruses 
(herpes-, adeno-, hepatitis and papovaviruses) form a very heterogeneous group (12) 
The RNA tumor viruses on the otherhand belong to a single taxonomie group of RNA 
viruses, the retroviruses They provide the most coherent view of oncogenesis now 
available and showed us possible ways to cancer inducing mechanisms without virus 
intervention (13, 14) 
Retroviruses are RNA viruses with a typical hfecycle After infection of the target cell, 
the single stranded RNA virus genome is copied by the viral enzyme reverse 
transcriptase in a double stranded circular DNA molecule that subsequently integrates 
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into the host genome The potential oncogenicity of this type of viruses is based on the 
close interaction between virus genome and host genome (15) The resulting provirus 
behaves as a cellular gene that can be transcribed into single stranded RNA This RNA 
is either packaged in virus particles or used as a polycistronic mRNA for the production 
of the viral proteins the gag coded core proteins, the pol coded reverse transcriptase 
and the env coded envelope proteins The retroviruses can be divided in two groups 
by their capability to induce transformation the acutely transforming and the slowly or 
non-transforming viruses The former group is able to induce transformation in tissue 
culture cells and tumongenesis in animals with a short latency period between infection 
and the appearance of the tumor In general, this group is replication defective and 
hence dependent for propagation on a helper virus belonging to the replication 
competent latter group That latter group lacks the transforming activity in tissue culture 
and does not induce tumors in animals or only after a long latency period 
1 Gene transduction 
Many different acutely transforming retroviruses (exhaustively described in ref 13) 
causing carcinomas, sarcomas, leukemias and lymphomas in animals like chicken, 
mouse, rat, cat and monkey were found Structurally their genomes differ from the 
genomes of their non-acutely transforming counterparts on the one hand by missing 
usually some virus-specific sequences, on the other hand by possessing unique 
sequences directly related to their acutely transforming properties These sequences are 
highly similar to normal genomic sequences of non-infected tissue of the host Moreover 
these sequences are very well conserved between the different species of eukaryotes 
suggesting an important role in fundamental processes of the eukaryotic cell 
The insight that the acutely transforming viruses are the result of recombination 
between the helper virus genome and the host genome by which viral sequences are 
replaced by particular cellular sequences marked the beginning of a new and important 
era in fundamental cancer research Retroviruses are able to act as vectors for cellular 
genes, a phenomenon known from bacteriophages as gene transduction Moreover they 
contain strong transcriptional promoters and have a high mutation rate As part of a 
retrovirus, a cellular gene can escape the controlling mechanisms of the cell and can 
give rise to mutated products that act in an abnormal way Looking for acutely trans-
forming retroviruses in natural occurring tumors is selecting for retroviruses that have 
recombmed with normal cellular genes with a potential oncogenicity (proto-oncogenes) 
In other words, independent isolates of acutely transforming retroviruses did for us what 
we never could have done with our limited techniques Out of a haystack of ten 
thousends of genes of the eukaryotic genome they picked up about twenty genes with 
a potential tumorigemcity 
A widely accepted model for the formation of recombinant retroviruses consists of the 
following steps (15) 
a) Accidental integration of a provirus upstream of a cellular gene in the same 
transcriptional orientation, thus establishing within a tissue a somatic clonal line 
with a new genotype, 
b) Initiation of the transcription of a viral/cellular hybrid transcript that after processing 
can be packaged in a virion by the presence of virus specific packaging signals 
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Because retroviruses are diploid, a heterozygotic genome consisting of a 
heterodimer of a hybrid transcript and a wild-type RNA can be formed, 
c) Template switching of the reverse transcriptase during reinfection and perhaps 
some other recombination-events yielding a recombinant virus genome consisting 
of a cellular sequence in between viral sequences 
The chance to occur for the rare events described in b) and c) may be increased by 
enhanced proliferation of cells of the new genotype by promoter- or enhancer insertion 
(see below) On the other hand, recombination between the provirus and trivial genes 
would remain unnoticed 
2 Insenional mutagenesis 
The second group, the slowly transforming viruses, lack these transduced cellular 
genes The mechanisms underlying their oncogenicity is based on the features of the 
inverted repeats at both ends of the proviral genome This DNA structure plays not only 
an important role during the integration of the provirus in the host-genome, but it also 
contains regulatory sequences for transcription a strong promoter, an enhancer and 
a termination signal (16) The integration of such a structure in the surrounding of a 
cellular gene may strongly influence the expression of the gene 
In retrovirus-mduced lymphomas and leukemias in mouse and chicken, proto-
oncogenes that are homologous to viral oncogenes of acutely transforming retroviruses, 
are frequently activated by proviral integrations (17, 18) By its mechanism of proviral 
integration at numerous, if not random sites in the genomic DNA (19) the retrovirus is 
also a powerful tool to find new cellular DNA sequences with a potential oncogenicity, 
by applying the 'transposon tagging' technique The virus-induced tumors tend to be 
clonal for the proviral integration sites The infected but normal tissue will never be 
clonal for these integrations Using the proviral DNA as a probe, the proviral integra-
tion sites in the cellular DNA of a tumor can be analyzed by cloning the viral-host DNA 
junctions When the cellular DNA of multiple independent tumors shares a common 
proviral integration domain it may be assumed that these specific integrations are 
involved in the tumongenesis of this particular type of tumors The final step is to 
identify the genomically linked gene (20) 
The pattern of proviral integration-sites within the common genomic domain is charac-
teristic for the hidden gene and reflects the underlying mechanisms by which the 
integrated provirus influences the expression of the gene In general, the promoter 
insertion model (21) allows the virus genome to integrate in a 5' (left) 3' (right) 
orientation upstream of and in rather close proximity of coding sequences of the gene 
Normally transcription of the viral RNA initiates within the 5' LTR and terminates in the 
3' LTR At low frequency a hybrid mRNA is generated by transcription initiated in the 
5' LTR promoter, which proceeds past the 3 poly(A) addition signal into the adjacent 
cellular gene Abnormal splicing events from a donor sequence within the provirus (e g 
within the gag domain) to an acceptor sequence in the downstream cellular gene result 
in a closer juxtaposition of viral and cellular gene sequences in the chimeric mRNA 
Sometimes (e g ALV induced B-cell lymphomas) insertional activation results from 
transcription initiating within the 3' LTR and continuing in the adjacent cellular gene 
Efficient utilization of the 3' LTR promoter may require deletion of critical regions within 
the provirus that abrogates the experimentally established suppression of initiation of 
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transcription at the 3' LTR (17, 22) Proviral integration within the transcribed region of 
a gene results in a 5' truncated mRNA When only non-coding sequences are missing 
it may influence RNA stability and translation efficiency as is proposed for the myc 
gene (23) When the proviral integration maps more downstream and 5 coding 
sequences are missing it can even give rise to truncated proteins, as is described for 
the myb- (24) and erb-genes (25) The 5 truncated c-onc and the viral gag sequences 
remaining in these hybrid transcripts are about the same as those that are found in 
rapidly transforming recombinant retroviruses It shows that not only an alteration in 
expression pattern but also a specific truncation can play an important role in the 
conversion of a normal cellular protein in a product involved in tumongenesis It may 
cause an alteration of the substrate specificity and cellular location, directed by the 
newly acquired leader protein, viral gag 
The relevance of viral integrations downstream of a gene in both transcriptional 
orientations or upstream in the opposite transcriptional orientation compared to the 
gene and dispersed over rather large regions can be explained by the transcriptional 
enhancer function of the LTR that acts orientation independent in cis, over a rather long 
distance (26, 27) Enhancer insertion within the 3' end of a gene results in truncation 
of the gene transcripts by use of the polyA addition signal of the LTR Truncation of the 
carboxy terminal sequences of the myb-protem by proviral integration in a 3' coding 
exon probably contributes to the transformation in addition to the effect of transcrip­
tional enhancement (24) All carefully mapped proviral integrations in the 3' noncodmg 
region of the p/m-1 gene in MLV induced Τ cell lymphomas (28) are found upstream 
of recently described mRNA destabilising ATTTA motifs (29) strongly suggesting that 
changes in mRNA stability may also play an important role in transformation (30) 
В Human cancer 
The success of the animal retrovirus system as a model system for transformation 
induced an intensive search for human retroviruses But until now only one human 
retrovirus has been found to be associated with cancer HTLV (human T-cell leukemia 
virus), that can be isolated from patients with an endemic form of T-cell leukemia (31) 
The viral genome does not show homology with any of the known (proto-)oncogenes 
An explanation for this phenomenon could be that many animal systems are 
manipulated Laboratory animals were exposed to extremely high amounts of viruses 
and inbred strains were made with a high amount of integrated proviruses in the 
germlme (endogenous viruses) and specific susceptibilities to virus infections (32) 
Recombinant viruses were propagated many life cycles under special laboratory 
circumstances And also poultry breeding, which forms a rich source of recombinant 
tumor viruses, is quite artificial Large populations of inbred animals live together in very 
close contact with each other In nature, recombinant retroviruses should hardly be able 
to survive 
Nevertheless, the relationship between the animal system with its high-tumongenic 
retroviruses and human cancer in which viruses seem to play a modest role could be 
demonstrated Experiments of gene transfer in tissue-culture (33, 34), and studies of 
highly regular chromosomal anomalies, characteristic for some malignancies (35, 36) 
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showed that the same cellular genes can be involved in both virus induced animal 
cancer and non-viral human cancer 
1 Gene transfer 
When normal tissues are cultured in vitro almost all cells will divide a few times and 
die subsequently Sometimes a few cells will overcome what is called a crisis in which 
they undergo changes that are not fully understood and start growing As a result 
different stabilized cell lines can be obtained Besides a variable amount of properties 
still remaining from the original primary cell new characteristics appear of which 
immortality is one of the most striking From many tissues, the only way to generate a 
stable cell line is to transform the primary cells by infection with a DNA tumor virus The 
changes these viruses induce are partially comparable with those found in cell lines 
obtained from primary cells that have survived a crisis Compared to their non-
transformed counterparts the transformed cells show, depending on their state of 
tumorigemcity, the following growth characteristics that can be used as markers for 
tumorigemcity immortalisation, substrate free growth e g in suspension, loss of contact 
inhibition and lowering of their requirement of exogenous growth factors (37, 38) 
From rat and mouse, fibroblasts cell lines were obtained that are immortalized but 
have maintained more or less their normal morphology and their normal growth 
characteristics When these so called NIH-3T3 - (39), Rat-1- (40), and Rat-2- (41) cells 
are infected with the highly transforming recombinant retroviruses their morphology will 
usually change while the growth characteristics will become more tumorigemc 
dependent on the virus used The real power of this transformation assay became clear 
when it was shown that transfection of the cells with total genomic DNA (42) from 
spontaneous human tumors can mimic transformation by retroviruses (43-45) The 
oncogenic circle was closed by the discovery that the gene that is responsible for the 
transforming capacity of genomic DNA of a human bladder carcinoma cell line was 
homologous to the already known viral H-ras oncogene (33, 34) The transforming 
capacity of this bladder carcinoma Η-ras gene is based on a point mutation within the 
p21 ras protein (46, 47) together with a mutation in an intron resulting in a 10 fold 
increase in expression (48) These observations strongly support the model that trans­
formation of a normal cell into a tumor cell is caused by dominant mutations in specific 
genes 
Sometimes there is no accordance between the mutations in the original tumor DNA, 
as scored by southern blot analysis, and those identified after the transfection of the 
same DNA (49) On the one hand it cannot be excluded that the detected mutations 
are induced during the experimental manipulations On the other hand primary tumors 
generally consist of heterogeneous populations of cells When only a small minority of 
cells contains a particular mutation this will not be detected by a current physical 
method but can easily be scored in a sensitive bio-assay like the DNA transfection 
assay The recently developed PCR (polymerase chain reaction) method seems to be 
also very useful for this purpose (50) 
In the DNA transfection assay new genes were discovered to be associated with 
different specific forms of human and animal cancer They include new genes like neu 
(44), mei (51), trk (52), db/ (53) and reí (54) besides oncogenes already known from 
viral gene transduction But the general assumption that the transforming capability of 
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an oncogene is tissue specific and associated with only one step in transformation limits 
the system All rodent fibroblast cell lines used are the representatives of one particular 
tissue and are already partially transformed 
The restrictions mentioned could be partially abandoned by the use of primary rat 
embryo fibroblasts (REF's) (55) These cells can only be transformed by combinations 
of activated oncogenes, like ras and myc (56) From these experiments and from the 
observation that activated c-myc is not able to transform NIH-3T3 cells it seems clear 
that myc is involved in the early step of immortalisation and ras in the later step of 
morphological transformation of the cell The inability of the co-transfected cells to seed 
tumors with unlimited growth in nude mice suggests that the cooperative action of myc 
and ras is not sufficient for a fully transformed phenotype (57) Based on the results 
with different combinations of oncogenes some of these genes can be classified in a 
group of myc- and others in a group of ras- like genes This functional assay showed 
also a surprising relation between some oncogenes and the transforming genes of DNA 
tumorviruses Adenovirus E1a and Polyoma large-T can replace myc by helping ras to 
transform the REF cells (55, 58) It should be noted that all three interchangeable 
proteins are associated with the cell nucleus (59, 60, 61 ) 
The so-called tumorigemcity assay (62, 63) is a useful alternative for the detection of 
transforming genes NIH-3T3 cells are co-transfected with cellular DNA and a plasmid 
containing a selectable marker and subsequently cultured under selective pressure The 
arising resistent cell-colonies are pooled and injected into nude mice The DNA of the 
tumors that appear is analyzed for the transfected sequences The involvement of the 
exogenous sequences in tumor development is tested by a second round in the 
tumorigemcity assay The mcf-2 (63) and mas gene (64) were identified by this assay 
Their ability to induce tumors in the assay is the consequence of amplification and 
rearrangement which occur during co-transfection (65) 
2 Chromosomal aberrations 
In cancer cells chromosome aberrations of all kinds can be detected and mapped 
with high resolution using different methods of chromosome banding or staining (66) 
In addition techniques are developed to map genes on chromosomes by the use of 
somatic cell hybrids (67) or even within a chromosomal band by in situ hybridization 
(68) 
Many solid tumors show an irregular and complex pattern of chromosome 
translocations, breakages, deletions and duplications that becomes even more complex 
during tumor progression On the contrary in many lymphoid malignancies chromosome 
anomalies are less complex and so characteristic that they are used as cytogenetic 
markers for a given class of malignancy (8, 69) 
a Translocations 
About 75% of the cases of Burkffl's lymphoma, a B-cell malignancy, show a 
reciprocal translocation between the chromosomes 8 and 14 t (8,14) (q24,q32) (70, 71) 
Distal parts of the q arms of each chromosome are exchanged resulting in a cell with 
a 8q-and a 14q-i- chromosome besides two normal homologs In the remaining 25% two 
other translocations of about the same fragment of chromosome 8 are seen Here either 
chromosome 2 or chromosome 22 is the recipient of the chromosome 8 fragment 
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t(2,8) (pi 1 ,q24) is about twice as frequent as (8,22) (q24,q11) (72) Because the human 
immunoglobulin genes are mapped on the chromosomes 2, band p11 (Ig Kappa) (73), 
14, band q32 (Ig heavy chain) (74), and 22, band q l l (Ig lambda) (75) it can be 
concluded that these translocations are non-random Moreover the c-myc proto­
oncogene is located in the site of chromosome 8, band q24 (35), involved in each of 
these translocations 
By the use of fragments of the immunoglobulin genes as probes several translocation 
breakpoints characteristic for different lymphoid malignancies could be cloned and 
studied in detail From these studies some conclusions can be made with respect to 
the genes that are involved, the mechanisms of translocation and the deregulation of 
oncogenes juxtaposed with the immunoglobulin genes on the rearranged chromosome 
Not only proto-oncogenes homologous to v-onc genes like c-myc and v-ab/ are 
involved in translocations The bcl-1 (76) and bc/-2 (77) genes were discovered by their 
involvement in translocations in respectivily chronic lymphocytic leukemia (CLL) and 
follicular lymphoma 
Antibody diversity is created by series of recombinations between the variable (V), 
diversity (D), joining (J) and constant (C) regions of the immunoglobulin gene during 
the course of В lymphocyte differentiation The hot spots of recombination within these 
genes coincide with the chromosomal breakpoints Mistakes of V-D-J recombmases 
early in В cell development and isotype switching enzymes at a later stage probably 
cause the characteristic translocations This is strongly supported by the observation 
that in T-cells in which the same recombmase enzymes are active sequenses 3' of c-
myc can be joined to a J segment of the TCRa-locus resulting in the T-cell acute 
lymphoblastic leukaemia (ALL) specific translocation t (8,14) (q24,q11) (78) The 
juxtapositions of c-myc, toc/-1 and bel 2 to an immunoglobulin gene are the clearest 
examples of tissue-specific oncogene activation by a purely cellular mechanism 
In Burkitt's lymphoma the breakpoints are dispersed over rather big areas within the 
immunoglobulin genes and the myc gene The feature all translocations have in 
common is that the myc gene is always located 5' of an immunoglobulin constant gene 
The expression of the myc gene is driven by genetic elements, like Ig enhancers and 
other elements not yet identified, within the Ig loci fragments which act in cis over a 
long distance in a lymphoid specific and differentiation dependent way (79, 80) Loss 
of trans-acting transcriptional control (81, 82) and translational control (83) or an 
increase of mRNA stability (84) might contribute to the deregulation of the oncogene 
In at least one case of Burkitt's lymphoma, mutations are found in a recently discovered 
orientation-dependent negative regulatory element near the end of the first exon of the 
myc gene that apparently mediates premature termination of transcription (85, 86) 
In human chronic myeloid leukemia (CML) a reciprocal exchange between 
chromosome 9, which bears the proto-oncogene с ab/, and chromosome 22 yields an 
extended chromosome 9, 9q-t-, and a shortened chromosome 22, the Philadelphia 
chromosome (Ph1) (87) All chromosomal breakpoints on chromosome 22 associated 
with the (9,22) translocation fell within a 5 8 kb segment, that for this reason is called 
ber (breakpoint cluster region ) (88) The breakpoints in chromosome 9 however are 
scattered over a region of at least 50 kb within the 5' region of the abl gene The ber 
spans two small exons of an unknown gene oriented in the same direction as the abl 
gene (89) As a result of the translocation a hybrid mRNA is made starting on the ber 
gene and spliced onto a downstream coding exon of the ab/ gene In the fusion protein 
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a small N-terminal part of the ab/ protein is substituted by a much larger N terminal part 
of the ber gene (90) It is intriguing that in v-ab/ the N-termmus of c-ab/ is replaced by 
a part of the viral gag protein It seems likely that the N terminal substitutions alter the 
substrate specificity of the gene product Perhaps the differences in alteration also 
explain why the v-ab/ gene preferentially transforms early В lymphoid cells whereas the 
bcr-abl gene is associated with transformed myeloid cells (91) 
In Ph+ ALL, chromosomal breaks occur in the putative first exon of the large bcr-
gene located far upstream of the two exons involved in CML (92) 
b Amplification 
Many tumors, particularly solid tumors, show gene amplification The prototype model 
system for the study of gene amplification in mammalian cells is the dihydrofolate 
reductase (DHFR) gene amplification that occurs in vitro when cells are grown under 
selective pressure of methotrexate (93) These gene amplifications can be detected as 
two different karyotypic abnormalities homogeneously staining regions and double-
minute chromosomes Double-minute chromosomes are highly amplified small pieces 
of a chromosome that can be present in large numbers in each cell (94, 95) 
Tumors sometimes show amplifications of proto-oncogenes, mostly as an occasional 
feature However certain tumor types show a distinct pattern of amplifications of specific 
oncogenes (2) In the more progressive stages III and IV of neuroblastoma tumors, 
which frequently carry homogeneously staining regions and double-mimute 
chromosomes, an amplification of a member of the myc family, N-myc is seen Because 
the N-myc gene maps on human chromosome 2, while the amplified gene copies are 
found in homogeneously staining regions of other chromosomes or in the double-
minute chromosomes, this type of amplification seems to be associated with transloca­
tion There appears to be a significant correlation between genomic amplification of N-
myc, anatomical progression, and disease aggressiveness of primary neuroblastomas 
(96, 97) In small cell carcinoma of the lung the correlation between the amplification 
of the different members of the myc family, с , N , and L myc, and the expression of a 
more malignant phenotype seems to be less clear (98 99) The c-myc and neu gene 
are frequently amplified in primary breast cancer (100, 101) The prognostic significance 
of the neu oncogene amplification is still controversial (101 102) But in all cases the 
level of mRNA expression is concordant with the amplification 
In vitro DHFR gene amplification by selective pressure of methotrexate occurs much 
more frequently in tumorigemc than in non-tumorigemc cells suggesting that tumor cells 
with their inherent genomic instability are predisposed to the development of gene 
amplification (103) This observation might explain why multi-drug resistance also based 
on gene amplification is a serious problem in chemotherapy (104) 
The DHFR gene amplification in methotrexate resistant mouse cells is rapidly lost 
when selective pressure is removed from the culture medium But the oncogene 
amplification in cultured human cells is quite stable strongly suggesting that such 
amplification is providing the tumor cells with a selective growth advantage These data 
suggest that oncogene amplification may play a role in tumor progression 
In a murine Τ cell leukemia, in many hemopoietic disorders in man and in Rous 
sarcoma virus induced tumors of the rat the commonest trisomy is trisomy of the myc 
carrying chromosome (105-108) This suggests that mitotic non-disjunction is another 
amplification mechanism of the myc gene Duplication of the rearranged myc allele or 
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even loss of the germlme fragment was also observed in some retrovirus induced Τ cell 
lymphomas in the mouse (109, 110) So the germlme rearranged ratio seems to be 
essential in these tumors This is not the case for mouse plasmacytomas and human 
Burkitt lymphomas where the normal myc allele is switched off (111) suggesting that the 
LTR-myc complex may be subject to some trans-acting regulation by the normal allele 
which can be overridden by the gene amplification (112) 
с Deletions 
Progression of chemically induced mouse skin papillomas to the carcinoma stage can 
be accompanied by amplification of the mutated ras or loss of the normal allele or both 
(113) Loss of the normal ras allele is also found in a variety of human tumors that carry 
mutated ras (114, 115) The normal allele may antagonize the tumorigemc effect of the 
mutated allele (112) Loss of the normal c-myc allele in some mouse Τ cell lymphomas 
is already discussed in section II В 2 b 
Chromosome deletions and their involvement in tumorigemcity lead us to a whole 
new chapter of cancer research All tumor induction models described so far are based 
on dominant genetic alterations But evidence has been obtained for the presence of 
recessive genetic lesions in about 18 different human cancers with significant 
frequencies As yet no mutations in the conventional proto-oncogenes are found to be 
involved in the inheritance of cancer On the contrary, recessive mutations in about 10 
different loci are associated with an inherited predisposition for different tumor types 
(summarized in ref 116) For instance children who inherit a deletion in the ñb-1 allele 
of chromosome 13 from one of their parents will develop a retinoblastoma if the second 
allele is lost by a somatic mutation (117) More recently loss of the Rb-1 gene is found 
to be associated with malignancies in several other tissues including osteosarcomas, 
soft tissue sarcomas, and small cell lung and breast carcinomas (118-121) 
In Drosophila about 20 recessive mutations exhibit a neoplastic phenotype at late 
larval stages In these cases the affected tissue fails to differentiate resulting in a lethal 
hyperprohferation (122-124) It is unclear whether the normal function of the genes 
involved is to suppress cell proliferation or to induce differentiation (125) 
The recessive oncogenes might be a special category of tumor suppressor genes 
that can antagonize the regular oncogenes (112) This category of genes has also been 
detected in different in vitro model systems Many stable somatic cell hybrids of 
transformed and normal cells (or even in one case of two different transformed cells) 
are low or non-tumorigemc (126-132) Reappearance of tumorigemcity is accompanied 
by the loss of certain chromosomes derived from the normal parent Moreover 
morphological and non-tumorigemc revertants, positively and negatively selected with 
different agents, have been isolated from different types of tumor cells (130, 133-138) 
The reversion is not necessarily caused by the loss or down-regulation of the original 
transforming gene Growth of some transformed cells can be suppressed by 
surrounding normal cells (139, 140) probably through excreted small growth regulatory 
polypeptides (141, 142) Finally, tumor cells blocked in their differentiation can be 
induced to mature by strong artificial but also natural inducers Their responsiveness 
may decrease during tumor progression (112) 
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III. (Proto-)oncogene activation and regulation of eukaryotic gene expression 
The search for cancer related genetic events as described above has resulted so-
far in the discovery of at least 50 genes which are somehow associated with the 
induction, maintenance and progression of many different types of tumors But the 
frequent involvement of the same proto-oncogene in the development of a wide variety 
of tumors suggests that the number of genes most frequently involved may be quite 
limited From most genes the transduced or mutated form (=oncogene) and the normal 
cellular counterparts (=proto-oncogene) from different species have been molecularly 
cloned and their structure analyzed in detail Moreover their chromosomal locations 
have been determined (for review see ref 13, 143, 144) 
Research on the activation mechanisms of oncogenes contributes strongly to an 
understanding of the complex regulation of eucaryotic gene expression By structural 
analysis of oncogenes and functional studies on structural elements of these genes 
many different mechanisms of regulation of gene expression were discovered I will 
illustrate this taking the myc and tos genes as examples 
The myc gene can be activated in various classes of tumors by a number of different 
mechanisms, including viral transduction, proviral integration (promoter and enhancer 
insertion), translocation and amplification (fig 1 ) Mobilization of the transforming 
potential of the c-myc proto-oncogene seems to be associated only with changes in the 
mode of its expression In normal cells the expression of the gene is subject to both 
transcriptional as well as posttranscriptional regulation (145) 
Walking from the 5' end to the 3' end of the gene the following regulatory regions 
can be found (see fig 1) 
1) Ρ , promotor region found in humans but not in mice Two minor transcripts of 2 5 
and 3 2 kbp starting in this not well characterized CG-rich promotor region show 
some 5' heterogeneity (146) and are generated by differential splicing The function 
of the one, respectivily, the two additional open reading frames present in these 
transcripts is unknown (146, 147), 
2) Negative regulatory elements (148), 
3)PV a promotor just at the beginning of the first (non-coding) exon, 0 5 kbp 
downstream of P0, 
4) P2, a second promotor within the non-coding exon, 150 nucleotides downstream 
of P, (149, 150) Transcription normally starts at both of the two well characterized 
TATAA-box' promoters with a 4 1 preference for transcripts initiated from P2 (151), 
5) A modulator region with positive effects on transcription (152), 
6) A structural element, just at the end of exon-1 involved in a partial block of 
elongation It is not known whether this is only a pause in elongation or a 
premature termination The resulting discontinuous transcription appears to be 
regulated by a secondary structure of the RNA which prevents elongation and 
also by short-lived proteins, since inhibitors of protein synthesis can partially 
release this block (153, 154), 
7) A region within the first intron with many possible 'cryptic' promoters activated 
only after loss of P, and P2 (155, 156, 157), 
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8) A region at the end of the non-coding 3' part of exon-3 with mRNA destabilizing 
motifs (29) The myc mRNA turnover in normal cells is extremely high (15-20 
minutes) (158, 159) Inhibition of protein synthesis in most cell types results in a 
dramatic stabilization of c-myc mRNA and increase of protein level (159, 160) 
suggesting that the controlmg element is itself a protein involved in RNA turnover 
(145) The role of non-coding part of exon-1 in RNA stability is quite unclear When 
the 5' exon-1 was attached to an otherwise stable transcript the instability was not 
increased but when the 3' non-coding end was appended instability was increased 
(161) The 10-fold higher translation efficiency of transcripts starting at P2 compared 
to P1 transcripts (162) might be explained by a difference in stability (145), 
9) Several DNAse-hypersensitive sites have been identified in c-myc chromatin of 
mouse (163) and man (164) which are thought to indicate places where an open 
chromatin structure would make the DNA accessible to controlling protein 
molecules The sites close to P, and P2 are thought to be promoter sites where 
RNA polymerase binds and initiates mRNA synthesis The role of the sites 
upstream and downstream are controversial They should bind positive and 
negative regulatory proteins (165) By employing the gel retardation technique at 
least 7 different nuclear factors were identified that bind to DNA sequences within 
1 1 kbp 5' of P, Two of them bind to negative transcription elements with the 
opposite properties of a transcriptional enhancer One element is very similar to 
a DNA sequence with dyad symmetry located within the Polyomavirus enhancer 
At least two transcription factors interact with the c-myc first exon One of these 
may also bind to the SV40 enhancer, whereas the other may be a more specific 
factor (166) 
Transcription of the complementary strand, so-called anti-sense transcription has 
been detected, in man only upstream of P1, but in mouse at several regions (153, 167) 
The role of antisense transcription of c-myc is so far totally unknown 
But even such a complex system of many different close linked elements does not 
guarantee the living cell the right control of gene expression in all circumstances as 
might be deduced from the fact that at least three loci, Mlvi-1, Mlvi-4, and pvt-1/mis-1 
are identified which might act in cis on the c-myc gene expression (20, 168-172) 
There is also a fast growing amount of data on myc gene regulation on the 
transcriptional level The three exons that comprise the c-myc gene in many different 
species contain only one ORF (open reading frame) beginning with an ATG This highly 
conserved ORF begins near the 5' end of exon-2 and extends through approximately 
two thirds of exon-3 Recently the use of a non-AUG initiation codon (CTG) near the 3' 
end of exon-1 is observed resulting in the generation of а с myc isoform in which the 
ammo acids coded by about 15 codons upstream of an ORF within exon 1 are added 
(173) This can also partially explain the conserved complex protein pattern after SDS-
polyacrylamide electrophoresis of immunuprecipitated c-myc proteins from cells of 
different species In MEL (Friend murine erythroleukemia) cells a temporal shift in the 
relative abundance of the two isoforms of the c-myc protein during the induction of 
differentiation was observed The decrease in the lower molecular weight species during 
differentiation may represent a shift to the preferential utilization of the CTG start site 
within exon-1 (174) 
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A controversial aspect of the myc translation is the role of the about 70 nucleotides 
long complementary regions found in opposite orientations in exon-1 and exon-2 of the 
human c-myc sequence ( Э) It was proposed that normal с myc mRNA might be poorly 
translatable by forming a stem-loop structure that would render the initiator codon in 
exon-2 inaccessible Transcripts of recombmed myc genes without exon-1 sequences 
are not able to form a hairpin and therefore more efficiently translated However different 
studies came to opposite conclusions (162, 175, 176) 
The most common site for breakpoints, proviral integrations and recombinations in 
viral gene-transduction is a quite broad area including the first non coding exon and the 
5' half of intron-1 (165) In most if not all cases of Burkitt's lymphoma mutations are 
found within exon-1 (111) All together this strongly suggests that normal c-myc 
transcription is mainly regulated in or around exon-1 Recently it was shown that the 
removal or specific mutation of exon-1 found in Burkitt's lymphoma correlates also with 
suppression of synthesis of the less abundant larger isoform of the myc protein Thus 
alterations on the protein level may contribute to the oncogenic activation of c-myc 
(173) In Burkitt's lymphoma expression of the recombmed locus results mostly in 
complete down-regulation of the normal allele (146, 163) There is no agreement about 
the mechanisms that cause this allelic exclusion (111) 
Despite the substantial amount of data on myc gene expression it might be 
concluded that, "c-myc gene regulation still holds its secret" (cited from 177) 
Regulation of the expression of the fos gene is also extensively studied Expression 
of c-fos is one component of a larger program of gene activation induced by a variety 
of agents ranging from mitogens, hormones, lonophores, differentiation-specific agents, 
stress, drugs, etc In all cases induction is very rapid and transient (145, 178, 179) 
Studies of the DNA sequences required for the responses to membrane-transduced 
signals (180-183) indicate that more then one growth-factor responsive regulatory 
element contributes directly to the regulation of the fos gene Its SRE (serum responsive 
element) a region some 300 bp 5 to the cap site, contains a DSE (dyad symmetry 
element) DSE is a palindromic sequence that is crucial for the response to serum and 
that binds SRF (serum regulatory factor) SRF is a protein always present in HeLa cells 
and inducible by EGF (epidermal growth factor) in some other cells (184, 185) A DSE 
is also located in the 5' flanking region of mammalian and Xenopus actm genes that 
are also responsive to serum (186, 187) A binding site 346 bp upstream of the cap site 
binds SIF (serum inducible factor) which is a factor present m NIH-3T3 cells transformed 
by the s/s oncogene (188) In extracts from the mouse В lymphoma cell line WEH1231, 
three protein complexes are identified binding to the с fos promotor/enhancer region 
One is probably SRF while the others appear to provide basal levels of c-fos 
transcriptional activity by binding to two regions some 100 and 150 bp upstream of the 
cap site and to a region 60 nucleotides upstream of the cap site (not conserved in 
humans) harboring a potential binding site for transcription factor Sp1 (178, 181, 183) 
Negatively acting factors binding to the 5' region between 100 and 711 nucleotides 
upstream of the cap site seem to be also involved in the regulation of the c-fos gene 
expression (189, 190) Although some observations are suggestive of an autoregulatory 
function of the c-fos protein this is not required for the induction of c-fos by growth 
factors, which is even increased in the presence of protein synthesis inhibitors (145) 
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The mRNA destabilizing UAAAU motif mentioned earlier (29) is also present in the fos 
messenger Activation of the transforming potential of c-fos requires not only linkage of 
a transcriptional enhancer but also elimination of the multiple ATTTA motifs within a 67 
bp element of the non-coding region 123-189 bp upstream from the polyA addition site 
(145) 
CELLULAR VIRAL 
TRANSLOCATION PROVIRAL INTEGRATION 
PRCVIRUS 
EX0N1 5 L T R 3LTR EXDN2 ЕХ0НЭ 
Fig. 1. The activation of the c-myc gene For explanation, see text 
Counterclockwise from top left 
- t(8,14) translocation present in about 75% of the Burkitt's lymphomas The c-myc locus Is fused 
to the immunoglobulin heavy chain locus (IgH) 
- Metaphase spread of small cell lung carcinoma cells that harbor DM s (Double Minutes) with 
amplified c-myc 
- Structure of the c-myc gene Exons,, are indicated by boxes and introns by horizontal lines 
1 Region involved in most recombination events. 2 dehancer sequence, 5 modulator region with 
positive effects on transcription, fi block or pausing in elongation of RNA transcription, fl mRNA 
destabilizing motifs, S nuclease hypersensitive sites 
- Structure of the acutely transforming avian virus MC29 that harbors the exons 2 and 3 of the 
c-myc gene 
- Integration of an ALV proviral genome within the first Intron of the c-myc gene Mostly 
transcription is initiated within the 3' LTR 5' LTR initiated transcription resulting in the synthesis 
of a fusion protein Is rare in this system (17) 
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IV. The (proto-)oncogene products: 
The normal cellular function of proto-oncogenes 
Starting with the molecular clones and data of the primary structure of the oncogenes 
there are many ways to disclose the real identity of the oncogene products Computer 
comparison of the predicted ammo acid sequences of oncogene products with 
accumulated amino acid sequence data revealed a striking similarity of some oncogene 
products with known proteins Proto-oncogenes have been found to be evolulionanly 
conserved in not only the genome of vertebrates but also in lower eukaryotes The 
genetic tools available in Drosophila melanogaster and Saccharomyces cerevisiae 
provide a powerful approach to study proto-oncogene function 
A Growth factors 
The simian sarcoma virus v-s/s oncogene is a transduced form of the PDGF-2 
(platelet-derived growth factor-2) gene (191) 
At least three oncogenes encode proteins that are structurally similar to bFGF (basic 
fibroblast growth factor) One is found to be activated in the human cancer Kaposi s 
sarcoma (192) and in a form ol human stomach cancer, hence the name hst (193) 
Another one is the mouse mammary tumor gene int 2 (194) The third one was isolated 
from human bladder cancer cells (195) bFGF is the prototype for a family of heparm-
bmdmg growth factors that not only stimulate the division of certain cell types but are 
also potent angiogenic agents that foster blood vessel formation essential for solid 
tumor growth to a significant size (195) bFGF may act also as an autocrine growth 
factor for human melanomas (196) 
In Drosophila at least 12 genes have been identified homologous to well known 
proto oncogenes (125) But only the homolog of the extremely well conserved mouse 
mammary oncogene Int 1 maps to an already known Drosophila locus with well defined 
mutations the segment polarity gene Wingless involved in pattern formation in 
segments during embryogenesis (197) 
В Growth-factor receptors 
The mas gene product (64) shares a conserved structural motif of seven hydrophobic 
membrane-spanning a-helices with a class of receptors coupled to GTP-bindmg proteins 
(198) like mammalian opsins (199), adrenergic receptors (200), the muscarinic receptor 
family (201, 202) and the substance К receptor (203) The mas gene shows the greatest 
homology to the substance-K receptor (a tachikimn neuropeptide receptor) By the use 
of transiently expressed mas genes in Xenopus oocytes and a stably expressed mas 
gene in transfected mammalian cell lines it could be demonstrated that the gene 
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product is a functional angiotensin receptor with mitogemc activity (204) This class of 
receptors operates by activating a membrane bound transducing protein termed a GTP 
binding or G protein (205) 
The v-eròB protein is a truncated version of the EGF (epidermal growth factor) 
receptor lacking the ligand (EGF) binding domain (206, 207) 
The similarity in tissue distribution and biochemical properties of the c-fms proto-
oncogene product and the CSF-1 (Mononuclear phagocyte colony stimulating factor) 
receptor together with the fact that antibodies prepared against a recombinant v-frns 
encoded polypeptide specifically react with the CSF-1 receptor indicate that the product 
of the c-fms proto-oncogene and the CSF-1 receptor are possibly identical molecules 
(208, 209) 
Both the EGF- and the CSF-1-receptor are protein tyrosine kinases which general 
and specific properties are described in section IV E 
С. Nuclear proteins 
The v-eròA gene product is a mutated ligand-mdependent form of a high-affinity 
nuclear receptor for thyroid hormone as could be demonstrated by structural and 
functional studies (210-213) In humans, the gene most closely homologous to -елЬА, 
TRo, is located on chromosome 17 whereas a slightly more distantly related gene, TRß, 
resides on chromosome 3 (213-216) Even more sequences that cross-hybridize have 
been found on both chromosomes 3 and 17 The different members of the gene family 
seem to be expressed in a tissue specific manner (145) 
In a wide variety of cell types the gene c-fos is usually rapidly and transiently induced 
by a variety of external signals The induced fos protein is subject to extensive post-
translational modifications, mainly phosphorylations of serine residues Because 
phosphorylation is less extended in transforming fos products than in their normal 
cellular counterparts and has an inhibitory effect on the binding of the fos proteins to 
DNA cellulose it might be assumed that this modulates some biological properties of 
the fos protein by interfering with the direct or indirect fos-DNA interaction (217-219) 
The fos protein forms an extremely stable complex with the ¡un protein (p39) that is 
associated with chromatin (220) The ¡un oncogene product is related to the yeast 
transcription factor GCN4, while the central best conserved part of the fos protein also 
shows limited homology with GCN4 (221) The consensus DNA-bindmg site of the 
GCN4 protein is closely related to that of the mammalian transcription factor AP-1 (222-
224) AP-1 preparations contain several proteins (225) In fact the name AP-1 stands for 
a whole system of regulation of transcription whose complexity is only partially 
understood The transcription factors seem to interact as dimers with half-sites of 
palindromic recognition sequences (226) As a general model to explain the dimer 
formation the 'leucme-zipper' is proposed (227), a periodic repetition of leucine residues, 
present at every seventh position over a distance of eight helical turns of an o-helix, 
aligns along one face The leucine containing region of GCN4 is required for 
dimensation (22 ) The putative zipper region, plus an adjacent highly charged domain 
containing stretches of acidic and basic amino acids, is similar in GCN4, ¡un, fos and 
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myc Replacement of the individual leucines within the leucine repeat structure of the 
tos protein destroys the ability to form a complex with /ил, strongly suggesting that the 
repeat of leucine residues also stabilises the interaction between the tos and jun protein 
Nuclear protein complexes containing both fos and ¡un bind to the TRE (TPA responsive 
element) with the consensus DNA seqúense TGACTCA The fos-¡un complex can bind 
to DNA more tightly than either protein alone The TRE specific stimulation of 
transcription induced by the ¡un protein is enhanced by the presence of the tos protein 
(229, 230) The highly conserved basic motif adjacent to the leucine repeat seems to 
be a potential DNA binding site Mutations in this motif abolish DNA binding potential 
without affecting complex formation (230) fos and ¡un together with their closely related 
¡un-B and Fras (tos related antigens) are elements of the 'AP-1 system' in which protein 
complexes with multiple and variable subumts bind to variants of the AP-1 binding site, 
thereby modulating gene transcription (226) In yeast it was shown that fos and ¡un 
can function as transcriptional activators (231 ) 
The myc, myb and ski gene products show also nucleic acid binding properties 
Despite considerable knowledge of the basic molecular biology of these genes their 
normal cellular function is unknown They all seem to play a role in the control of the 
normal cell-cycle and might act as nuclear switches in signal-transduction systems by 
which short-term events that occur on receptor occupation are coupled to long-term 
alterations in gene expression 
myb is also a member of the class of sequence specific DNA binding factors 
presumably involved in gene regulation The DNA binding domain of v-myb, localized 
in the highly conserved ammo-terminal region recognizes the DNA sequence pyAACG/TG 
(232) The v-myb protein contains also a potential α-helical 'leucine zipper' sequence 
(227) but the ammo-terminal DNA binding domain shows no significant homology with 
consensus sequences of either hehx-turn-helix' or 'zinc-finger-type' (233) DNA binding 
proteins like SP-1 
The c-myc RNA and protein levels in human and avian cells have been shown to 
be invariant throughout the cell cycle, except for a transient increase observed upon 
mitogemc stimulation (160, 234-237) Not only the myc mRNA but also the protein 
shows a very brief half-life (20-30 minutes) (238, 239) The so called PEST region, rich 
in proline, glutamic acid, serine, and threonine, and flanked by clusters of positively 
charged ammo acids might be responsible for rapid protein degradation because it has 
been identified in 10 unstable proteins, including c-myc, c-fos and E1a (240) At a 
position equivalent to the basic motif of ¡un and fos the myc protein shows substantial 
homology with the 'hehx-turn-helix' DNA binding region of the ell protein of phage λ 
suggesting that the myc protein possesses a 'helix-turn helix' related stucture (230) The 
observation that c-myc is expressed at low levels in quiescent cells and rapidly 
increases upon exit from the G0 state and its decline in terminal differentiation suggest 
that activation of c-myc expression may be related to the competence of cells to enter 
and progress through the cell cycle rather than with proliferation per se (234, 237, 241, 
242, 243) 
p53 is a cellular nuclear protein without DNA binding properties that forms stable 
complexes with the DNA tumor virus proteins SV40 iarge-T antigen and adenovirus E1b 
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proteins (244-247) Formation of these complexes stabilizes p53, increasing its half-life 
and its steady-state levels in the cell (100-fold higher) In some non-virally transformed 
cell lines also an increased half-life and stability of p53 was detected These p53 
proteins appeared to be mutated All mutations cluster between ammo acids 120 and 
230 (out of 390 ammo acids) Binding studies showed that the mutant proteins bind 
poorly or not at all to the SV40 large-T antigen In these cases the functional analog of 
the DNA tumor virus antigens appears to be hsp70 (a heat-shock protein) (248-250) In 
cooperation with activated ras, mutant p53 clones that code for a p53 with an increased 
hsp70 affinity transform efficiently primary cells in vitro (251) A higher expression of 
the mutant p53 contributes to an mcease of the transformation frequencies (252) The 
normal mouse or human p53 genes are not able to cooperate with an activated ras 
oncogene to transform primary cells However overproduction of the wild-type human 
p53 protein is sufficient to confer a tumorigenic phenotype on established rodent 
fibroblasts as was shown by a tumorigemcity assay (253) Moreover the normal mouse 
p53 is capable of rescuing primary rat cells from senescence (254) Additional 
experiments are necessary to test the hypothesis that the p53 gene belongs to the 
recessive oncogenes 
The Rb-1 gene product is also like the myc, myb and fos proteins a nuclear 
phosphoprotem associated with DNA binding activity The protein forms stable 
complexes with several DNA virus products like adenovirus E1a proteins (255) and SV40 
large-T antigen (256) E1a proteins and large-T antigen are nuclear proteins that 
stimulate cell growth and activate and repress transcription (257, 258) Both contain a 
10 ammo acid region m which mutations reduce or abolish both Rb-1 protein binding 
and transforming activity (256, 259) Moreover, a mutant Rb-1 gene was discovered in 
a bladder carcinoma that encodes a protein that cannot bind E1a proteins (260) The 
Polyomavirus large-T antigen/flò-i protein complex may also involve other cellular 
components Immunoprecipitations of the complex contain also a fraction of the cellular 
nuclear p53 presummgly because it was bound to large-T (256) Both E1a proteins and 
SV40 large-T antigen immortalizes primary cells, but large-T antigen also transforms 
cells by itself, while E1a proteins require a second oncogene such as ras (55, 58) to 
generate a transformed phenotype The data mentioned may be explained by the 
following model Large-T antigen and Eia protein may inactivate the Яо-ί protein by 
occupying an essential site on the protein, while also carrying out other activities 
affecting cell growth (260) 
D The ras gene family 
From studies with yeast mutants it could be deduced that the members of the 
complex ras-family belong structurally and in some functional aspects to the signal-
transducmg guanme-nucleotide-binding (G) proteins (261, 262) From earlier work 
however it seems that ras actions are not initiated by stimulation of a known second 
messenger pathway, such as control of adenylate cyclase or inositol phosphate 
production (263) Recent work has demonstrated that changes in inositol-lipid 
metabolism may result from indirect consequences of ras activation (264) ras proteins 
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do appear to cause rapid changes in phospholipid metabolism, leading to 
phosphohpase Aj stimulation (265) and increased production of diaglycerol from an 
unknown source (266, 267) Activation of the transforming potential of Η-ras, K-ras and 
N-ras on the protein level is based on very specific point mutations that cause a 
dramatically decreased ability to hydrolyse GDP or/and changes in the ability to 
interchange prebound GDP or GTP resulting in the stabilization of ras proteins in their 
GTP-bound active state (26Θ) 
E The protein kinases 
By protein purification and enzyme assay for catalytic activity and, especially, by 
comparison of the deduced protein sequences of the oncogene products among 
themselves and with other sequences about 18 different oncogenes could be placed 
within a large gene family of protein kinases with a conserved catalytic domain The 
majority belongs to the class of tyrosine specific kinases (prototype src (269)) while 
only a few belong to the class of cytoplasmic serine/threonine specific protein kinases 
like mos and raf. Within the primary structure of the 250-300 ammo-acid residues long 
catalytic domain, mostly located near the carboxyl terminus, certain short ammo acid 
stretches are characteristic for each class (270) 
Novel protein kinases are isolated by the use of two different experimental 
approaches Screening cDNA libraries by using the conserved catalytic domain of 
protein kinase genes as hybridization probes under low stringency conditions or, more 
recently, by using degenerate oligonucleotides as probes (270-276) and 
complementation or suppression of genetic defects in invertebrate regulatory mutants 
(277-279) The number of proven or putative protein kinases has risen to nearly a 
hundred (280) Primary structure alignments of many protein kinases were used to 
construct a phylogenetic tree of the protein kinase catalytic domains (281) In 
Drosophila over 6 genes show homology with protein kinase genes like src, abl, erbB, 
raf, the insulin receptor gene, and protein kinase С genes Each of these genes is more 
similar to its vertebrate counterpart than to the other members of the Drosophila protein 
kinase family This indicates that the major gene duplication events which gave rise to 
the family took place before the divergence of chordates and arthropods, over 800 
million years ago In the meantime it suggests that the Drosophila genes are functional 
homologs of the vertebrate genes On the contrary in yeast these tyrosine specific 
protein kinases are not found at all suggesting that tyrosine kinases represent a class 
of enzymes specific for process control in multicellular organisms This is supported by 
the fact that many of the tyrosine kinases are growth-factor receptors (125, 280) 
The detailed alignments of many catalytic domains showed that eleven major 
conserved subdomams can be distinguished separated by regions of lower conservation 
wherein fall larger gaps or insertions An arrangement of alternating regions of high and 
low conservation is a common feature of homologous globular proteins (282) and gives 
some clues to higher order structure Within the subdomams highly conserved individual 
ammo acids are found which probably play important roles in catalysis Many of these 
most highly conserved residues directly participate in ATP (adenosine triphosphate) 
binding and phosphotranster Others may play a role m recognition of the correct 
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hydroxyamino acid because they are specifically conserved in either the protem-
senne/threonine or the protein-tyrosine kinase (281) Very near the ammo terminus of 
the catalytic domain the consensus Gly X-Gly-X-X-Gly, known from many nucleotide 
binding proteins, is found (283) Fifteen to thirty positions on the carboxyl-termmal site 
of the consensus an invariant lysine is located that appears to be directly involved in 
the phosphotransfer reaction (284) For different kinases it was shown that the ATP 
analog p-fluorosulfonyl-5 -benzoyl adenosine that reacts with this lysine inhibits enzyme 
activity (285-287) Ammo acid substitutions, including arginine, result in loss of protein 
kinase activity (284, 288-293) In many protein kinases an autophosphorylation site is 
found in the second half of the catalytic domain near what is thought to be the catalytic 
site (294) For several protein tyrosine kinases like src phosphorylation of the tyrosine 
residue at this position leads to increased catalytic activity (295-300) On the other hand 
in the gene products of frns, kit and ret as well as the receptors EGFR, neu, and 
PDGFR, the site is not present Usually spacing between the different subdomams is 
conserved but there is no experimental evidence whether this is critical The PDGF 
receptor, fms, kit and ret stand out from the other protein tyrosine kinases by a much 
longer spacer region located approximately in the middle of the catalytic domain (269) 
Outside the catalytic domain sequences are located probably involved in the cellular 
localization and substrate specificity of the enzyme The src,yes,fes,fgr and ab/ gene 
products shares several conserved domains with phophatidyl-mositol-specific 
phosphohpase C, which suggests some shared forms of regulation (301) In their 
carboxy-termmal end downstream of the catalytic domain some protein tyrosine kinases 
contain one or more tyrosine residues whose phosphorylation regulates kinase activity 
Depending on the kinase, the effect of phosphorylation can be positive or negative 
Phosphorylation of Tyr-527 of the c-src protein inhibits its kinase activity (302, 303), 
whereas autophosphorylation of Tyr-1150 and Tyr-1173 of respectively the insulin and 
EGF receptor enhances their kinase activities (304) Viral transforming gene products 
generally lack this regulatory domain Loss of the domain may lead to uncontrolled 
activity In general covalent modification of plasma membrane receptors by 
phosphorylation plays a key role in the regulation of receptor function Negative 
modulations are associated with heterologous phosphorylation of serine/threonine 
residues of the receptor proteins (305) 
It is extremely hard to find a specific substrate for a particular protein kinase In the 
living cell phosphorylation of proteins is a usual manner to modulate protein activity A 
single protein kinase can phosphorylate different proteins on different sites within the 
protein Almost every protein is phosphorylated to some extent Some 90% of the 
protein-linked phosphate is coupled to serine, 10% to threonine and only 0 05% to 
tyrosine Arginine linked phosphate is found also Many physiological processes are 
regulated by protein phosphorylation metabolic pathways such as glycogen 
metabolism, protein synthesis, alterations in cytoskeletal organization and signal 
transduction (306) An attractive hypothesis to explain the rapid, protein synthesis 
independent, induction of genes by growth factors is phosphorylation of preexisting 
transcription factors in the nucleus Although many nuclear proteins are phosphorylated 
(e g the proto-oncogene products of fos and myc) in mammals so far little is known 
about the consequences this has on protein activity, with the noticeable exception of 
CRE (cyclic AMP responsive element) binding protein (307) SNF1 is a yeast protein 
kinase that seems to play a role in transcriptional regulation (308) 
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In yeast, one critical point for controlling cell division is in the early Gl It is controlled 
by a cascade of at least three protein kinases (309-311) The last protein of this 
cascade, called cdc2 in fission yeast, occupies a central role in controlling the cell 
cycle because it is not only required for Gl-S but also G2 M transitions A mutation in 
cdc2 can be complemented by a human gene (278, 279) Moreover recently was shown 
that a homolog of the yeast kinase cdc2 is a subumt of the cell-cycle regulated and M-
phase-specific H1К (histone H1 kinase) described in a wide variety of eukaryotic cell 
types and MPF (maturation promotion factor), a major control element of the G2-M 
transition in activated or fertilized Xenopus eggs (312) All these 32-36kDa proteins have 
a perfectly conserved 16 ammo acids long peptide in common outside the consensus 
sequences of the kinase domain The striking homology between cell cycle regulating 
factors of yeast and higher eukaryotes implies that at least some aspects of cell cycle 
control are the same in yeast and vertebrates 
RNA expression of the evolutionanly less well conserved c-mos gene can hardly be 
detected in adult tissues The highest levels of expression are found in gonadal tissues 
restricted to male and female germ cells The mos protein can be detected during 
progesterone-induced maturation of Xenopus laevis oocytes Microinjection of mos-
specific antisense oligonucleotides in oocytes inhibits meiotic maturation by blocking 
germinal vesicle breakdown It has been suggested that pp39 mos acts directly or 
indirectly upstream of MPF to activate pre-MPF (313) 
Protein kinases are intrinsic parts of many signal transduction pathways of the cell. 
Extracellular signal molecules (ligands) activate target cells by binding to cell surface 
receptors which transduce a signal into the cell by phosphorylation of target proteins 
(internal effectors) In most cases this is mediated by transducers like G-protems (e g 
proteins of the ras family) and one or more second messengers such as cyclic AMP, 
diacylglycerol and Ca2+ Cyclic nucleotides generated by hormone dependent 
membrane associated cyclases activate the cyclic nucleotide regulated protein kinases 
A and G Diacylglycerol, produced by hormone- or growth factor-induced turnover of 
phosphomositides, activates protein kinase С (PKC) In the presence of Ca2 +, the 
ubiquitous Ca2+ binding protein calmodulin activates at least five protein kinases 
Phosphorylase kinase, myosin light-chain kinase and calmodulm-dependent protein 
kinases I, II and III (314, 315) 
In vitro at least overexpression of PKC can result in a transformed phenotype (316, 
317) Moreover tumor promoters that activate PKC have the same effects on proliferation 
as activated ras But, surprisingly, PKC does not correspond to a previously identified 
oncogene (318), nor do the other second messenger dependent protein kinases 
The protein kinases that are recognised as proto-oncogenes products are involved 
in the transduction of external stimuli, using, at least partially, other pathways as 
mentioned above The tyrosme-specific kinases among them are divided into two 
groups the integral membrane tyrosine-kinases (receptors) encoded by the erb-B-, frns-
kit-, ms-, neu and mei genes, and the cellular tyrosine kinases encoded by the src, yes, 
abl and fes/fps genes (269) From the latter group at least two members src and abl 
are bound to the inner surface of the cell membrane by their mynstilated N-termmal 
ends (covalently bound fatty acid) Characteristic domains can be distinguished in the 
receptor molecules a) an intracellular tyrosine kinase domain, involved in the 
phosphorylation of one or more specific substrates, b) a transmembrane domain, c) an 
extracellular domain involved in ligand binding that may contain one or more cysteme-
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rich regions. The frns- and tof-oncogene products and the PDGF receptor lack cysteine 
rich domains (269). 
The normal cellular function of most of the proto-oncogenes coding for protein 
kinases is unknown. As mentioned before, fms and erbB code for receptors with known 
ligands and recently evidence is provided that in mouse the c-Wî protein is encoded by 
the Dominant-White Spotting (W) Locus (319, 320). Mutations at this locus have 
pleiotropic effects on both embryonic development and the regulation of hematopoiesis 
in adult life. Animals homozygous for mutations in the locus are sterile, have extensive 
white-spotting and a severe anemia that results in prenatal death (321, 322, 323). The 
phenotype can be attributed to the failure of stem cell populations to migrate and 
proliferate effectively during development (323, 324, 325). 
CYTOPLASM 
Fig. 2. Schematic drawing of the predicted cellular localization of the proto-oncogene products 
GF = Growth Factor, GFR = Growth Factor Receptor 
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V. Conclusions 
In summary, oncogene products are components of very complex signal transduction 
circuitries which not only regulate cellular proliferation but also the development from 
oocyte to adult multicellular organism including differentiation, regeneration, recruitment 
and ageing 
We distinguish the following classes of proto-oncogene products 
a) polypeptide hormones acting on the cell-surface (sis, hst, int-2), 
b) receptors for this type of hormones (ros, met, trk, erB, neu, f ms, kit, sea, ret, mas), 
c) links of the signal transduction pathways between these receptors and the cell-
nucleus (members of the ras family via second messengers and tyrosine kinases 
bound to the inner surface of the cell membrane (src, abl) together with 
cytoplasmic tyrosine - {fes.yesjgr) and serine/threonine kinases (mos, raf, p/m-1)), 
d) nuclear thyroid hormone receptors (enbA) and nuclear factors which mediate the 
long term effects in the nucleus of growth factors and other transmembrane 
signaling agents (myc, myb, fos, ski, ¡un, fìb-1 and p53) (Fig 2) 
The argument to collect this wide variety of genes under the common name (proto) 
oncogenes is based only on the common feature that these genes could be involved 
in tumor development when they are hit by particular genetic events 
There are different explanations as to how genetic alterations might cause malfunction 
of these genes Disconnection of gene expression modulating elements and the 
structural parts of oncogenes can result in constitutive expression (some c-myc 
translocations) or abundant expression (retroviral transduction, gene amplification and 
translocation into the vicinity of a strong transcriptional enhancer) of a normal gene 
product Mutations can also induce constitutive activity of the gene product itself by 
inactivating or even removal of the elements that normally are involved in the limitation 
of the duration of their own action (point mutations in ras genes, removal of 
phosphorylation-sites in tyrosine kinases, removal of ligand-bmdmg regions in receptors 
like erb-B and erb-A together with conformational changes characteristic of the active 
state of the receptor as is found also in the neu protein) 
Probably DNA tumor viruses cause the same effects by the physical interaction of 
particular viral gene products (Polyoma virus middle-T, SNMO large-T, Adenovirus E1a 
and E1b) with cellular proteins involved in cell-growth and differentiation (src, Rb-1 and 
p53) 
It seems reasonable to assume that mutations that change the substrate specificity 
of proteins like the tyrosine kinases or the specificity of a transcriptional factor may play 
an important role but so far no evidence has been found for that 
The genetic alterations mentioned result in an inaccurate behavior of the oncogenes 
Some can block the differentiation programm of the cell on a specific stage A constant 
stimulation of proliferation by constantly produced growth factors or growth factor 
receptors or signal transducers in an 'on-state' may achieve a similar effect The 
mechanism by which activated nuclear oncogenes that can mediate the response to 
growth factors favors proliferation over maturation is less well understood 
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The effect of many different mechanisms is the expansion of a specific cell 
compartment The enlarged but still restricted cell population will persist until another 
(onco)gene becomes activated During a microevolution, the cells will develop step by 
step towards a fully transformed phenotype What oncogenes contribute to the 
development of a more malignant phenotype depends on the differentiation stage of the 
cell Activated oncogenes can only contribute to transformation if they are permitted to 
act on their target within a specific so called 'differentiation window' (326), at a point 
where they can prevent further maturation Temperature-sensitive mutants of v-src and 
- гЬВ transform cells and block their maturation in tissue culture at the permissive 
temperature But terminal differentiation is induced when the cells had been incubated 
for even a short time at the non-permissive temperature After the maturation has started 
subsequent reexpression of the transforming protein could not longer stop this process 
In vivo tumor induction experiments in B-cells suggest also strongly that the 
transformation of cells in different stages of differentiation in the same lineage is brought 
about preferentially by different oncogenes (e g ab/, myb, туе) (5) 
VI. Perspectives 
In a short time fundamental cancer research became part of developmental biology 
Studying oncogene activity is studying the effect of mutations in signal transduction 
genes There are several other approaches to study signal transduction Carcmogenes 
like tumor promotors activate specific components of the signal transduction pathways 
(protein kinase С for instance (327)) and peptide analogs of their own putative 
pseudosubstrate regions will inhibit specifically protein kinases (315)) Together with 
these experimental approaches oncogene research will help to understand the 
mechanisms by which cell division and differentiation are regulated and will add a new 
dimension to the understanding of cell to-cell communication 
Lower eukaryotes like yeast, Nematodes and Drosophila are very useful model 
systems to study cell and developmental biology The striking homology between cell 
cycle controlling proteins of yeast and vertebrates suggest that vertebrate cells will have 
a commitment point m G1 analogous to the yeast 'start' and a second control acting 
in G2 at the initiation of mitosis A model is proposed that places the cdc2 homolog at 
a point in Gì just downstream of a convergence point of various parallel signal 
transduction pathways originating from different growth factors and from other 
processes important in cell growth control, while the G2-M transition is also controlled 
by a cdc2 homolog (MPF) (311 ) The cdc2 homolog is a protein kinase controlled by 
phosphorylation So in this model a signal transduction pathway originating from a 
receptor on the cell surface leads to the regulation of nuclear proteins by 
phosphorylation 
Many components of the signal transduction circuitries are already identified but little 
is known about their connection to one another Observations on revenants of tumor 
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cells may give some understanding From cultured v-K-ras transformed fibroblasts non-
transformed revertants were obtained that still express the v-ras transforming protein 
The dommantly acting cellular gene or genes that cause the reversion could also cancel 
the transforming action of other members of the ras family and src and fes but not s/s, 
fms, raf, polyoma virus and SV40 (130) Revertants of v-fos transformed fibroblasts were 
resistant to transformation by v-fos, v-Η ras, v-abl and v-mos but could be transformed 
by trk and polyoma middle-T (13B) Oncogenes that are not able to transform revertants 
would presumably interact at a point upstream of the block within the pathway On the 
contrary, oncogenes that still transform the revertants may use a pathway totally 
independent of the blocked path Alternatively, the re-transforming oncogenes may use 
the same pathway but interact with this path downstream of the block Blocking of ras 
activity in vitro by microinjection of ras specific monoclonal antibodies showed that 
transformation of NIH-3T3 cells by v-src, v-frns and v-fes is dependent on an active 
cellular ras protein (32Θ) Only v-raf and v-mos, both serine/threonine protein kinases 
located predominantly in the cytoplasm are dominant over the ras antibody block 
These observations can be explained by a pathway in which all the blocked oncogenes 
are positioned upstream of the ras protein and the dominant oncogenes are located 
downstream from ras (329) 
A second handle on gaining information on the relationship between different 
oncogene products is synergism Synergism between oncogenes was first shown by 
transfection of REF cells with activated ras and myc genes (see section U B I ) Some 
acutely transforming viruses transduce more than one gene AEV (avian erythroblastosis 
virus) contains two genes, v-eröA and v-erbB The ν елЬВ gene is sufficient for 
transformation In contrast, v-erbA alone has no transforming capacity but enhances the 
erythroid transformation by v-erbB but also other non-related growth promoting 
oncogenes by completely arresting the transformed erythroblasts at an immature stage 
in differentiation (330) Comparison of the transforming activities in vivo and in vitro of 
naturally occurring v-milN-myc (MH2) transducing viruses and v-mil (v-га/) or v-myc 
transducing viruses showed clearly the synergism between the two oncogenes Their 
combined action is associated with the induction of factor-independent growth in 
culture A model is proposed in which are provided in the G1 phase of the cell cycle 
both a 'competence' or early Gl signal (= v-myc) and a 'progression or late Gl signal 
(= v-raf) (329) 'Competence' growth factors like PDGF might induce a family of genes 
including fos and myc which make the cell responsive to a second group of factors, the 
'progression' factors such as EGF Sequential action of competence and progression 
factors is required for induction of cellular DNA synthesis EGF causes the previously 
PDGF-treated cells to proceed into the S-phase (331 -334) 
Tumor models based on msertional mutagenesis by proviruses have also clearly 
shown the cooperative action of activated (putative) oncogenes MoMuLV induced rat 
thymic lymphomas containing provirus insertions in /W/w-1 always contain proviral 
insertions in a second locus, Mlvi-2 in the same population of tumor cells (171) An 
other example is pim-Mc-myc (or N-myc) synergism in MoMuLV induced T-cell 
lymphomas in mice (26, 335) A high percentage of primary tumors contains cells with 
proviral integrations near both p/m-1 and c-myc or N-myc Transplantation of these, 
primary, tumors resulted in selective outgrowth of minor subclones of tumor cells 
carrying insertions in an unknown locus suggesting that this so called p/m-2 locus is 
associated with later stages of disease (336) This also supports a multistep 
transformation model The chance that two oncogenes become activated by proviral 
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integrations within one cell is extremely small A single insertion in the first common 
integration site in the genome of the target cell near a gene that stimulates proliferation 
results in expansion of a cell clone that will serve as a target for second proviral 
integrations A second hit may cause an additional growth advantage by which a new 
subclone of cells with a new phenotype is created The new subclone may replace its 
predecessors as the result of a selection process or becomes part of a balanced 
polyclonal cell population If the growing cell population allows that the process is 
repeated a polyclonal or monoclonal tumor with many proviral integrations within the 
genome will arise (337) 
The cooperativity of oncogenes is also studied in transgenic mice Transgenic mice 
with an activated oncogene have proven to be good model systems to study tumor-
development in vivo (for review ref 338-340) Transgenic mice with a rearranged myc 
(Едтус) gene activated by the immunoglobulin enhancer as a transgene develop B-
cell-lymphomas with a very high incidence after a rather short latency period The preB-
cell compartment of polyclonal origin is greatly enlarged in the prelymphomatous state 
(341, 342) It could be deduced from the following observations that for the 
development of tumors f^myc expression is not sufficient 
a) Tumor induction is a stochastic process tumors appear after a variable latency 
period, 
b)A distinct preneoplastic state can be recognized, 
c) The tumors are monoclonal 
The preß cells of the prelymphomatous state are used for different in vitro studies 
The cells appeared not to be autonomous, since they died rapidly when cultured 
without feeder cells With feeder cells initially the preß cells grew like normal cells but 
after 14-20 weeks they started to grow to 10 fold higher densities, implying a reduced 
requirement for growth factors And after 25 weeks the one remaining culture had 
become feeder-independent and tumongenic Deregulated с myc expression in B-cell 
precursors seems to increase the rate of cell turnover, thereby increasing the frequency 
of genetic changes resulting in autonomous growth (343) But it is not excluded that 
myc also can influence directly or indirectly the stability of the genome of the 
prelymphomatous cell 
In imitation of in vitro transfection experiments, transgenic mice are made with 
activated ras and myc genes by interbreeding established strains of mice carrying either 
a myc- or a ras-gene-construct with a MMTV promotor The tumor formation appeared 
to be much more rapid in the F, generation than in the parent strain carrying a single 
oncogene Moreover other tumor types developed in the animals suggesting that 
cooperation of both proteins resulted in a greater penetrance in several tissues (344) 
As could be expected the cooperative action of myc and ras seems not to be sufficient 
for tumor formation The tumors appeared to be clonal 
In another approach, the potential of bone marrow cells from the Εμ-myc transgenic 
mice mentioned before in the preneoplastic state were compared with those of their 
normal httermates for transformation by Harvey murine sarcoma virus and Abelson 
murine leukemia virus by assessing colony formation in semi-solid medium The Εμ-
myc bone marrow appeared to yield more lymphoid colonies than normal marrow after 
infection with Harvey virus, and confirmed the results with the ras/myc transgenic mice 
However, the number of lymphoid colonies induced by Abelson virus was not enhanced 
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Probably the primary target of Abelson virus is more primitive than the expanded pre-
B cells of the Εμ туе mice and is therefore not present at increased frequency in the 
Εμ-myc marrow (345) The last mentioned in vitro result could be confirmed in vivo by 
Abelson virus infection of newborn mice from matmgs between normal and Εμ туе 
transgenic mice The Εμ туе transgenic mice did not show a higher susceptibility to 
lymphoma induction by Abelson virus compared to the non transgenic littermates (J S 
Verbeek, unpublished) 
The bone marrow cells of pre-neoplastic Εμ-myc mice and normal mice were also 
infected with constructed retroviral vectors containing the bcl-2 coding sequence Only 
Εμ-myc marrow cultured after infection in soft agar in the absence of mitogemc stimuli 
yielded compact colonies containing non-adherent cells with a lymphoid morphology 
The colonies could survive for several weeks m liquid culture but did not proliferate, 
even in the presence of stroma cells or many different hemopoietic growth factors In 
only three independent experiments infected bone marrow cells from Εμ-myc mice 
directly seeded into liquid medium continued to proliferate, infected normal cells never 
did The infected Εμ-myc populations appeared to represent oligoclonal immortal cell 
lines with a pre-B lymphocyte phenotype that yielded tumors in nude and syngeneic 
mice Together, these data strongly suggest that be/ 2 cooperates with c-myc to 
immortalize pre-B cells but again the enforced expression of two cooperative oncogenes 
is not sufficient for autonomous growth and tumorigemcity Infection of different growth 
factor dependent hemopoietic cell lines with the bcl-2 virus showed that bcl-2 
expression allows prolonged survival of factor starvation with nearly all the cells in G 0 
As a model to explain the contribution to transformation of constitutive bcl-2 expression 
induced by the 14,18 translocation it is proposed that bcl-2 maintains the affected cell 
clone until other genetic alterations generate the more aggressive later stage (346) 
To find new combinations of cooperative oncogenes in T-cell lymphomas newborn 
mice from matmgs between normal and pirn 1 transgenic mice were infected with 
MoMuLV Using MuLV as an msertional mutagen the system was asked what gene 
would be preferentially activated in addition to the transgen The transgenic mice 
appeared to be highly susceptible for MoMuLV induced Τ cell lymphomas as could be 
deduced from a strongly reduced latency between virus infection and tumor induction 
as compared to non-transgemc littermates A further analysis showed that in 85% of the 
p/m-1 lymphomas c-myc is activated by proviral insertion The remaining 15% contained 
proviral insertions within N-myc The lymphomas in the non transgenic littermates carried 
less frequent proviral myc integrations So in p/m-1 transgenic mice myc activation 
seems to induce the highest selective growth advantage compared to other gene 
activations suggesting a strong synergistic action between p/m 1 and myc (347) 
Transgenic mice carrying a human c-myc gene activated with a murine 
immunoglobulin heavy chain enhancer were crossed with transgenic mice carrying a 
functional rearranged human gene that encodes the membrane-bound form of the 
immunoglobulin heavy chain ( ιη^μ) In the m y c / m ^ double transgenic mice π ι^μ 
delayed the onset of malignancy and reduced its incidence, moreover influences also 
the phenotype of the tumors that did occur The specific reduction of pre-B 
lymphoblastic malignancies might be explained by assuming that ι τ ι ^ μ expressing pre-
B cells should bypass entirely the stage in which heavy chain rearrangements occur by 
which the size of the population of cells that is most susceptible to transformation by 
the myc transgene is reduced (348) This is again an indication that differentiation may 
suppress tumor inducing mechanisms 
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The possibilities to develop transgenic mouse models will enormously increase when 
the techniques for homologous recombination in embryonic stem cells become 
operational, because this will create the possibility to switch off specific genes 
The examples collected here are very recent and partially preliminary data, real 
experiments with a topping of inspiring imagination that at least show the way to fruitful 
strategies to uncover the signal transduction pathways used in the induction, outgrowth 
and metastasis of different types of tumors 
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I. Introduction 
A fes/fps transducing viruses 
The fps oncogene was discovered as part of five isolates of avian sarcoma virus 
(ASV) and the fes oncogene as part of three isolates of feline sarcoma virus (FeSV) 
Later it appeared that both oncogenes are homologous to the same evolutionary well 
conserved cellular locus It is unclear whether the structurally closely related avian 
sarcoma viruses PRCII and PRCIV are really independent isolates (1) All viruses are 
found in tumors of field animals except for 16L that was isolated from a chicken tumor 
induced in the laboratory after an avian sarcoma virus infection (2) The fps containing 
avian sarcoma viruses induce myxosarcomas (2, 3, 4) and the fes containing feline 
sarcoma viruses induce fibrosarcomas (5, 6, 7). All viruses induce efficiently 
morphological transformation in cultured fibroblast cells They are replication defective 
and dependent for reproduction on a helper virus, ALV (avian leukemia virus) and FeLV 
(feline leukemia virus) respectively From PRCII, FSV (Fujinami sarcoma virus), ST-FeSV 
(Snyder-Theilen feline sarcoma virus) and GA-FeSV (Gardner-Arnstem feline sarcoma 
virus) sequence data are available A detailed comparison revealed that all four 
sequences have exactly the same fes/fps 3' termini The recombination took place within 
the same viral gag domain, p27 for ASV and p30 for FeLV but not in the same position 
of the gag sequence The left hand junction of fes and gag sequences might have been 
formed by homologous recombination at the DNA level (8) The right-hand junction 
appears to be generated by recombination at the level of RNA (8, 9) A poly(A) addition 
signal of cellular origin is present in PRCII and SFV The 5' termini of fps sequences in 
PRCII and FSV are the same but in the other viruses they differ 
В The cellular homolog c-fes/fps 
The cellular homologs of fes/fps from chicken, man and cat have been molecularly 
cloned and characterized in detail The gene is mapped to human chromosome 15 (10, 
11) and to mouse chromosome 7 (12, 13) All cellular genes show the same overall 
structure (1) The size of each of the 18 coding exons is identical in chicken, man and 
cat The 5' border of the 5' non-coding exon remains to be established (1, 8, 14, 15) 
Exon-2 contains a potential ATG initiation codon at the start of an open reading frame 
of about 2 5 kb that ends in an TGA termination codon in exon-19 FSV contains all 19 
chicken c-Cps exons In PRCII the 3' end of exon-2, the complete exons 3, 4, 5, 6, 7, 
8 and the 5' end of exon-9 are missing (16, 17) GA-FeSV contains 16 nucleotides of 
the 3' end of exon-1, the complete exons 2, 3 and 4, the 5' end of exon-5, the 3'end 
of exon-9, and the complete exons 10 to 19 The c-fes homologous sequences of ST-
FeSV start at the 3' end of exon-8 and end at the stopcodon in the 19th exon (8) From 
these data it can be concluded that the 5' end (exon-1 to 8) of fes/fps is not necessary 
for transformation Except for the internal deletion the sequences of PCRII v-fps and 
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chicken c-fps differ only in 4 out of 1700 shared nucleotides resulting in no difference 
in their putative proteins (9, 1Θ) FSV shows 26 ammo-acid substitutions compared to 
chicken c-fps protein (18) GA-FeSV and ST-FeSV have only a few ammo-acid 
substitutions compared to the feline с fes protein but both contain deletions (Θ) These 
viruses have in common that the feslfps sequences are linked to ammo-terminal gag 
sequences 
С The fes/fps related gene products 
All protein products of the different v-fes/fps genes are associated with a tyrosme-
specific kinase activity and are capable of phosphorylatmg themselves and exogenously 
added substrates (19, 20, 21, 22, 23, 24) Beside the highly conserved catalytic domain 
at the carboxyl-termmal end, a stretch of about 100 ammo acids located directly 
upstream of the catalytic domain, called SH2, was found to be conserved among all 
cytoplasmic tyrosme-specific protein kinases such as the src ,yes,abl and fgr products 
(25) and also in the fes/fps protein (26) The function of this region, that is also present 
in PLC (phosphohpase C-148) is unknown (27) 
Both the FSV and FeSV fes/fps proteins seem to be associated with the plasma 
membrane (28, 29) The ammo terminus of the more tightly associated FeSV gag protein 
is mynstylated (30) while the ammo terminus of the avian gag proteins is acetylated at 
the first methionine residue (1) 
A 98 kDa (NCP98) and a 92 kDa (NCP92) c-fes/fps protein can be detected in 
respectively normal chicken and normal murine and human cells (31, 32) They also 
have tyrosme-specific protein kinase activities that phosphorylate themselves and 
exogenous substrates in an immune-complex assay (24, 33, 34) The specific activity 
may be lower then that of v-fes/fps proteins (35) Moreover NCP98 lacks detectable 
tyrosine phosphorylation in vivo (34) The proteins are predominantly present m 
granulocytes and macrophages (31, 32, 36) 
D Activation of the oncogenetic potential of fes/fps 
Various DNA constructs were made to test what genetic changes are responsible 
for the transforming activity of the v-fes/fps genes By replacing the entire src sequences 
m RS-RSV (Rous sarcoma virus) with the v-/ps sequences of FSV a virus was 
constructed .named F36, that codes for a 91 kDa v-fps protein without gag (37) The 
virus is able to induce tumors m chickens and to transform cells in vitro But when the 
chicken c-fps sequences were substituted for the v-src sequences of RS-RSV the 
resulting virus, named Fc51, is not able to induce tumors in vivo or to transform cells 
in vitro (35) When the same c-Zps sequences are linked at the 5' end to gag 
sequences, the resulting FSV-hke viral construct is again able to transform cells (35) 
Comparable results are found with the human с fes/fps gene in retroviral vectors (38, 
39) 
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In all cases the transforming potential of the fes/fps containing viruses is strongly 
associated with their tyrosme-specific kinase activity (22, 40, 41,42, 43, 44, 45, 46) F36 
is highly active in a kinase assay but Fc51 has a significantly reduced kinase activity 
From these data it can be concluded that the transforming potential of fes/fps could 
be activated by scattered mutations in the 5' non-catalytic domain of the gene (F36) or 
fusion to gag sequences In the natural occurring virus isolates fusion to gag sequences 
seems to be the first step in the activation of the transforming potential of the fes/fps 
gene followed by selection of mutations (FSV) or deletions (PRCII, GA-FeSV and ST-
FeSV ) which contribute to an increase of the transforming activity of the gene 
E Proposed function of the fes/fps protein 
Chicken myeloid cells infected with v-fes/fps expressing retroviruses do not require 
exogenous growth factors to differentiate in vitro (47) Thus the fes/fps protein may be 
related to cellular responses to growth factors specific to these cell types 
In the proximity, within less than 1 1 kb , of fes/fps a gene is located, named fur, that 
codes for a protein with a transmembrane domain (4Θ, 49) There is no evidence that 
the fes/fps protein and this fur protein form a membrane bound receptor complex 
Moreover, both genes differ in their tissue-specific expression (4Θ) So far p56 lek is the 
only non-receptor protein kinase that is found to be associated with a membrane 
protein (the Τ cell surface antigens CD4 and CD8) (50) 
To study the activated fes/fps gene in vivo transgenic mice have been made with 
an oncogenic gag-fes/fps gene construct under the transcriptional control of the human 
6-globin promoter The many different phenotypes observed were probably caused by 
the surprisingly widespread expression of the transgene In 8 to 50 weeks, 10 to 50% 
of the animals developed a variety of tumors of lymphoid or mesenchymal origin (ι e 
thymoma, lymphoma, fibrosarcoma, angiosarcoma, neurofibroma) Others show strong 
cardiovascular abnormalities or neurological defects (51) 
Uke that of all other tyrosme-specific protein kinases that are not integral membrane 
proteins the normal physiological role of c-fes/fps is still unknown The difference in 
biological activity between the normal cellular gene product and the oncogemcally 
activated tyrosine kinase is not understood Identification of the physiologically 
significant substrates of these tyrosine kinases in their 'normal' as well in their activated' 
status may resolve these questions Identification of the highly concerved cellular 
phosphoprotem, designated P150, that appears to be a substrate for the v-fes 
associated tyrosine specific protein kinase activity in tissue culture cells, might be a 
good starting-point (52, 53) 
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Summary 
A vanant clone of Snyder-Theilen feline sarcoma virus (ST-FeSV) encoding a 
polyprotein with a molecular weight of approximately 104 kDa (P104) was com-
pared to the P85 encoding prototype clone of ST-FeSV. Analysis of chimenc genes 
constructed with the viral oncogenes of the two clones indicated that the variant 
clone coded for a larger polyprotein than the prototype clone because of genetic 
differences in its 3' portion. Comparative DNA sequence analysis revealed that one 
nucleotide just upstream of the termination codon TGA in the prototype proviral 
DNA was deleted from the variant clone resulting in a 468-bp larger open reading 
frame. Furthermore, it appeared that the U3 regions of the long terminal repeats 
(LTRs) of the variant clone contained an insertion of 71 bp as compared to the 
LTRs of the prototype clone. In addition, both clones differed also from each other 
with respect to genetic sequences deleted from their env gene regions. 
Feline sarcoma virus; V-fes oncogene; Genomic organization 
Introduction 
Acutely transforming RNA tumor viruses have acquired their malignant poten-
tial upon insertion of proto-oncogene sequences into their genomes (Bishop and 
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Varmus. 1982, Fishinger. 1982) Three independent FeSV isolates, including the 
Gardner-Arnstein strain (GA-FeSV) (Gardner et al., 1970). the Snyder Theilen 
FeSV strain (ST-FeSV) (Snyder and Theilen, 1969) and the Hardy-Zuckerman 1 
strain (HZl-FeSV) (Snyder et al., 1984), captured sequences from the feline c-fes 
proto-oncogene (Frankel et a l . 1979: Franchini et al., 1981; Hardy et al.. 1981: 
Hampe et-al., 1982; Roebrock et al.. 1987). All isolates induce fibrosarcomas in vivo 
and transform fibroblasts in cell culture (Gardner et a l , 1970; Snyder and Theilen, 
1969; Snyder et al., 1984) The major translation products of GA-FeSV and 
HZl-FeSV are polyproteins of 115 kDa (Stephenson et al., 1980; Van de Ven et al., 
1980a) and 100 kDa (Snyder et al., 1984), respectively. In the case of ST-FeSV, two 
clones are described (Reynolds et al.. 1981). One. which we will call the 'prototype' 
clone, codes for a polyprotein of 85 kDa (Barbacid et al., 1980; Reynolds et al., 
1981; Sherr et al., 1978). The other, which we designated the 'variant ' clone, 
encodes a polyprotein whose mol. wt. was reported earlier as 115 kDa (Van de Ven 
et al., 1980a). Now, based upon amino acid sequence data presented in this study, 
the mol. wt. of the polyprotein encoded by this clone appears to be 104 kDa. It was 
shown that the translation products of GA-FeSV and prototype ST-FeSV, which are 
studied in greatest detail, possess tyrosine-specific protein kinase activity in vitro 
and are capable of autophosphorylation as well as phosphorylation of certain other 
proteins (Barbacid et al., 1981; Beemon, 1981: Mathey-Prevot et al.. 1982; Ruscelli 
et al., 1980; Van de Ven et al.. 1980a,b; Snyder et al., 1984). Analysis of transforma-
tion-defective mutants of prototype ST-FeSV revealed that this enzyme activity 
which is located in the carboxy-terminal region of the polyproteins (Barker and 
Dayhoff. 1982; Levinson et al., 1981; Weinmaster et al., 1983) is required for 
malignant transformation (Donner el a!.. 1980; Reynolds et al., 1981). In Ihe case of 
ST-FeSV. a single tyrosine acceptor site within the polyprotein is involved (Blom-
berg et al.. 1981). 
To elucidate genetic differences between the two clones of ST-FeSV. the genome 
of the variant clone was molecularly cloned and its genetic organization and 
structure compared with that of the prototype. Differences observed in coding and 
regulatory sequences are discussed. 
Materials and Methods 
Cell lines and media 
Cells were grown in Dulbecco's modified Eagle's Medium (DMEM) supple-
mented with 10% newborn call' serum (GIBCO). Cell lines used in this study 
included CCL64, a highly contact-inhibited mink lung cell line (Henderson et al., 
1974), rat-2 (Topp, 1981), CCL64 nonproductively transformed by GA-FeSV (Van 
de Ven et al., 1980a). prototype ST-FeSV (Sherr et al., 1978) and by the Mc-
Donough strain of feline sarcoma virus (SM-FeSV) (Van de Ven et al., 1980a). 
Normal rat kidney (NRK) cells nonproductively transformed by the variant clone of 
ST-FeSV were obtained from E.M. Scolmck. 
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Purified DNA was transferred into cells by the calcium phosphate precipitation 
technique (Graham and Van der bb, 1973) or by electroporation (Narayanan et a l . 
1986) For electroporation, cells were resuspended in Ca2"1" and M g 2 4 free phos­
phate-buffered saline to a final concentration of 2 Χ 107 cells/ml 50 μg of purified 
DNA was added to 0 5 ml of a cell suspension and incubation was for 10 mm at 
0 o C Electroporation was carried out with an electric pulse of 2 0 kV for 0 9 ь 
Preparation of probes and hybridization 
S, and S
r
 are 5'- and З'-specific probes of the \-fes oncogene of prototype 
ST-FeSV (Franchini et a l . 1981) These probes were obtained from С J Sherr 
pC014 is a recombinant of the prototype ST-FeSV provirus subcloned in pSVBR94 
Isolation of DNA probes, nick translation, and hybridization analysis of Southern 
blots were carried out as described by Schalken et al (1985) 
Construction of a genomic library and selection of recombinant clones 
To isolate the complete proviral DNA of the variant clone of ST-FeSV, a gene 
library was constructed with the pJB8 cosmid vector system (Ish-Horowicz and 
Burke, 1981) using high-A/
r
 DNA isolated from N R K cells nonproductively trans­
formed by the variant clone of ST-FeSV For screening of the library, a combination 
of S, and S
r
 was used as a molecular probe Isolation of cosmid DNA from selected 
clones was performed according to the alkaline lysis procedure described by Davis 
et al (1979) 
DNA sequence analysis 
Upon ligation of DNA fragments into the polylinker region of M13mp8-19 
(Yanisch-Perron et a l , 1985), DNA sequences were determined by the dideoxy 
method as described by Sanger et al (1977) Gel readings were recorded, edited and 
compared using the Staden programs (Staden, 1982) 
Immunoprecipitation analysis 
Cell labeling, immunoprecipitation of polyproteins, and subsequent sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
as described by Van de Ven et al (1980b) 
Results 
Analysis of the translation products of the prototype and variant clones of ST-FeSV 
In earlier studies, we reported on the characterization of the polyprotein encoded 
by the independently isolated variant clone of ST-FeSV (Reynolds et a l , 1981, Van 
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de Ven et al., 1980a). In these studies, its mol. wt. appeared to be similar to that of 
the polyprotein encoded by GA-FeSV and was estimated to be approximately 115 
kDa. In recent studies, however, we observed a slight difference in electrophoretic 
mobility between the polyproteins encoded by GA-FeSV and the variant ST-FeSV. 
This is illustrated in Fig. 1, which shows the results of an immunoprecipitation and 
SDS-PAGE analysis of the polyproteins encoded by GA-FeSV (lane 1), prototype 
ST-FeSV (lane 3) and variant ST-FeSV (lane 5). The greater mobility of the 
polyprotein encoded by the variant clone of ST-FeSV as compared to GA-FeSV 
P115 is clear. Based upon this observation and upon additional data presented 
below, we estimated the mol. wt. of the polyprotein of the variant clone as 104 kDa 
and will therefore designate the product as PI04. To determine whether the 
difference in mol. wt. of the translation products of the prototype and variant clone 
was due to glycosylation, synthesis of the polyproteins was studied in cell lines 
cultured in the presence of tunicamycin. Goat antiserum directed against FeLV p l 5 
(Reynolds et al., 1981) was used. As a control to test the inhibition of glycosylation 
by tunicamycin, we studied the synthesis of the glycosylated polyprotein encoded by 
the McDonough strain of FeSV. In the absence of tunicamycin, the previously 
described polyprotein P170 was found (Van de Ven et al., 1980c). In the presence of 
tunicamycin, no PI70 could be detected. Instead, a polyprotein with a mol. wt. of 
155 kDa containing pl5, p l2 and p30 antigenic determinants was observed (data 
not shown). Immunoprecipitation analysis of GA-FeSV and prototype ST-FeSV 
kDa 
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Fig. 1. Immunoprecipitation and SDS-PAGE analysis of high-molecular-weighl polyproteins in mink 
cells nonproductively transformed by GA-FeSV (lanes 1 and 2) or prototype ST-FeSV (lanes 3 and 4) 
and normal rat kidney cells nonproductively transformed by the vanant clone of ST-FeSV (lanes 5 and 
6). Cells were grown in absence (lanes 1, 3 and 5) or presence (lanes 2. 4 and 6) of tunicamycin (5 μg/ml) 
for 7 h. After incubation for 4 h. ("SJmethionine was added (50 /iCi/ml). Immunoprecipitation analysis 
was performed with goat antiserum directed agamsl FeLV pl5. Immunoprecipitaled proteins were 
visualized by autoradiography using Kodak XAR-2 film. 
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transformed mink cells cultured in the presence of tunicam>cin revealed a major 
band of 115 kDa (Fig 1. lane 2) and 85 kDa (Fig 1. lane 4), respectively No 
differences compared to the polyproteins synthesized under normal conditions 
could be observed Similar analysis of the variant clone of ST-FeSV m the presence 
and absence of tunicamycin did also not reveal any detectable change in electro-
phoretic mobility of the variant polyprotein (Fig 1, lanes 5 and 6) No FeLV-related 
proteins were precipitated with control sera or found in extracts prepared from 
control mink or rat cells (data not shown) These results indicated that the 
difference in mol wt of P85 and P104 was not due to glycos>lation To explain the 
difference in mol wt of the two polyproteins, the possibility of a genetic modifica-
tion, e g insertion or deletion of genetic sequences, or a frameshift point mutation 
was considered To test this possibility, molecular cloning of the variant ST-FeSV 
provirus was required 
Molecular cloning of the proviral genome of the variant clone of ST-FeSV 
To molecularly clone the proviral DNA of variant ST-FeSV, we constructed a 
cosmid gene library with DNA from NRK. cells nonproductively transformed by 
variant ST-FeSV, as described in the Materials and Methods section Upon screen-
ing of the cosmid gene library (approx 750000 colonies) with a combination of the 
S | and Sr probes, three cosmid clones, designated cos 4, cos 9 and cos 11 were 
identified and isolated for further analysis Analysis of these cosmid clones revealed 
that all three cosmid clones contained the complete provirus Cosmid clone 9 was 
selected for further studies It appeared from restriction endonuclease analysis that 
the size of the proviral DNA was 4 9 kbp This is slightly smaller than the proviral 
DNA of prototype ST-FeSV, which is 5 3 kbp It should be noted that also a 4 3 
kbp proviral DNA clone of prototype ST-FeSV has been described (Groffen et a l , 
1983) The difference between the 5 3 kbp and 4 3 kbp proviral DNA lies in the env 
gene region and both isolates code for the same polyprotein P85 Hybridization 
analysis of the proviral DNA of variant ST-FeSV with a GA-FeSV-specific probe 
(Pst\-Sac\ fragment) (Hampe et a l , 1982) revealed that such sequences were not 
present (data not shown) This observation indicated that sequences homologous to 
feline c-fes exon 1-6 were not represented in the variant provirus (Roebroek et a l , 
1987) 
A restriction map of the vanant proviral DNA (Fig 2) was obtained on the basis 
of restriction endonuclease analysis using the restriction endonucleases BamWl, 
Bglll, EcoKl, HindlU, Kpnl, Sad, Sail and Xhol or combinations of these in 
sequential digestions (data not shown) Comparison of the restriction maps of the 
prototype and variant clone of ST-FeSV provided no clues as to where to localize 
potential insertions or deletions 
77ie prototype and variant strain of ST FeSV differ in the 3' portion of the polyprotein 
encoding region 
In an effort to determine the map position of genetic modifications that causes 
the enlargement of the open reading frame in the vanant clone, chimeric genes were 
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Fig. 2. Restriction endonuclease map of the provi ral DNA of the variant clone of ST-FeSV. The heavy 
bar represents \-fes sequences. 1). HglW; Ha. ΜκιιΙΙΙ; l·. /.cr)Rl: K. KpnV. S. Sac·I: Sa. .Sa/1; X. A'Aol. 
I IR. Long lenninal Repeal. 
constructed using the 5' and 3' halves of the proviral DNAs of the two ST-FeSV 
clones. A Sail restriction endonuclease site present in both x-fes genes and an 
£coRI restriction nuclease site located in the I.TRs were used in the construction as 
schematically outlined in Fig. ЗА. In addition lo these two chimeric constructs, 
recombinant DNA clones that contained the parental prototype proviral DNA 
(clone pCOH) or the parental variant proviral DNA (clone pMCl) were also 
studied. Upon introduction of recombinant plasmids pSV60, pSV61, pCOH, or 
pMCl into rat-2 cells, iransformed clonal cell lines were obtained by selection of 
single cells in microliter plates. Introduction of DNA into cells by electroporation 
seemed more efficient than transfection of DNA. Furthermore, linearized DNA 
gave better results in electroporation than closed circular DNA (data not shown). 
Cell lines coded rat-2-pSV60-C17. rat-2 pSV61-C18. rat-2-pC014-C19 and rat-
2- pMCl-C12, respectively, were selected for further analysis. 
To characterize the translation product(s) encoded by the chimeric genes, total 
cell lysates were studied by immunoprecipitation and SDS-PAGE analysis. Goat 
antiserum prepared against GA-FeSV PI 15 (Fig. 3B) (Reynolds et al., 1981) or 
FeLV pl5 (data not shown) were used. In Fig. 3B. the results of the immunoprecipi­
tation analysis are presented. Just like cell line rat-2 pC014-C19 (data not shown), 
cell line rat-2-pSV61-C18 (Fig. 3B. lane 1) appeared to express a polyprotein with a 
mol. wt. of 85 kDa. Cell line rat-2-pSV60-C17 (Fig. 3B. lane 2) however, expressed 
a polyprotein with a similar mol. wt. as PI04 expressed in cell line rat-2-pMCl-C12 
Fig. 3. Construction of chimeric genes and characteri/ation of translation producl(.s). (A) Plasmid 
pCO14. containing a single copy of prototype ST-FeSV punirai DNA (open segment), was digested with 
restriction endonucleases /;<»R1 and .S'a/1. The \-les containing DNA fragments were isolated and 
suhcloned in pBR322. resulting in pSVÍ4 and pSVSS. I'sing the orientation of the prototype of ST-FeSV 
provirus as a reference. pSV54 and pSV5? contain the 5 ' and 3' part of the proviral DNA, respectively. 
Similarly, plasmid pMCl containing a single copy of the variant ST-FeSV provirus (black segment), was 
digested with restriction enzyme EcoKl and .S'a/1. The \-fes containing DNA fragments were subcloncd 
in pBR322 resulting in pSV56 and pSV'57. The insert of pSVS-4 and the insert of pSV56 were ligated and, 
upon digestion with rcstriclion endonuclease /-.VoRI. suhcloned in р С О І З . which resulted in pSV60. The 
same procedure was followed in constructing pSVfil using pSV55 and pSV57. (B) Immunoprecipitation 
and SDS-PAGP; analysis of the polyproteins expressed in rat-2 cells transfected with pSV60 or pSV61. 
Cell lines rat-2-pSV61-C"lS (lane 1). and rat-2- pSVWH'I? (lane 2). were metabohcally labeled for 3 h 
with [^S] methionine (50 μ Π / η ι Ι ) . Proteins were imniunopiecipitaied with goat antiserum raised against 
FeLV p l 5 . Autoradiography was performed as described in the legend to Fig. 1. 
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(data not shown). No FeLV-related proteins were precipitated with control sera or 
found in extracts prepared from control rat-2 cells (data not shown). These data 
indicated that the genetic difference between the two ST-FeSV clones that causes 
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the synthesis of the larger polyprotein P104 is located in the 3' portion of their 
genomes 
Nucleotide sequence analysis of the proi irai DNA of the variant clone of ST FeSV 
Although the experiments with the chimeric genes strongly suggested that genetic 
differences in the 3' halves of the genomes of the two ST-FeSV clones could explain 
the differences in mol wt of the polyproteins, the precise nature of the genetic 
differences remained to be established Furthermore, the possibility of genetic 
modification in the 5' portions could not be ruled out either To resolve these 
matters the nucleotide sequence of the proviral DNA of variant ST-FeSV was 
determined The results are presented in Fig 4 The sequence data of the proviral 
DNA of variant ST-FeSV were compared with those of the \-fes oncogene of the 
prototype strain (Hampe et al, 1982) and with FeLV helper virus sequences 
(Hampe et al, 1983, Nunberg et al, 1984) since the complete nucleotide sequence of 
the proviral DNA of prototype ST-FeSV has not been determined yet Such 
comparative analysis indicated that one nucleotide (G) just upstream of the termina-
tion codon, as present in the prototype strain, was deleted from the variant clone of 
ST-FeSV, resulting in an extension of the open reading frame with 468 bp up to the 
termination codon (TAA) located at nucleotide position 3776-3778 (Fig 4) Fur-
thermore, three major other differences were observed and these are depicted in Fig 
5 First of all, 71 nucleotides of the U3 region of the LTR of the variant clone were 
not present in the prototype ST-FeSV In addition nucleotide sequences encoding 
FeLV gp70 and the amino terminal portion of pl5E were present in the prototype 
clone of ST-FeSV but not in the variant clone Finally, the 3' portion of the env 
gene was present in the variant clone (nucleotide position 3817-4290) (Fig 4) but 
not in the prototype clone of ST-FeSV In addition to the four genetic differences 
mentioned above, the two ST-FeSV clones also differed from each other by a 
number of point mutations (see Discussion) 
Discussion 
The ST-FeSV isolate that encodes the P85 polyprotein is extensively studied and 
can, therefore, be considered as the prototype clone of this virus strain In this 
report, we describe the characterization of a variant clone of ST-FeSV It encodes a 
polyprotein of 104 kDa (P104) Calculation of its mol wt was mainly based upon 
DNA nucleotide sequence data This was a reasonable approach, since P104 is 
either not significantly, or not at all, glycosylated, as concluded from the studies 
with tunicamycin Therefore, a better estimate of the mol wt of the polyprotein of 
variant ST-FeSV is 104 kDa and not 115 kDa as was reported before (Van de Ven 
et al, 1980a) 
The close relationship between the prototype and the variant clone was estab-
lished in earlier studies based upon radioimmunoassay analysis of the gag-gene 
encoded domains (pl5, pl2) m P85 and P104 (Sherr et al, 1978, Van de Ven et al, 
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gcatggaaaa 
c t g t g g t t a a 
a t t e a a c e t t 
t tgaccgecc 
_ c ^ . l t M « l · 
t tacccaagc atgagecage 
gcacctgggc c c c g g c t l g a 
c c g t c t c a t t t a a a c l a a e c 
gegtacecgt gtacgaataa 
clcgtccggg atagagaccc 
t a t t g e a g t a 
flgccaagiac 
a a t c c c c a c i 
a g e c t e t t g e 
ccaaccceag 4SI 
601 g g a c c a e c i * c c c a c c a t c a g g a g g t a a g c t g g c c g g c g a e c a t a t c t g t t g t c c t l g t a t a a g t g t c t c t g t c a a c t g a t e t g a t t t t g g c g g t g g a a c e g a a g g a g e t g a e s a g e t c g 
721 t a c t t c g c c c c c g c a a c e e t g g a a g a c g t t c c a c g g g l g t c t g s t g t o t g g a g e c t e t a g t g g g a e a g c c a t t g g g g c t c a l c t g t t l g j g g t e t e a c e t g a a t a c a g g g t g t t g a t c g g 
6*1 a g a e g a g f g a ffccuaccei c a a a g t c t c t t t c t g a g f t t t c a t t l t g g g t t t g g t a t c g a a g o c g e g c g g o a c g t e t t f t c a t t c t t t g t c t t g t t g c g t c t t t c c t t g t e e c c t f t c t 
r * p t t 
9ΐ1 a a c c t m t a a t t g e a g a a g ccgtcJlTOKl CCAAACTCTA ACTACCCCCT TAAOCCTCAC CCTTGACCAC TOCTCCGAGC TCCGGCCACC AKCCATiAT CHOCCTCTCC iCCTCCGGAA 
1 0 ê l AiAGAAATCC ATTACTTTAT QTCAACCCCA ITCOCTGATC ATCUTCTAC CCTGCCCCCG AGAACCAACT TTTTCTCTTC ATAACATTTC TCACCTTAAC AACAAGATCT TCCCCCCCCC 
1201 ACCACATOCA CACCCCCACC AACTTCCTTA CATTACCACA TOGACATCCT 70GCCACAGA CCCCCCTTCA TCSCXTTTCOCC CGTTCCTACC CCCCCCCAAA CCTCCCACAC CCCTCCCTCA 
p - p 1 2 
1321 СССТСПТСС CCCCACCCCT CCCÎCCCCTCT TACCTCCTCC CTCTACfccCC TTGTCCCCAA QCCACACCCC CCCAAACCOC CTCTCTTACC CCCTCATCCT ТСГТССССТТ ТААТТЫТСТ 
m a i CTTAACAGAA CAQCCACCTC CCTATCCGCG CCCTCACGCG CCACCQCCAT CAGCCCCTAG CACCCCOGCC OCTTCCCTCA TTOCAAQCCC GCTAAGCGAA*CQCCGACAAA ACCCTOCTCA 
Г-РЭО 
1561 AGAATCTCAA CCCCTCCCCT TGACCCAACC CCCCAACTAC CGACCCCACT АТТОСССАП CTCGCCCTCA CACCTCTATA ATTOCAâUTC GCACAACCCC CCTTTCTCCC AACACCCGGT 
Ι ί β ΐ GCCCCTAACT AACCTAATTC АСГССАТТТТ ACTAACCCAC CAACCAACCT OCCACGACTC CCAOCAACTC TTXACCCAC TCCTCACACC CCAAGAAAGC CAAAGACTCC TTCTTGACOC 
1801 CCGAAAGCAA CTTCCACOCC AACACCOGCC GCCAACCCAA CTCCCCAATC TCATTCACCA GACTTTCCCC TTCACCCACC ССССССДССА GCTGCAGCTG CTCCCCAACA ACCACGTCTT 
1921 CCAACACCCC CTOCAOGCGC TXAXTOOC CTTOTOCAOC CAQCCCAAX TCXACOCCCA XGGCAOCTC CTXAGGCCA A OCT OC* OC A QCTCCCCCCC CCCGAOCCCC CGCCCOTCCT 
20*1 GCTCCTCCAC QATGACCCCC ACTCCACCTC CTCCTCGGAC CAOCAOCGAG AAGGCCCAAC GACACCCACC TTCCAGATCC TTAAQAOCCA CATCTCAOUA ATCTTCCQCC CCAACTTCTC 
21 i l CCTCCCTCCA CCCCTCCAOC TCCTACCACA CCTOCAGAAC CCCCTOCACC AXACCTUTC CTACCACCCC CCCCTCCLAC CCCCAGACCT GCCTCAOCTC TTGACCCACT CTOGOCACTT 
2291 TCTGGTOCOC GAGACCCAGC CCACCCACGA ATATCTGCTG TCGCTGCTCT GSGACCCCCA GCCCCGCCAC TTCATCATCC AGTCCCCTGA CAACCTCTAC CCACTCGAAC OAGCTCOCTT 
2*01 TGCGAOCATC СССПЧХТСС TCGACCACCT OCTtEOCTCC CAOCACCCCC TCACCAAGAA САОСССТАП (ТГССТСААСА ССССТСГОСС CAAGCACAAC TCCCTOCTAA ACCACGACCA 
2521 ССТОСТСПТС GCTGAGCACA TCCCOCCCGC CAACTTTCGA СААСТСПСА CTGCACCCCT GAGOOCCGAC UCACTCTAG TGCCCCTCAA ATCTTCTTCOC aCACACTCC CACCTUCAT 
26*1 CAACOCCAAG TTTCTTCAGG AAOCUAGAT CCTGAAOCAG TACAXCACC CCAACATCCT OCCTCTCATC GCCCTCTXA CCCAGAAXA OCCCATCTAC ATCCTCATGG AQCTCCTOCA 
2761 CGGGGGCGAC TTCCTGACCT TCCTGAGGAC CCACCCAOCC CGCCTOCGGA TGAAGACGCT GCTGCAGATG CTCCOCGACC CGGCCXGGG CATGGACTAC CTGGAGAGCA AOTCCTCCAT 
2981 CCACCGQCAC СТА X T OC Τ С OC A A CT X CT OCT GA С CC A С AAUACCTCC TGAAGATCAC ТОАСПСССС ATCTCCCCOG AGGAAQCCGA TOMA Τ CT А С XGCCCTCAC GGOCCCTCAC 
3001 ACTAGTTCCC CTGAAOTGGA CGCCACCCCA OGCTCTTAAC TACGGCCOCT ATTCCTCTGA GAXGACGTG TCGAGCTTCC GCATCTTOCT ATGGGAGACC TTCAOCCTGC XKCTCCCC 
3121 CTACCCCAAC CTCAXAATC AQCAGACCCC CGACTTTOTO GAAAAOGOTG ŒCXCTGCC CTXCCCGAG CTCTXCCCG ACGCTCTCTT CAGGCTCATG GAOCACTXT GGCCCTACGA 
# I 
32*1 CCCCGCCCAG CGGCCCAGCT TCAXCCCAT CTACCACtUQ CTGCAGAOCA TCCGAAAXG GCATCCTGâC XCGGCCCTO CTTCTCAAOC CGŒCCCCTC GACACCCAAG ATCGTACCTC 
3361 CTCCTŒCCC TTGTTCTATA XGGCTTCX TACCTCCCCC A CT A T X А ОС CACATTTACG CCCCCTCCAC CTACTCCAAG AAGAGATCCA GAGACCTCTA XGGCGGCCT ACCGAGAAAC 
3*81 GCTCGAGACC CCGCTTCTK CTCACCCCTT CAAACCACOA GACTCCCTCT GGCTTCGGAC АСАТСАДАСС AACAACCTCG AACCXCUTC GAAACGACCA CATATCCTCC TTCTGACCAC 
3601 CCCCACAOCC TTAAAGGTAG ACGCACTTX TXTTGCATC CACXCTCAC ATCTAAACGC TXACGOCCA ACCACCAATC AGGACCCCTC AGAAGACCCC AOCTCGCACG ATCCATCGAG 
3721 ATGGAAGGTC CAACGCACCC AAAACCCTCT AAAGATAAGA C H I U C O f c GGACCTAAtg a t t t t g f t g g g g g t c t t a t t a a g a c t a g a c C t U M * t g g c c a t g c a o a c a g a c a t c c a g 
3841 g e c c t g g a a a a g t o a a t t a j t g e c t t a p a a a a t c e o t g a o c t e c c t c t o t p g g t a g t c t t a o a u a c a g g e g a u c e t a g a t a t t e t g t t c c t a c a g g a u g a g g g c t a t g t g c a g c g 
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ceggcttgag gecaagtaca gttaagcetc ggacatagct gaateagcag aagtttcaag gccactgcca gcagtctoca ggetccccaa tttaccagaa ttcaaccttc cgtcccactt 
aaactaacca atccccacgc ctetcgcttc tgtacgcgcg etttctgeta taaaaaacga gccatcagcc cccacaggeg cgcaagtett tgttgagact tgaccgccgg ggtaccegtg 
tacgaataaa gcctcttgct gtttgeatet gaetegtggt cteggtgetc egtgagcacg gggtcteatc gecgaggaag aoctaetccg ggggtctttc a| 
Fig 4 Nucleotide sequence of the proviral DNA of the variant clone of ST-FeSV Nucleotide sequences 
representing the LTRs are placed in a box Nucleotide sequences encoding the polyprolein are depicted 
in capitals The start of pl5, pl2, p30 and v-fes is indicated by arrows. The termination codons TAA or 
TGA at the ends of the open reading frames for the polyproteins of the vanant and prototype clone of 
ST-FeSV are represented by β and by -Cr, respectively The end of v-fes is indicated by • 
1980a). This is now confirmed by comparative nucleotide sequence analysis of the 
truncated gag-genes in both viral genomes (Hampe et al., 1982; Fig. 4). It is 
furthermore evident from the observation that the same portion of the feline c-fes 
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Fig 5 Schematic represtnialion of the major geneut différences in the proviral DNAs of the variant and 
prototype clone of SI FcSV The heavy bars represent the ν /is sequences LTRs are depicted as open 
boxes Start and stop codons of the sequences encoding the polyproteins are marked bv ATG and ТАЛ 
for the variant clone and ATG and TGA for the prototspc clone ol ST f-eSV I he shaded bar in the 
variant clone represents the extension of the poKprotem encoding sequences Lines connecting the two 
viral DNAs indicate deletions or insertions 
proto-oncogene is present in the two clones However, there are also a number of 
genetic differences between the prototype and variant clone The most interesting 
one is the frameshift point mutation that extends the open reading frame of the 
variant viral oncogene with 468 bp The termination codon for the variant clone is 
TAA at position 3776-3778 (Fig 4) The additional 468 bp DNA region is of FeLV 
helper virus origin Apparently, covaient linkage of the translation product of these 
sequences to the protein kinase domain in the polyprolein does not influence the 
transforming potential of the variant clone It is possible that the extended carboxy 
terminal portion does not affect the tvrosme-specific protein kinase activity of the 
polyprotein, which activity is necessary for maintenance of the transformed state 
(Reynolds et a l , 1981) However, it is also possible that the carboxy terminal 
extension is cleaved off during post-translational processing of the polyprotein 
resulting in the generation of P85 as in the prototvpe clone As can be seen in Fig 1 
(lane 5), a pl5-containing protein of 85 kDa can be observed in transformed cells 
expressing P104, suggesting that such cleavage indeed might occur Whether or not 
P104 is a transforming polyprotein remains to be solved 
In addition to the frameshift point mutation the two clones differed from each 
other with respect to a number of other point mutations As far as viral oncogene 
sequences are concerned, these point mutations included one substitution in the pl5 
encoding sequence, three in that encoding pl2 two m that encoding p30 and four in 
the fe% sequence Seven of these mutations led to amino acid substitutions in the 
polyprotein Also the LTRs of the two clones and the helper virus-derived DNA 
regions downstream of the oncogenes appeared different The difference found in 
the LTRs appeared to constitute a stretch of 71 nucleotides in the U3 region, from 
nucleotide position 58 to 134 (Figs 4 and 5) The insert appeared to contain repeats 
as found in the LTRs of FeLV isolates (Nunberg et a l , 1984) Apparently, this 
stretch does not contain control elements vital for the expression of the viral 
oncogene 
In the helper virus sequences downstream of the oncogene, each clone had a 
typical deletion The variant clone missed 1420 nucleotides including sequences 
encoding FeLV gp70 and a small amino terminal portion of p l5E The FeLV 
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genome sequences were flanked by the same seven nucleotides and, therefore, 
deletion of the FeLV sequences could have occurred during a recombination event 
involving these seven nucleotides. From the proviral DNA of the prototype ST-FeSV 
clone, 121 nucleotides encoding the amino terminal portion of pl5E were deleted. 
All deletions appeared to be located in DNA areas not vital for the induction of 
malignant transformation or helper virus supported replication of the virus. Dele­
tions in genetic regions of acutely transforming RNA tumor viruses that are not 
essential for replication or transformation are frequently observed. 
A question that is not resolved by this study pertains to the way in which the 
prototype and variant clone of ST-FeSV were generated. As an early event in the 
generation of acutely transforming RNA tumor viruses, integration of the proviral 
DNA of a helper virus in the vicinity of a proto-oncogene is proposed. For the two 
cases discussed here, this would mean integration of FeLV proviruses close to c-fes 
of the cat. The possibility that the original fibrosarcoma arose as the result of the 
integration of two different FeLV proviruses (because of the different LTRs) close 
to c-fes is unlikely. We, therefore, hypothesize that both clones resulted from the 
same proviral insertion. Thereafter, two alternative routes can be considered to 
explain the genetic differences of the two clones. Either the two clones were 
generated by independent but very similar recombination events between viral and 
feline c-fes genetic sequences, maybe followed by secondary genetic modifications, 
or they are progenitors from the same ancestral recombination virus that arose in 
the primary fibrosarcoma of the cat (Snyder and Theilen, 1969). In the latter case, 
the differences between the two clones would be explained only by secondary 
genetic modifications. 
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SUMMARY 
The feline c-fes proto-oncogene, different parts of which were captured in feline leukemia virus (FeLV) to 
generate the iransforming genes (v-feï) of the Gardner-Am stein (GA) strain of feline sarcoma virus (FeSV) 
and the Snyder-Theilen strain (ST) of FeSV, was cloned and its genetic organization determined. Southern 
blot analysis revealed that the c-fes genetic sequences were distributed discontinuously and colmearly with the 
v-fes transforming gene over a DNA region of around 12.0 kb. Using cloned c-fes sequences, complementation 
of GA-FeSV transforming activity was studied. Upon replacement of the 3' half of v-fes0* with homologous 
feline c-fes sequences and transfection of the chimeric gene, morphological transformation was observed. 
Immunoprecipitation analysis of these transformed cells revealed expression of high Afr fusion proteins. 
Phosphorylation of these proteins was observed in an in vitro protein kinase assay, and tyrosine residues 
appeared to be involved as acceptor amino acid. 
Theilen, 1969), appear to have captured genetic 
sequences from the same feline proto-oncogene 
(Frankel et al., 1979; Hampe et al, 1982; Groiïen 
et al., 1983b). The genetic locus involved is called 
c-fes (Frankel et al., 1979; Franchini étal., 1981). 
Nucleotide sequence analysis indicates that the two 
proviral genomes contain common as well as unique 
c-fes genetic sequences (Hampe et al., 1982). Both 
virus isolates encode as their major translational 
products high Mr polyproteins (Khan et al., 1978; 
SheiT et al., 1978). Serological and tryptic-peptide 
analyses have indicated that they are related and 
consist of FeLV gag-gene-encoded structural pro-
teins fused to nonstructural components encoded by 
INTRODUCTION 
Two independent isolates of FeSV, GA-FeSV 
(Gardner et al., 1970) and ST-FeSV (Snyder and 
* To whom correspondence and reprint requests should be 
addressed 
Abbreviations bp, base pairs, FeLV. feline leukemia virus, 
FeSV, fclmc sarcoma virus, GA-FeSV, Gardner*Amstem strain 
of FeSV, kb, kilobase(5) or kilobase pair(s), nt, nucleotide(5), 
PAGE. Polyacrylamide gel electrophoresis, SDS, sodium dode-
cyl sulphate, S,. left 0 5-kb Psll-Psli, S,. right 0 5-kb ft/l-ftrl 
DNA fragmenl of v-foS T , SSC. 0 15 M NaCl, 0015 M Na, ci-
trate, pH 7-8, ST-FeSV, Snvder-Theilen stram of FeSV 
0378-1119/8S/S03 30 Θ 1985 Elsevier Science Publishers 
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the newly acquired cellular genetic sequences (Rus-
celli et al ,1980, Van de Ven et al, 1980a, Barbacid 
et al, 1981) Both polyproteins exhibit tyrosine-
specific protein kinase activity (Van de Ven et dl, 
1980b, Barbacid cl al, 1980a) and from analysis of 
transformalion-defcctivc mutants, it appeared that 
this enzyme activity is required for malignant trans-
formation (Donner et al, 1980, Reynolds et al, 
1981 ) The carboxyl portions of the viral polvproleins 
resemble tyrosine-specific protein kinases encoded 
by other retrovirus isolates as well as the catalytic 
chain of the mammalian cyclic 3 , S -adenosine 
monophosphatc-dependent protein kinase (Groffen 
et al, 1983a) Tyrosine-phosphor>lation ol the poly-
proteins themselves has been reported (Van de Ven 
etal , 1980b, Barbacid étal , 1980a), for the 
ST-FeSV gene product, this seems to be limited to 
a single tyrosine acceptor site (Blomberg et al, 
1981) An Mr 92000 cellular protein has been identi-
fied m cells of cats and related mammals as the 
putative c-fes translational product (Barbacid et al, 
1980b) It is likely that this protein has some 
functional characteristics in common with the v-fet 
polyproteins However, its precise structure and role 
under normal physiological conditions is still un-
known 
To study directly the differences between the two 
transforming v-fes oncogenes and their immediate 
progenitor gene, the normal (non-transforming) fe-
line c-fes proto-oncogene, we have cloned all v/es-
homologous sequences in the cat genome and pres-
ent some of their biological and biochemical charac-
teristics 
MATFRIAI S AND MFTHODS 
(a) Cells 
Cells were grown in Dulbecco's modification of 
Eagle's medium supplemented with 10"o calf scrum 
(GIBCO) Cell lines used have been previousK 
desenbed and included a highly contact-inhibited 
mink lung cell line, CCI64 (Henderson et al, 1974), 
a mink cell line nonproductively transformed bv 
GA-FeSV, 64F3 (Sherr etal , 1978), rat-2 cells 
(Topp, 1981), and the feline fibroblast cell line AZ 
(kindly provided by A V Lauver) 
(b) Gel electrophoresis and hybridization 
Restriction endonucleases were purchased from 
cither Boehnngcr or Belhesda Research Labora-
iones (BRL) Analysis of restriction endonucleasc-
digesled DN^ was essentially as described by 
Southern (1975) using molecular probes nick-trans-
lated lo specific activities of about 2-5 χ 10" cpm/fig, 
according to the method of Rigby etal (1977) 
Hybridization experiments were routinely performed 
at 42 С for appropriate periods of time in a 20 mM 
sodium phosphate buffer (pH 7 0) containing 5 mM 
LDTA, 50°
o
 formamidc, 5 χ SSC (0 15 M NaCl, 
0 015 M Na, citrate, pH 7-8), 1 χ Denhardt's 
solution (0 2 mg ml Ficoll, 0 2 mg ml poly vim 1-
pvrrohdone, 0 2 mg ml bovine serum albumin), 
100 /ig ml denatured salmon testes DNA and 
0 2-1 χ К Г с р т т І nick-translated DNA Upon 
hybridization, filters were washed as described 
(Jones et al, 1980) using 0 1 χ SSC at 65 С in the 
final step and dried, autoradiography was performed 
by exposing XAR-2 film (Kodak) for up to four days 
at -70 С with Dupont Lightning Plus intensifying 
screens 
(c) Preparation of DNA probes 
I he S, and the S
r
 probes, each representing an 
0 5 kb Pvl-Pul DNA fragment of v-/eçST, were 
obtained from С J Sherr (Franchini et al, 1981) A 
human t-fes probe, РР0 1, representing genetic se­
quences homologous to GA-FeSV v-fes (nt 
posilion 1111 to 1227, Hampe el al, 1982) and sub-
cloned in MllmpS (Messingand Vieira, 1982), was 
used as an independent 5 -specific/ev probe (A J M 
Roebrock, unpublished data) Other molecular 
probes homologous to ν fes were prepared from 
pHHl, a recombinant clone of pBR322 containing 
the I4 4kb ftoRl DNA insert of /GA-PeSV 
(Fedele et al, 1981) ASO 6 is an 0 6-kb Aval-Sail 
DNA fragment, BS 1 8 is a 1 8-kb Bglll-Sall DNA 
fragment, PA0 3 is an 0 3-kb Pvull-Aval DNA 
fragment and RR0 5 is an 0 5-kb Rsa\-Rsa\ DNA 
fragment isolated from GA-FcSV proviral DNA (see 
Fig 1) Upon digestion of DNA with appropnate 
restriction endonucleases, DNA probes were puri­
fied by electrophoresis through low-melting-point 
agarose (BRL) as described (Weislander, 1979) 
72 
(d) Construction of genomic libraries and selection 
of recombinant clones 
To construct a feline gene library of phage recom­
binants, punficd £coRI cellular DNA fragments of 
about 12 kb were ligated to purified EcoRl vector 
arms of / Charon 4A Ligation products were pack­
aged in vitro into phage particles (Hohn, 1979), 
yielding 2 5 χ 105 plaque forming units 
Construction of a representative feline genomic 
library in the pJB8 cosmid vector system was per­
formed essentially as desenbed by Ish-Horowicz 
and Burke (1981) Ligated DN As were packaged in 
vitro as described (Hohn, 1979) and propagated in 
E colt 1046 Approx 5 χ IO5 individual colonies 
were plated al a density of about 2 0 χ IO4 colo­
nies/plate (plate diameter IS cm) 
For isolation of recombinant clones containing 
v-yèi-homologous cellular sequences, replica filters 
of both the recombinant bacteriophage and cosmid 
libraries were screened as desenbed (Benton and 
Davis, 1977, Hanahan and Meselson, 1980) For 
screening of the bactenophage recombinants a com-
bination of two v-/ei-specific probes, S, and Sr, was 
used In the screening of the cosmid library an 0 7-kb 
£coRI-№ndIII DNA fragment isolated from pA089 
and representing a unique S DNA sequence of the 
insert ofpSVJ (Fig 2) was included as an additional 
probe (probe EHO 7) 
Analytical and preparative isolation of cosmid 
DNA from selected clones was performed according 
to a combination of the alkaline lysis procedure of 
Bimboim and Dolv (1979) and the procedure de­
scribed by Davis et al (1979) 
RESULTS 
(a) Identification of feline v-/"eî-homologous genetic 
sequences 
To study v-/ei-homologous genetic sequences 
within the cat genome, five subgenomic v-fes restric-
tion fragments were used as molecular probes S,, Sr, 
ASO 6, PAO 3 (GA-FeSV v-fes, 5 -specific) and 
RRO 5 (GA-FeSV v-fes, 3 -specific) (Fig 1) Probes 
were punfied and tested for contaminating FeLV-
denved genetic sequences, since the genome of the 
domestic cat (cat No 031182) used in this study 
contained multiple FeLV related sequences (Fig 1 A, 
lane a) None of the probes revealed hybndizalion 
with FeLV sequences in AHF60 (Mullrns et al, 
1981) (not shown) In Fig 1A, the analysis of 
high-Mr human and cat cellular DNA digested with 
restriction endonuclease £coRI is shown A single 
human EcoRl restriction fragment of about 12 kb 
(Fig 1A, lane b), which had been shown before to 
contain all human v-/ei-homologous sequences 
(Groffen et al, 1982, Franchini étal , 1982), was 
clearly detected by a combination of all five probes, 
indicating the specificity of the molecular probes 
Similarly, strongly hybridizing bands of about 14 and 
12 kb were detected in genomic DNA isolated from 
feline lung tissue (cat No 031182) (Fig 1A, lanec) 
Only the 12-kb fco RI DNA fragment appeared to 
hybridize with the 3 -specific fes probe RRO 5 
(Fig 1A, lane d) and only the 14-kb £coRI DNA 
fragment with the 5 -specific probe PAO 3 (Fig 1A, 
lane e) Similar observations were made in an analy-
sis of genomic DNA isolated from a feline fibroblast 
cell Ime (AZ) (not shown) These data show that all 
v-yëj-homologous sequences within the cat genome 
are distributed over two £coRI DNA fragments 
These observations imply, furthermore, the existence 
of only a single feline c-fes locus 
(b) Molecular cloning of feline c-fes proto-oncogene 
sequences 
For the molecular cloning of the feline c-fes 
sequences, high-jWr AZ DNA was digested with 
restriction endonuclease EcoRl and fractionated by 
agarose gel electrophoresis Selected DNA fractions 
were ligated to an equivalent amount of / Charon 4A 
fcoRI vector arms Multiple c-/ej-contaming re-
combinant bacteriophages were identified upon ini-
tial screening of about 2 S χ 10s plaques with a 
mixture of the S, and S
r
 probes Five plaques were 
selected for further analysis after their inserts had 
been subcloned in pBR322 Restriction endonucle­
ase analysis indicated that the feline DNA inserts in 
these five subclones were all different (not shown) 
Only one of them, designated pSV3, appeared to 
contain a 12-kb DNA insert as delected in genomic 
blot analysis (not shown) 
Nucleotide sequence analysis of the 5 end of the 
DNA insert of pSV3 revealed the presence of a 
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Flg. 1. Identification of -ует sequences by Southern blots (A) Identification ofv/eï-homologous genetic sequences in feline DNA High-
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 DNA was prepared from lung tissue of a domestic cat (No 031182) (lanes a. c, d and e), or normal human liver (lane b). digested 
with EcoRI and electrophorcsed through an 0 8 0 0 agarose gel After transfer of DNA to nitrocellulose, filters were hybridized with 
nick-translated FeLV proviral DNA (lane a) or a combination of subgenomic \-fes probes (lanes b, c, d and e) DNA probes included 
ASO 6, PAG 3, RRO 5. S,, and S
r
, as schematically indicated below the autoradiogram The upper map is the GA-FeSV proviral genome 
Open boxes represent the long terminal repeats, and the solid bar represents \-festJA The lower map is the ST-FeSV proviral genome. 
sizes and positions of the S, and S
r
 probes are indicated (B)£Í - Í )RI restriction pattern of DNA isolated from cosmid clones cosi, cos3. 
cos5 and cos6 and recombinant plasmid pSV3 (lanes a-e, respectively) obtained upon electrophoresis through an 0 80o agarose gel and 
visualization by hybridization with a mixture of the individual clones as probes The positions of Λ/
Γ
 markers are indicated with arrows 
m panel В and include //indlll-digested 1 DNA and HaelU-aigeslcd фХП4 DNA fragments (С) Autoradiogram of fcoRI restriction 
pattern shown in panel В upon hybridization with the same combination of subgenomic v-fes probes as described under section A A. 
Aval. Bg, Bglll. P. Psl\. Pv. PvuU, R. Rsal, Sa, Sail 
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v-/ej-homologous region of about 100 ni flanked by 
consensus splice-site sequences (A J M R , unpub­
lished observation) This putative feline c-fes exon 
corresponds to coding sequences in GA-PeSV pro-
viral DNA from nucleotide position 1447 to 1543, as 
numbered by Hampe et al (1982) Most of the 400 
5 -/е5с'А-5ресіГіс nt upstream of nt position 1447 
are apparently missing in the 12-kb £coRI DNA 
fragment and are probably represented in the 14 kb 
fragment Because of the major rearrangements 
observed in most of the DNA clones, the /Charon 
4A library was not screened with a 5 -specific \-fes 
probe to isolate the 14-kb fco RI DNA fragment and 
an alternative approach was chosen for the mole-
cular cloning of the feline z-fes locus 
To facilitate the isolation of all v-/M-homologous 
sequences in a single recombinant clone, the pJB8 
cosmid vector system (Ish-Horowicz and Burke, 
1981 ) was applied for the construction of a represent-
ative feline gene library propagated in E coli 1046 
For the preparation of DNA inserts of 35-45 kb, 
high-Mr DN A isolated from lung tissue of a domestic 
cat (cat No 031182) was used Identification of 
cosmid clones with v-/ei-homologous DNA inserts 
was performed with a combination of the S„ Sr and 
ЕН0 7 probe Upon screening of approximately 
5 χ 105 colonies, four cosmid clones, designated cos 
1, 3, 5 and 6, were identified and purified further for 
restriction analysis £coRI digestion of the recom­
binant pJB8 cosmid clones resulted in excision of the 
DNA inserts and thus provided estimates of their 
sizes Such digestion of the four cosmid clones 
followed by agarose gel electrophoresis resolved 
multiple fco RI restriction fragments in all four 
clones, and the sizes of the various DNA inserts 
were estimated to lie between 33 and 47 kb (Fig IB) 
Further characterization of the DNA inserts in the 
cosmid clones was performed by hybridization anal­
ysis None of the cosmid clones exhibited any 
homology with the FeLV proviral DNA isolated 
from /ΉΡόΟ (not shown) Using the complete 
GA-FeSV proviral genome as a probe, two hybrid­
izing bands of 14 and 11 kb were observed in cosmid 
cosi (Fig 1С, lane a) Cosmid cos3 contained hy­
bridizing bands of 14 and 4 kb, cos5 of 12 and 3 kb, 
and cos6 of 14 and 12 kb (Fig 1С, lanes b-d) 
Restriction maps of the inserts were generated and 
the v-Zei-homologous genetic sequences within the 
clones were localized using the DNA probes indi­
cated in Figs 1 and 2 (hybridization data not 
shown) As summarized in Fig 2, the recombinant 
phage and the four cosmid clones contain over­
lapping cellular genetic sequences corresponding to 
a single contiguous region of cat cellular DNA of 
about 70 kb The feline c-fes sequences are distri­
buted over a DNA region of about 12 0 kb and, in 
this respect, resemble the human c-fes locus Within 
the latter region, at least two DNA stretches of 
nonhomology were identified and these probably 
include intervening sequences It appeared that the 
14-kb fcoRI fragment contained only GA-FeSV-
specific sequences (not shown) Further analysis of 
the 12 0-kb DNA region with subgenomic \-fes 
probes revealed that the cloned DNA region of the 
cat contains the complete ν-fes homolog in an orien­
tation colinear with the viral oncogene (Fig 2) 
(c) Construction of a chimeric gene and transfection 
analysis 
To determine whether or not the cloned feline c-fes 
sequences can functionally complement the v-/eç 
oncogene, a recombinant between the c-fes locus and 
the GA-FeSV provirus was constructed A Salì 
cleavage site located in the middle of the x-fes gene 
of GA-FeSV was selected for use in an experiment 
to replace a major portion of the viral protein kinase 
domain, including the tyrosine phosphorylation site, 
with the putative cellular protein kinase domain 
(Hampe et al, 1982, Groffen et al, 1983a) Con-
struction of the chimeric gene in pAOSO is outlined 
in Fig 3 and its genetic organization was confirmed 
by restriction endonuclcasc analysis 
The chimeric gene was transfected (Graham and 
Van der Eb, 1973, Wigler et al, 1978) into rat-2 cells 
to test its transforming capacity As a positive 
control, the insert of pHHl (i e , the integrated DNA 
provirus of GA-FeSV subcloned in pBR322) was 
used Transfection of recombinant plasmids pA021 
and pA028, which contain \-fes or c-fes DNA 
fragments, did not result in morphological trans-
formation of rat-2 cells Neither were foci induced 
when pSV3 was transfected However, recombinant 
plasmid pAOSO, which contains the 5 half of the 
GA-FeSV genome fused to the 3 half of the feline 
c-fes DNA region, was able to induce foci in ral-2 
cells An efficiency tenfold lower than that observed 
upon transfection of the GA-FeSV provirus was 
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Fig 2 Restriction map o f the feline с fes region In Ihc cerner of ihc figure ι schemain. restriction map of the 20 kb ïimàYW £tí>RI 
fragment that contains the feline сугт gene is depicted Above ihc restriction map black segments on a solid line indicated the relative 
positions of the ν fes homologous regions w n h m this 20 kb f rd imeni At ihc top of Ihc ligure restriction fragments of the feline с fes 
locus that h\bndize to the complete G A FeSV provi la] genome ppO l BS I 8 Sj and S, are indicated The position of the 20 kb 
tfmdlll £ a ) R I fragment wnhm a 70 kb contiguous sequence of feline D N A is indicated by the dashed lines The organi7ation of this 
70 kb sequence was deduced as a composite of individually m ippcd ovcrl ipping feline sequences represented within p S V I and the four 
cosmid clones The 0 7 kb probe I HO 7 indicated on the map serves also is the scale for the map В Bam\\\ Bg fl^/II Ï f a i R I 
H / / i n d i l i К Kpn\ S S a d Sa Sa/1 Xb \ 6 i i l X Kho\ I he restriction т а р ol the 70 kb sequence is incomplete as far as the EcoRl 
and / / i / i d l l l sites are concerned as indicated bv (E-) and (M) svmbols 
repeatedly found From two independent trans-
fection experiments, transformed clonal cell lines. 
designated R2-AO50-C11-1 and R2-AOi()-C12-l. 
were obtained upon selection of single cells in micto-
tiler plates Cells of these clones exhibited anchorage-
independent growth in soft agar Southern blot 
analysis of DNA isolated from one such clone. 
R2-AO50-C12-1, revealed h\bndizdtion pattern ь 
that could be expected from integration of the intact 
DNA insert of pAO50 (Fig 3B) Furthermore, 
hybridization signals indicated the presence of multi­
ple copies of pAO50 These transfeclion data indi­
cate the possibility that the chimeric gene m рЛОМ) 
has transforming potential and that the 3 hall ol the 
normal feline c-/et locus encodes functional protein 
kinase components Similar results were reported for 
the human z-fes proto-oncogene (Sodrowski et al 
1984) 
(dl Immunoprecipitation analysis of translational 
producl(s) encoded by the chimeric gene and in vitro 
protein kinase activity 
Ίο identify and characterize translational pro­
duces) encoded by the chimeric gene, a total lysate 
from R2-AO50-C12-l cells was analyzed by im­
munoprecipitation (Van de Ven et al, 1980a) 
(Fig 4) Anticipating that the chimeric gene would 
code for fusion proteins that contain both FeLV 
çuif-gene related and /ev-specific antigenic deter-
minants, conventional antisera prepared against 
Fcl V pl5 and GA FeSV PI 10 and a monoclonal 
antiserum prepared against GA-FeSV PI 10 (Ve-
ronese et al, 1982) were included With all three 
antisera, proteins were precipitated with migration 
characteristics in SDS-polyacrylamide gels 
(1 aemmli 1970) as expected for GA-FeSV-encoded 
PI 10 (Fig 4) Furthermore, an 80-kDal protein was 
detected (Fig 4, lanec), presumably representing a 
cleavage product of the 110-kDal protein No FeLV-
related proteins were precipitated with control sera 
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Fig. 3. Construction ofachimenc gene and identification of v-/M-homologous sequences Left panel plasmid pHHl, containing a single 
copy of GA-FeSV proviral DNA including mink flanking sequences within a 14 4>kb Eco RI DNA insert (black segment), was digested 
with fcoRI + Sail and the v-/w-containing EcoRhSall DNA fragments were isolated for subclomng Using the onentation of the 
GA-FeSV genome as a reference, only the 5 half of the pHHl insert was subcloned Similarly, only the 3 half of the 12-kb feline c-fes 
insert (open segment) of pSV3 was subcloned pAO50 was constructed as indicated Plasmid pATI53 was used in all cloning experiments 
(not indicated) Right panel identification of v-/ei-homologous sequences in rat-2 cells transformed by pAOSO-denved sequences DNA 
was prepared from R2-AO50-C12-1 cells (lanes a, c, and d) and control rat-2 cells (lane b), digested with EcoRl (lanes a and b), 
EcoRl + Sail (lane e), or fco RI + S a d (lane d) and examined by Southern blot analysis using the complete v-fes oncogene of GA-FeSV 
as a molecular probe As Mt markers a HtndlU digest of Я DNA was used (see right margin) 
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Fig 4 Immunoprecipitalion and SDS-polyacrylamide gel elec­
trophoresis (PAGE) analysis of hlgll-A/f fusion proleins ex­
pressed in ral-2 cells upon transfection of pAO50 Ceil lines 
includingR2-AO50-C12-1 (lanes a,c,d ande),control rat-2cells 
(lanes b, j and k), mink cells nonproductively transformed by 
GA-FeSV (lanes f, g and h) and control CC164 mink cells (lane ι) 
were metabolically labeled by 4 h incubation in [35S]methionine-
containing medium (25 μΟ/πιΙ), and proteins were immuno-
precipitated with antiserum prepared against GA-FeLV PI 10 
(monoclonal Rl 13-263) (lanes a and b), GA-FeSV PI 10 (poly­
valent) (lanes c, f. ι andj), FeLV pl5 (lanes d, g and k)or bovine 
serum albumin (lanes e and h). Immunoprecipitates were anal­
yzed by SDS-PAGE as described in RESULTS, section d M, 
standards include Phosphorylase В (92 5 к Dal), bovine serum 
albumin (68 kDal), ovalbumin (43 kDal), a-chymotrypsinogen 
(25 7kDal), ^-lactoglobuhn (18 4 kDal) and cytochrome! 
(12.3 kDal) (sec left margin). 
or found in extracts prepared from untreated rat-2 
cells. These data demonstrate that the identified 
chimeric gene products are fusion proteins similar in 
structure to the GA-FeSV-encoded polyprotein 
Ρ110, in that they consist of FeLV gag-gene-encoded 
structural proteins and /«-gene-encoded nonstruc­
tural components. In an in vitro protein kinase 
assay, the chimeric gene products were shown to 
possess such activity (Fig. 5). Phosphoammo acid 
analysis revealed that tyrosine residues were phos-
phorylated (not shown). Comparable results have 
been reported by Sodrowski et al. (1984) with chi­
meric constructs of the human c-jes proto-oncogene 
and the GA-FeSV viral oncogene. 
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Fig 5 Analysis of protein kinase activity associated with fusion 
proteins expressed in rat-2 cells morphologically transformed 
upon transfection of pAO50 Immunoprecipitates were prepared 
from extracts of GA-FeSV-transformed mink cells (lanes a-c), 
CC164 control mink cells (laned), R2-AO50-C12-1 cells 
(lanes e-h) and control rat-2 cells (lane ι) using antiserum pre­
pared against FeLV virion proteins (lanes a, d, e and i), 
GA-FeSV PI 10 (polyvalent) (lanes b and 0. FeLV pi5 (laneg) 
or bovine serum albumin (lanes с and h) Using [/-,2P]ATP as 
substrate, immunoprecipitates were assayed for phosphotrans­
ferase activity and analyzed by SDS-PAGE Μ
τ
 standards are as 
described m the legend to Fig 4 
DISCUSSION 
The isolation and characterization of feline c-fes 
proto-oncogene sequences is described in this report. 
Genomic blot analysis indicated that the feline 
genome contains a single c-fes proto-oncogene. Its 
isolation was accomplished by construction of two 
different gene libraries. One library consisting of 
recombinant λ phages was instrumental in resolving 
the genetic organization of a major portion of the 
locus. The genetic organization of the complete 
v-/éj-homologous region was finally resolved by 
analysis of recombinant clones from a cosmid gene 
library. A contiguous region of feline genomic se-
quences of 70 kb was isolated and shown to contain 
ali v-^éí-homologous genetic sequences detected in 
genomic blot analysis. The c-fes sequences were 
found to be distributed discontinuously over a 
12.0-kb region, and colinearity with the v-/« onco-
78 
gene was established Nucleotide sequence analysis 
indicates the presence of extensive noncoding or 
intervening sequences in the feline c-fes locus 
(A J M R , unpublished observations) With respect 
to these characteristics, the feline locus closely resem-
bles the previously described human c-fes proto-
oncogene (GrofTen et al, 1982, Franchini étal, 
1982) The precise size of the feline z-fes coding 
sequences remains to be determined Based upon the 
complexity of\-fesc'A and v-fessr, this size is at least 
1 95 kb (Hampe et al, 1982) However, sequence 
analysis of the human and feline c-fes locus indicates 
that some c-fes coding sequences have not been 
captured in either of the viral oncogenes Such se-
quences have been found between the DNA regions 
that are homologous to the ν-/βίΟΑ and the v-fesST 
unique sequences and at the very 5 ends of the 
human and feline c-fes loci (A J M R , unpublished 
observation) Furthermore, the fps oncogene of 
Fujinami sarcoma virus, which represents the avian 
vanant of GA- and ST-FeSV, has a complexity of 
approx 2 6 kb (Shibuya and Hanafusa, 1982) and 
the size of c/ej-specific mRNA detected in human 
acute myelogenous leukemia has also been reported 
to be 2 6 kb (Slamon et al, 1984) 
The availability of cloned feline c-fes proto-onco­
gene sequences provided the opportunity to study 
characteristics of its translalional product In an 
initial approach, the possibility was tested whether 
or not c-fes genetic sequences could functionally 
complement the protein kinase activity of the viral 
oncogene product Therefore, a chimeric gene was 
constructed in which v-fes sequences encoding a 
major portion of the kinase domain were replaced by 
feline c-fes genetic sequences Transfection experi­
ments indicated that this chimeric gene in pAOSO 
had oncogenic potential Transfected cells exhibited 
a transformed phenotype, grew in soft agar and 
expressed a tyrosine-specific protein kinase activity 
associated with the high-M
r
 fusion protein These 
results demonstrate that the carboxyl half of the 
GA FeSV-transformmg protein can be functionally 
complemented by feline c-fes protein components 
The observation that the fusion protein encoded by 
the chimeric gene is not only functionally but also 
structurally highly similar to GA-FcSV PI 10 sug­
gests that all coding sequences present in that 3 part 
of feline c-fe* have been captured in GA-FeSV 
These feline cellular sequences apparently encode a 
protein component of approx 33 kDal, and they 
presumably represent about one-third (carboxyl 
portion) of the norma] cellular protein desenbed by 
Barbacid eta] (1980b) However, the possibility 
cannot be excluded that deletion of some of the 
c-yès-coding sequence is necessary to allow malig-
nant transformation, as has been desenbed for the 
fos oncogene (Miller et al, 1984) In that case, the 
same genetic sequences can be expected to be deleted 
from the viral as well as the newly constructed 
chimenc oncogene Transfection data, however, are 
not strongly in favor of this possibility They rather 
support the hypothesis that preservation of the 
3 -proximal sequences that encode the protein 
kinase domain is a prerequisite for the malignant 
potential of the locus (Sodrowski et al, 1984) This 
is in contrast to particular genetic sequences farther 
upstream in the feline c-fes locus whose presence 
does not seem to be essential for induction of trans-
formation, since both v-fesc'* and \-fesST contain 
unique oncogene-speciTic sequences at their S ends 
Furthermore, protein components of approx 
25 kDal present m the 92-kDal normal c-fes cellular 
protein seem to be missing m the viral transforming 
proteins (Barbacid et al, 1980b, Hampe étal , 
1982) The role of this NH2-terTmna] portion of the 
fes polypeptide is not yet clear However, studies on 
the v-fps gene, which contains a major portion of the 
avian cellular homolog, may provide some clues 
Expenments by Foster and Hanafusa (1983) have 
indicated that without the gag gene sequences, the 
viral fps gene can still transform cells in culture and 
induce tumors in chickens Protein analysis indicates 
that in the generation of Ihefps viral oncogene some 
of the 5 c-fpf sequences were not captured and were 
replaced by gag sequences, resulting in the removal 
of potential cellular regulatory elements and estab-
lishing viral control over the expression of the gene 
Insertion mutagenesis has identified functional 
regions in the 5 portion of the transforming gene 
(Stone et al, 1984) It is possible that the NH2-
termmal part of the protein is not only involved in 
regulatory functions but also in substrate recognition 
or in positioning of the protein in a particular cellular 
compartment Further studies with the molecularly 
cloned c-fes proto-oncogene should define the 
functional domains of the feline c-fes translational 
product both in its normal form and after the malig-
nant conversion of this gene 
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I. Introduction 
A The frns transducing viruses 
The fms oncogene has been identified in two independent FeSV isolates with very 
similar genomic organization SM-FeSV (Susan McDonough strain (1) and HZ5 (Hardy-
Zuckermann strain 5) (2) These С type replication defective transforming retroviruses 
were isolated from spontaneously occurring fibrosarcomas in the domestic cat Cell-
free filtrates of the original neoplasms could induce fibrosarcomas in kittens In tissue 
culture SM-FeSV induces morphological transformation not only m NIH-3T3 cells but 
also in NRK cells, mink lung epithelial cells and feline embryo fibroblasts (3, 4, 5, 6) In 
standard DNA transfection assays the molecularly cloned v-fms oncogene is biologically 
active as a transforming gene (3) In both SM-FeSV and HZ5 the same gag sequences 
are fused to 5' sequences of the original cellular fms proto-oncogene of the cat, 
suggesting that recombination between FeSV and c-frns may have been facilitated by 
short regions of homology between the viral gag and the 5 part of the cellular gene 
As a result the primary translation product of the viruses is a fusion polyprotem with a 
gag-coded ammo terminal part (7) 
В The cellular homolog c-frns 
The feline, and human cellular homologs of v-frns have been molecularly cloned 
(8, 9, 10, 11) The human, mouse and feline cDNA sequence and the primary structure 
of the complete coding region of the human gene have been determined (7, 12, 13, 14) 
The fms coding sequences that map to the long arm of human chromosome 5 at band 
q33 2-q33 3 are arranged in 21 small exons dispersed over 34 kb of genomic DNA (7, 
9, 15, 16) A non-coding exon is located 26 kb upstream of the protein coding 
sequences (7) The 3' end of the PDGF receptor gene is located less than 0 5 kb 
upstream from this exon Similarities in chromosomal localization, organization, and 
encoded ammo acid sequences suggest that the genes encoding the CSF-1 and PDGF 
receptors arose through duplication (17) 
The putative initiation codon falls within a Kozak consensus sequence for the 
initiation of translation located 102 nucleotides downstream from the corresponding 
FeLV recombination site of the feline locus Thus at the gag-fms junction the viral fusion 
polyprotem contains 34 feline c-fms derived ammo acids that are not normally translated 
from the proto-oncogene mRNA The distal 40 ammo acids of the normal human c-fms 
product are unrelated to the last eleven residues in the truncated carboxyl terminus of 
the SM-FeSV transforming protein (12, 18) In SM FeSV v-frns a 554 bp deletion of the 
original feline c-fms sequences has removed the last 50 codons of feline c-fms and 
allows the open reading frame to continue into 3' untranslated sequences until it 
terminates 11 codons later (7) The v-frns gene of HZ5 has lost only the last 24 ammo 
acids present in c-fms and has replaced them with 2 novel residues (2) This extreme 
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C-terminus is strictly conserved between man, mouse and cat implying a consen/ed 
function for this domain A single tyrosine residue (Y969 in man), four residues away 
from the carboxyl terminus, may represent a negative regulatory site of phosphorylation 
in the normal c-fms gene product The proteins encoded by the SM-FeSV v-frns and 
feline c-fms differ by 9 dispersed ammo acid substitutions (12, 14) 
С The fms related gene products 
The primary translation product of the full-sized genomic 8 2 kb SM-FeSV RNA is 
a 170 kDa protein in which 536 ammo terminal gag coded residues are fused to 975 
carboxyl terminal v-fms coded ammo acids The 536 gag residues consist of a 77 ammo 
acids leader sequence that includes a 20 residues long hydrophobic signal for 
membrane insertion and the complete sequences of the individual gag proteins p15, p12 
and p30 and the first fourteen ammo acids of gag protein p10 The fms coded part 
consists of a 34 residues long ammo terminal segment, that is not translated from c-
fms mRNA, followed by a hydrophobic stretch corresponding to the amino-termmal 
hydrophobic sequence of the с fms gene product (12, 19) In about the middle, the fms 
coded part contains a 26 ammo acid transmembrane segment on the ammotermmal 
side of the kinase domain The primary translation product undergoes complex со- and 
post-translational processing during cellular transport (7, 20, 21) The following model 
is proposed (21) The nascent polypeptide, synthesized on membrane bound 
polyribosomes, is co-translationally translocated into the lumen of the rough 
endoplasmatic reticulum until the second hydrophobic segment of 26 ammo acids stops 
the transfer and anchors the polyprotem in the membrane, thus orienting the distal 406 
residues long carboxyl-termmal segment in the cytoplasm In the mean time, the 11 
canonical sites for the addition of asparagme (N) linked oligosaccharides, that are 
clustered in the v-fms sequence on the ammo terminal side of the transmembrane 
segment, are accessible to glycosyl transferases within the lumen of the endoplasmatic 
reticulum This results m a 180 kDa glycosylated polyprotem This gP1 BOgag-fms is post-
translationally cleaved at a site near the gag fms junction to yield a free unglycosylated 
55 kDa fragment and a membrane bound 120 kDa glycoprotein The p55 gag peptide 
includes the 34 residues encoded by the 5' untranslated region of the c-fms mRNA and 
the 19 ammo acids of the fms coded hydrophobic signal sequence Thus this model 
predicts that the processed v-fms and c-fms gene products have identical ammo termini 
During the transport through the Golgi complex to the plasma membrane the N-lmked 
carbohydrate chains of gP120v fms are processed to complex type oligosaccharides, 
which results in a mature cell-surface form of the glycoprotein of 140 kDa (20, 22, 23, 
24, 25) 
The v-fms gene products possess tyrosine kinase activity and are capable of 
phosphorylatmg themselves and exogenously added substrates The tyrosine specific 
phosphorylation levels are low in the v-fms transformed tissue culture cells (26, 27, 28, 
29, 30) Both cell surface expression and kinase activity are required for transformation 
(27, 31, 32, 33, 34) 
The human, murine and feline c-fms loci code for mature glycoproteins of 
respectively 150, 165 and 170 kDa The variation in size of the c-fms products in 
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different species may be do, at least in part, to differences in the pattern and extents 
of glycosylation (7) They also have an associated tyrosme-specific protein kinase 
activity (35) 
Both the mature v-frns and the c-fms encoded proteins contain four distinct 
domains an extracellular (ligand binding) domain, a hydrophobic 26 residue membrane-
spanning sequence, a cytoplasmic domain possessing tyrosine kinase activity, and a 
C-termmal tail TTie structure resembles that of several growth factor receptors like the 
EGF (epidermal growth factor) receptor In about the middle of the kinase domain a 
long stretch of approximately 70 residues is located that is not present in most other 
kinases The proteins encoded by the kit, ret and PDGF receptor genes contain 
analogous but not identical inserts (36, 37) 
The v-frns-encoded glycoprotein differs from its cellular counterpart in the following 
properties 
* it is partially blocked in its transport to the cell surface (23) 
* it is constitutivily phosphorylated on tyrosine (28, 29) 
* it induces tyrosine phosphorylation of heterologous proteins in transformed cells in 
the absence of the ligand CSF-1 (Colony stimulating factor 1) (27) 
* it is relatively refractory to down-modulation induced by phorbol esters (38) 
D The proposed functions of the c-frns protein 
Antisera to a recombinant v-frns-coded polypeptide expressed in bacteria precipitate 
the presumptive c-fms product from murine macrophages The 165 kDa glycoprotein is 
the same size as the murine CSF-1 receptor Purified CSF-1 stimulates tyrosme-specific 
phosphorylation of the c-fms gene product of purified membrane fractions from CSF-
1-dependent murine macrophages (21) The ν fms coded glycoprotein specifically binds 
murine CSF-1 (39) Murine c-frns cDNA encodes afunctional CSF-1 receptor (13) NIH-
3T3 cells infected with a recombinant retroviral expression vector that expresses the 
human c-fms protein can form colonies in semisolid medium in response to human 
CSF-1 (40) Co-transfection of vectors expressing c-/ms and CSF-1 genes induces 
transformation of NIH-3T3 cells by an autocrine mechanism Thus, it can be concluded 
that c-fms and the gene that encodes the cell surface receptor for the mononuclear 
phagocyte colony stimulating factor CSF-1 are the same 
While the 4 kb fms transcript (15) is predominantly expressed in normal monocytes 
and macrophages( 29, 35, 41, 42, 43) the fms RNA has also been detected in murine 
and human placenta and in human choriocarcinoma cell lines derived from malignant 
placental trophoblasts (29, 42, 44, 45) In the mouse transcription of the CSF-1 gene 
has been demonstrated in uterine glandular epithelium (46) The levels of uterine CSF-
1 production increases during gestation and are highest at parturition (47) Thus in 
addition to serving as a lineage specific growth factor in hematopoiesis, CSF-1 may 
also play a role in normal trophoblast development during embryogenesis 
The physiologically relevant substrates for the tyrosine specific kinase of the c-fms 
gene product are unknown Cells transformed by v-fms do not show markedly elevated 
levels of phosphotyrosme in total cellular proteins (7) Tyrosine phosphorylated proteins 
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have been detected in a CSF-1 stimulated macrophage cell line (26) and in v-frns 
transformed cells (27) 
Binding of the ligand CSF-1 to the с fms encoded receptor protein stimulates rapidly 
transient expression of the c-fos proto oncogene (4Θ, 49) and stimulates DNA synthesis 
(50) What signal-transduction pathway is involved is unknown Recently was shown that 
v-frns expression increases raM phosphorylation and associated serine/threonme-
specific kinase activity It is unclear whether this activation is direct or indirect (51) 
E The activation of the oncogenic potential of fms 
To determine what genetic alterations are related to the oncogenic activation of 
the fms gene, chimeric constructs between feline and human c-frns and SM-FeSV 
v-frns sequences were made and specific point mutations analyzed (14, 52) 
The transforming ability of the various frns constructs was determined in three 
assays The efficiency of focus formation of the fms gene constructs was tested in 
standard transfection assays The cells that expressed these genes were tested for their 
ability to form colonies in soft agar and to induce tumors in nude mice On the basis 
of the results of these assays the constructs can be placed in an ascending order of 
oncogenicity The normal feline с fms gene and a feline c-frns gene with all point 
mutations found in v-frns do not form foci and do not form colonies in soft agar A 
feline c-frns gene with the C-termmal modification as found in v-frns produced 
transfectants with a partially transformed phenotype that form low numbers of small 
colonies in soft agar but cannot induce tumors in nude mice When the feline c-frns 
construct not only contains the C-termmal modification but also an ammo acid 
substitution either at position 301 or 374 the resulting partially transformed transfectants 
formed tumors after a latency period of 6 to 9 weeks A double mutant that contains 
both ammoacid substitutions besides the С terminal modification produced fully 
transformed foci and the transfected cells formed tumors in nude mice with a short 
latency of 3 to 4 weeks 
The efficiency of transformation and colony formation could be increased by adding 
exogenous CSF-1 or co-lransfection of a CSF-1 coding gene In the presence of CSF-
1 expression of a construct with a wild type c-frns gene results in transformation by an 
autocrine mechanism However, the c-frns construct with the truncated v-frns 3 end was 
more active than the wild-type gene was in inducing transformation by this autocrine 
mechanism Thus, the mutated forms of fms code for functional receptors that are still 
capable to bind their hgand 
When constructs were used with human fms sequences the results were slightly 
different However the experimental procedures were also slightly different The 
constructs with feline c-frns sequences were tested in Rat 2 cells, the human c-frns 
recombinant genes in NIH-3T3 cells To test the effect of the modification of the C-
termmus in v-fms, in the human c-fms constructs only tyrosine residue 969 was 
substituted by phenylalanine neglecting the influence of the deletion of 50 other 
residues The important role of this substitution was demonstrated with a chimeric 
construct that contains v-fms with a human wild-type 3' end The chimera was non-
transforming But loss of Tyr969 abrogated the inhibitory effect of the human C-termmus 
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(40) The use of this type of chimeras is quite complicated because of the species 
specific ammo acid substitutions that are brought together in new combinations The 
overall homology between human c-fms and v-frns is 84% Species specific differences 
in the transforming activities have also been reported for several src mutants (53) 
A human c-frns gene in which leucine residue 301 was substituted by serine (as 
is the case in v-frns) induced morphological transformation, anchorage-independent 
growth, and tumongemcity in nude mice Substitution of Tyr969 by phenylalanine 
augmented the transforming efficiency of mutant ser301 although insufficient to induce 
transformation by itself Analysis of the protein products of the different constructs 
showed that the block to glycosylational processing seen with the viral protein is due 
to the point mutations present in the v-frns gene These point mutations result also in 
the constitutive phosphorylation of the mature cell surface form of the receptor on 
tyrosine Pulse-chase experiments showed that the half-lives of the v-frns and c-frns 
proteins are similar but that the processing of the v-frns proteins is both slower and less 
efficient The C-terminal modification increases the relative kinase activity, the point 
mutations alone do not do so 
From these data it can be concluded that both substitution of leucine 301 and 
deletion of the carboxyl terminus are important for the activation of the transforming 
potential of the c-frns protein Conversion of leucine 301 to serine in human c-frns is an 
activating mutation, whereas elimination of tyrosine 969 disrupts a negative regulatory 
restraint normally imposed by sequences at the receptor carboxyl terminus It was 
shown that the v-frns encoded glycoprotein also retains a high-affinity binding site for 
CSF-1 and is able to respond biologically to the growth factor So in its natural host 
both autocrine and non-autocrme mechanisms may contribute collaborativily to tumor 
formation 
The c-frns gene was also found to be a target for msertional mutagenesis by 
F-MuLV (Friend murine leukemia virus) (54) This strongly suggests that aberrant 
expression of the c-frns gene can serve as an initiating event in leukemogenesis 
A significant subset of human AMLs (acute myelogenous leukemias) that lack 
evidence of monocytic differentiation shows an aberrant c-frns expression The 
mechanism of activation is unknown (7) Because the genes for human CSF-1 (55), GM-
CSF (56), IL-3 (57), II-5 (58), PDGF-R (59), aFGF (acidic fibroblast growth factor) (60) 
and c-fms (CSF-1 R) (15), all map to chromosome 5q (22) any of these genes might 
potentially be implicated in the pathogenesis of the '5q- syndrome' (61) and several 
forms of AML (62, 63, 64) 
The transforming activity of v-frns has also been studied in vivo Mouse bone 
marrow cells infected with SM-FeSV were transplanted into lethally irradiated mice 
Several primary recipients developed splenomegaly within a month or myeloproliferative 
disorders that were provirus-positive without evidence of clonalrty Secondary recipients 
transplanted with spleen cells from provirus positive primary recipients developed clonal 
erythroleukemias or В cell lymphomas expressing the v-frns encoded glycoprotein Thus, 
v-frns can contribute to proliferative abnormalities of multiple hematopoietic lineages 
(65) 
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Molecular Cloning and Characterization of Feline Cellular Genetic Sequences 
Homologous to the Oncogene of the McDonough Strain of Feline Sarcoma Virus 
J O S E P H S. V E R B E E K , P A U L D E R U Y T E R , H E N R I P . J. B L O E M E R S , 
A N D W I M J M. V A N D E V E N 1 
Molecular Oncology Section, Department of Biocfiemwtry, University of 
Nijmegen, Nijmegen, The Netherlands 
Received September 10, 1S8Í, accepted November 6, 1984 
The organization within the cat genome of cellular genetic sequences homologous to 
the viral oncogene \-fms of the McDonough strain of feline sarcoma virus (SM-FeSV) 
was determined Four cosmid clones containing overlapping v-fms homologous cellular 
DNA inserts representing a contiguous region of cellular DNA of approximately 80 kbp 
in length have been isolated from a feline cosmid gene library Within this region of 
the cat genome, the c-fms genetic sequences are dispersed over a region of around 
30 kbp and are interspersed with at least three intervening sequences © 1985 Académie 
Ргевв Ine 
The McDonough strain of feline sarcoma 
virus (SM-FeSV) represents an acutely 
transforming RNA tumor virus that was 
initially isolated from a naturally occur­
ring fibrosarcoma of a domestic cat (20). 
Its genome contains feline leukemia virus 
(FeLV) as well as cellular genetic se­
quences of cat origin (4, 7, 8). SM-FeSV 
resembles the majority of other mam­
malian and avian transforming retrovi­
ruses in that it is replication defective (1, 
Ц, 16) The primary translational product 
of SM-FeSV is a polyprotein of 170,000 
molecular weight, Ρίτοβ^-'"18, and consists 
of amino terminal structural proteins en­
coded by the FeLV gag gene and a car-
boxyterminal component encoded by the 
acquired feline cellular sequences (1, Ц, 
16). With respect to its function m vivo, 
polyprotein P170Ba|î fms lacks tyrosine-spe-
cific protein kinase activity (2, 13, Ц, 16) 
although sequence homology with tyro-
sine-specific protein kinases encoded by 
other viral oncogenes such as v-fes and 
v-src has been observed (7). In vitro, ty­
rosine phosphorylation of Pl70 g a g- f m 3 has 
been reported (2). 
1
 Author to whom requests for reprints should be 
addressed 
As an initial approach to determine the 
complexity of the feline genetic sequences 
homologous to the viral transforming gene 
v-fms, Southern blot analysis was per­
formed (25). Analysis of genomic cat DNA 
(cat No 031182) digested with restriction 
endonuclease Ì7coRI and hybridized with 
a 32P-labeled FeLV-specific probe (a 5.3-
kbp Xhol/Xhol DNA fragment represent-
ing gag- and poZ-specific genetic sequences 
isolated from X-HF60 which contains the 
entire proviral genome of FeLV (12)) re-
vealed numerous strongly hybridizing 
DNA fragments. This observation indi-
cates the presence of multiple FeLV-re-
lated genetic sequences (Fig. 1, lane A). 
For analysis of the feline v-fms homolo-
gous genetic sequences, subgenomic DNA 
fragments as indicated in the upper part 
of Fig. 1 were used. These included three 
Pstl/Pstl restriction fragments of about 
0 4, 0.7, and 1 45 kbp in size, a Smal/Pstl 
DNA fragment of 0.4 kbp, and a 1.2-kbp 
Haell/Haell DNA fragment which is lo-
calized at the 5' portion of v-fms. Based 
upon DNA sequence analysis of v-fms, it 
appeared that the 1.45-kbp DNA fragment 
contains about 300 bp of FeLV-specific 
genetic sequences at its 3' poition (7). It 
should be noted that about 40 nucleotides 
of the very 5' end of v-fms were not 
0042-6822/85 $3 00 
CopjriKhl © 1985 by Academic Prees Ine 
All riKhls of reproduction in any form reserved 
322 
95 
SHORT COMMUNICATIONS 323 
D-η— 1 1 D FeLV 
Sm X 
04 07 04 145 
| | I - ^ ¡ ^ ^ ^ ^ ^ - - 1 v - t m s 
H Sm Ρ H P Ρ Ρ 
В С D E 
I mi '»J 
— 23 
— 20 
** 
FlG. 1. Identification of v-fms homologous genetic 
sequences in cat cellular DNAs. High-molecular-
weight DNAs were prepared from lung tissue of two 
different cats (cat No. 031182 (lanes A, D, E) and 
cat No. 8410141 (lanes В, C)), digested with restriction 
endonuclease ЯсоШ (lanes А, С, E) or BomHI (lanes 
B, D) and electrophoresed through an 0.8% agarose 
gel. After transfer of DNA to nitrocellulose, filters 
were hybridized with a 3 2P-nick-translated FeLV 
Xhol/Xhol probe (lane A) or a combination of four 
v-fvw probes, including the 0.4-kbp SmaVPstl, the 
0.7-kbp Pstl/Pstl, the 0.4-kbp Pstl/Pstl, and the 
1.45-kbp Pstl/Pstl DNA fragment (lanes B-Ε). Mo­
lecular probes used are indicated in the upper part 
of the figure. Molecular-weight markers included are 
№ndIII-digested XDNA fragments. H, ЯаеІІ; Ρ, 
Pstl; Sc, Sad; Sm, Smal; X, АТгоІ. 
included in any of the probes used in the 
genomic blot analysis. Total high-molec­
ular-weight DNA of two different cats 
digested with restriction endonuclease 
BamHl (Fig. 1, lanes B, D) or EcoRl (Pig. 
1, lanes С, E) and hybridized under strin­
gent conditions with a combination of the 
first four v-fms probes mentioned above 
disclosed a number of strongly and weakly 
hybridizing bands. As far as the strongly 
hybridizing DNA fragments are con­
cerned, hybridization patterns were highly 
similar for both cats using restriction 
endonuclease BamHI. They included DNA 
fragments of 15, 6.5, 5.5, 1.6, and 0.7 kbp. 
A possible restriction fragment-length 
polymorphism was detected using restric­
tion endonuclease EcoRl. An 16-kbp DNA 
fragment detected in the DNA of cat No. 
031182 was missing in the DNA of cat No. 
8410141; however, stronger hybridization 
was observed in the DNA of the latter 
with DNA fragments of 9.7 and 6.6 kbp. 
In an analysis with only the 1.2-kbp 
Haell/Haell DNA fragment as a 5'-spe-
cific v-fms probe, hybridization was de­
tected with a 0.6-kbp BamHl and a 3.7-
kbp EcoRl DNA fragment (data not 
shown). The patterns of the weakly hy­
bridizing DNA fragments were different 
for the two cats. Southern blot analysis 
using individual probes revealed that most 
of these weakly hybridizing DNA frag­
ments could only be detected with the 
1.45-kbp probe (data not shown) which 
contains some FeLV-specific genetic se­
quences. Furthermore, these DNA frag­
ments seem to comigrate with those de­
tected with the FeLV probe and, therefore, 
they most likely represent FeLV-related 
genetic sequences. 
The numerous feline DNA EcoRl or 
BamHl restriction fragments hybridizing 
to v-fms, which itself has a complexity of 
only 3.0 kbp, could reflect the presence of 
extensive intervening sequences within the 
feline c-fms locus. The genomic blot anal­
ysis further indicates that the complexity 
of the feline c-fyns locus can be estimated 
to be between 30 and 40 kbp in size, if 
these genetic sequences are confined to a 
single locus. 
To facilitate a more detailed structural 
analysis of feline c-fms, a gene library of 
feline genomic DNA was constructed using 
the pJB8 cosmid vector system (9). In Fig. 
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F I G . 2. Characterization of cosmid clones isolated from a feline cosmid gene library (A) Feline 
cosmid gene library construction in the pJB8 cosmid vector system. DNA isolated from lung 
tissue of cat No. 031182 was used. (B) i7coRI restriction pattern of cosmid clones 9, 11, 14, and 18 
(lanes A, B, C, and D, respectively) obtained upon electrophoresis through an 0.8% agarose gel 
and ethidium bromide staining. Molecular-weight markers included are HïndIII-digested ADNA 
fragments (lane E). (C) Autoradiogram of EcoRl restriction pattern as shown in (B) upon 
hybridization with a combination of five ^-n ick- t rans la ted v-fms probes, including the 3.0-kbp 
Sacl/Sacl, the 0.4-kbp Smal/Pstl. the 0.7-kbp Ps(I/Ps(I, the 0.4-kbp Pstl/Pstl, and the 1.45-kbp 
Pstl/Pstl DNA fragments. Positions of the molecular probes within the SM-FeSV proviral genome 
are indicated in Figs. 1 and 3. 
2A, a schematic representation of the 
procedures involved is depicted. From the 
cosmid library, a total of five clones, des-
ignated PFLL-clones 9, 11, 14, 16, and 18, 
have been identified upon screening of 
about 2.8 X 105 bacterial colonies with the 
1.45-kbp Pstl/Pstl v-fms probe and these 
have been propagated for further analysis. 
Upon screening with a subclone of pBR322 
containing the entire FeLV proviral ge-
nome, PFLL-clone 16 appeared to contain 
FeLV-related genetic sequences. None of 
the four other cosmid clones exhibited 
detectable hybridization with this FeLV 
probe (data not shown). 
Restriction endonuclease EcoRl diges-
tion of cosmid clones 9, 11, 14, and 18 
followed by agarose gel electrophoresis 
and ethidium bromide staining of the 
DNA fragments gave a first characteriza-
tion of the DNA inserts in the various 
clones (Fig. 2B), since the pJB8 cosmid 
vector possesses EcoRl cleavage sites on 
both sites next to its BamRl cloning site. 
From this analysis, it appeared that the 
size of the cellular DNA inserts in the 
various cosmid clones varies between 35 
and 41 kbp in length. Two of the cosmid 
clones, PFLL-clones 11 and 14, showed a 
highly similar pattern of .EfcoRI restriction 
endonuclease fragments, indicating the 
clones contain almost the same feline 
genetic region. For further characteriza-
tion, five molecular probes with specificity 
for subgenomic regions of y-fms were used 
(Fig. 2C). As shown in Fig. 3, these probes 
(a-e) included in addition to some of those 
used in the genomic blot analysis a 3.0-
kbp Sacl/Sacl probe containing the 5' por-
tion of v-fms (about 1.2 kbp) and some 
FeLV ffafli-gene-specific genetic sequences. 
It should be noted that the hybridizing 
5.3-kbp DNA fragment present in all four 
clones represents cosmid vector pJB8. 
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FIG 3 Restriction endonuclease map of the feline c-fms region In the upper part of the ligure, 
the SM-FeSV proviral genome is shown The open boxes represent the long terminal repeats, the 
solid bar the acquired feline cellular sequences representing v-fms. Directly below the SM-FeSV 
genome, subgenomic restriction endonuclease fragments (a-e) used as probes in this study are 
indicated On a separate line, feline DNA restriction endonuclease fragments homologous to v-
fms genetic sequences are represented as solid boxes Above each region, probes that exhibit 
homology are indicated Boxed areas labeled with "r" directly above the restriction endonuclease 
map indicate highly repetitive sequences detected in the feline c-fm£ region The EcoRl site 
involved in the restriction fragment-length polymorphism is indicated with a broken line Beneath 
the map, cellular inserts within cosmid clones 9, 11, 14, and 18 are shown B, BamHl, C, Clal, E, 
EmKl, H, tftndlll, X, Xhol 
Clone 9 appeared to contain hybridizing 
EcoRl fragments of 16, 3.7, 1.9, and 0 65 
kbp Similar analysis of clone 11 revealed 
hybridizing .EfcoRI fragments of 9.7, 6.6, 
4.3, and 1 9 kbp Clone 14 which contains 
a DNA insert highly similar to the one in 
clone 11 appeared to contain an additional 
3.0 kbp hybridizing DNA fragment. In 
clone 18, v-fms homologous EcoRl frag-
ments of 9 7 and 2.1 kbp were observed. 
Restriction maps of the cosmid clones 
were generated using various combina-
tions of the restriction endonucleases 
EcoRl, Ватт, HinAlll, Xhol, and Clal. 
Furthermore, in Southern blotting anal­
ysis using individual probes, the v-fms 
homologous genetic sequences within the 
cosmid clones were localized in more detail 
(data not shown). As summarized in Fig. 
3, the four cosmid clones contain overlap­
ping cellular sequences corresponding to 
a single contiguous region of cat cellular 
DNA of about 80 kbp in length. Within a 
30-kbp region, four distinct regions of 
v-fms homology, interspersed by at least 
three nonhomologous regions representing 
probably intervening sequences, were 
identified Furthermore, the feline se­
quences homologous to v-fms are colinear 
with the viral v-fms oncogene. With re­
spect to the size of the DNA region over 
which the v-fms homologous sequences 
are distributed, the feline c-fms locus re­
sembles the human locus (unpublished 
observations; 8) 
To establish whether the complete feline 
v-fms homolog is represented in a non-
rearranged way in clones 9, 11, 14, and 
18, the cloned sequences were compared 
with the DNA fragments detected in the 
genomic blot analysis Special attention 
was given to the 5' portion of v-fms since 
a probe for the very 5' part of the locus 
was excluded from the genomic blot anal­
ysis, initially. Comparison of Figs. 1 and 
3C reveals that, with the exception of a 
98 
326 SHORT COMMUNICATIONS 
0.7-kbp BamHl fragment, all hybridizing 
BamHl and EcoRl restriction fragments 
observed in the genomic blot analysis are 
present in the four cosmid clones. These 
also include the 0.6-kbp BamHl and the 
3.7-kbp EcoRl DNA fragments detected 
with the 5' v-/7№S-specific Haell/Haell 
probe (data not shown). The 0.7-kbp 
BamHl DNA fragment appeared to be 
FeLV related, since it hybridized to a 
probe representing the complete FeLV 
provirus and it could also be detected in 
cosmid clone 16 (data not shown) which 
contains FeLV-specific sequences. 
The presence of a restriction fragment-
length polymorphism in the DNA of the 
two cats, as observed in the genomic blot 
analysis, has been confirmed by analysis 
of the cosmid clones. An EcoRl restriction 
site in cosmid clone 14 is missing in clone 
9 and, as a result, a 16-kbp EcoRl DNA 
fragment is present in clone 9. 
To determine whether genetic sequences 
homologous to the 5' end of w-fms are also 
present in cosmid clone 9, the 3.7-kbp 
EcoRl DNA fragment was further ana­
lyzed (Fig. 4). Restriction endonuclease 
digestion of the 3.0-kbp Sacl/Sacl DNA 
fragment of the SM-FeSV proviral genome 
with Haell generates a 1.8-, 1.2-, and 0.07-
kbp DNA fragment and digestion with 
Ball results in DNA fragments of 1.2, 0.9, 
0.7, and 0.2 kbp. The 1.8-kbp Haell DNA 
fragment contains the first 38 nucleotides 
of v-fms and the 0.2-kbp Ball DNA frag­
ment contains the first 130 nucleotides 
(Г). Using the 3.7-kbp EcoRl DNA frag­
ment isolated from cosmid clone 9 as a 
probe in Southern blot analysis of the 
DNA fragments mentioned above, the ob­
served hybridization pattern indicated 
cosmid clone 9 contained most if not all 
of the 5' v-fms homologous genetic se­
quences (Fig. 4B, lanes A and B). From 
the results obtained in this study it can 
be concluded that the cat genome contains 
a single v-fms homologous protooncogene 
which is completely represented in the 
four isolated cosmid clones. 
In a further characterization of the 
feline c-fms region, the localization of 
highly repetitive feline genetic sequences 
was determined in a hybridization anal-
A в Kbp 
— 3 0 
1 — 18 
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FIG. 4. Presence of genetic sequences homologous 
to the very 5' end of v-fms in cosmid clone 9. (A) 
Restriction endonuclease map of the 3.0-kbp Soci/ 
Soci subgenomic v-fms DNA fragment subcloned in 
pAT153. The thicker bar at the 3' end represents 1.2 
kbp of the 5' end of v-fms. (B) Purified 3.0-kbp Soci/ 
Soci DNA was digested with Bau (lane A) or partially 
digested with Haell (lane B) and electrophoresed 
through an 0.8% agarose gel. After transfer of DNA 
to nitrocellulose, the filter was hybridized with the 
S2P-nick-translated 3.7-kbp EcoRl DNA fragment 
obtained from cosmid clone 9. Molecular-weight 
markers included are JïaelII-digested 0X174 DNA 
fragments. В, Bail; H, ЯаеІІ; Sc, S a d 
ysis using total cat DNA as a probe. Only 
regions with strong homology are indi­
cated in Fig. 3. 
Characterization of feline c-fms using 
v-fms as a tool may lead to an underes­
timation of the complexity of c-fms. It is 
possible that during the original genera­
tion of the transforming viral oncogene 
or during subsequent diversion, substan­
tial deletions have been introduced in 
v-fms, as can be seen with the oncogenes 
of the Gardner-Arnstein and Snyder-
Theilen strain of feline sarcoma virus (6, 
17). Other protooncogene loci such as c-/os, 
c-myc, and c-ras have been reported to 
contain exon sequences not found in their 
related viral oncogenes (5, 5, 11). In addi­
tion, in a particular isolate of Abelson 
murine leukemia virus, about 800 bp of 
coding sequences, present in another iso­
late, are missing (18). It is possible that 
c-fms genetic sequences have been ex-
9 9 
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eluded from v-fms, in a similar way. The 
availability of molecular clones of feline 
c-fms will facilitate experiments to resolve 
this question and it is clear that precise 
mapping of all feline c-fms coding se­
quences within the 30-kbp region will 
require extensive DNA sequence analysis 
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A hereditary abnormal c-fms proto-oncogene 
in a patient with acute lymphocytic leukaemia 
and congenital hypothyroidism 
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Free University, Amsterdam The Netherlands 
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SUMMARY A patient with congenital hypothyroidism and acute lymphocytic 
leukaemia was found to be homozygous for a 0 4 kbp deletion in the c-fms 
proto-oncogene This was established by studying DNA from the patient's 
leukaemic cells, from cultured skin fibroblasts of the patient and from normal 
white blood cells of both parents The uncertain relevance of this finding to the 
condition of the patient is discussed 
Proto-oncogenes are thought to fulfill important functions in growth regulation and 
development of multicellular organisms (Mueller et al 1982) They have also been implicated 
in tumongenesis (Cooper 1982) In that case however, specific genetic changes such as 
point mutations or UNA rearrangements seem to be required (Yums 1983) 
Mutations can cause restriction fragment length polymorphisms (RFLP) that can be 
detected by Southern blot analysis Using the v-/ms viral oncogene of the McDonough strain 
of feline sarcoma virus (SM FeSV) as a molecular probe we have analysed genomic DNA of 
four normal individuals and 12 cancer patients and found an abnormal form of the c-/ms 
proto-oncogene in DNA of one patient 
RbSULTS AND DISCUSSION 
The abnormal proto-oncogene was found in the DNA of a 16 year old boy who was under 
treatment for congenital hypothyroidism during the last 14 years and who developed an 
acute lymphocytic leukaemia A cell rich bone marrow aspirate showed 82% of the cells to be 
lymphoblasts 80% of which w ere positiv e in an immunofluorescence assay for the common 
AI L antigen T-cell or B-cell markers were absent Chromosome analysis of the leukaemic 
blood cells revealed the presence of 50 chromosomes m 13 of 14 analysed mitoses Nine 
metaphases showed trisomies of the chromosomes 3 8 10 and 17 AH metaphases exhibited 
Correspondence Dr W I M Van de Ven Department of Biochemistry University of Nijmegen Geert 
Grooteplein Noord 21 6S2S K7 Nijmegen The Netherlands 
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the presence of two chromosomes 5 on which the human c-/ms proto-oncogene has been 
localized (Groffen ft я/, 1983). 
Initially, restriction endonuclease analysis indicated the presence of multiple RFLPs. As 
can be seen in lane A of Fig 1, Southern blot analysis revealed seven bands of hybridization in 
A B C Kbp 
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Fig 1. Analysis of human DNAs for restriction fragment length polymorphisms in genetic sequences 
homologous to the viral oncogene v-fms of the McDonough strain of feline sarcoma virus. High 
molecular weight DNAs were prepared from normal human liver tissue (A), from leukaemic blood cells 
of the patient (B). from blood cells of his mother (C). 20 /ig DNA samples were digested with restriction 
endonuclease BamHI: DNA fragments were size selected by electrophoresis through an 0-8% agarose 
gel, transferred to nitrocellulose and analysed by hybridization using 32P-nick-translated v-/ms as a 
molecular probe. Molecular weights of human c-fms fragments were deduced from co-electrophoresed 
restriction endonuclease Hindlll digested /. DNA. 
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human liver DNA cleaved with restriction endonuclease BamHI. Their sizes were 9-7, 4-2, 
4-0. 3-3. 2-0, 1-3 and 0-8 kbp. The same hybridization pattern was observed in a restriction 
endonuclease BamHi digest of DNA isolated from the leukaemic blood cells of the patient, 
except that the 3 · 3 kbp band is missing and a new 2-8 kbp band was detected (lane B). Similar 
results were obtained using restriction endonuclease EcoRI and HindJII (data not shown). 
Molecular cloning of both the normal and abnormal c-Jms loci and heteroduplex analysis 
(Figs 2A and 2B) indicated the observed RFLPs to be induced by a deletion. (For a schematic 
representation of the data see restriction map in Fig 2C.) 
Human с fms ι—« 
Ikbp 
Fig 2. ( A ) Heteroduplex analysis of the 3 • 3 and 2 8 kbp BamHI DNA fragments isolated from the human 
c-Jms locus and moleculary cloned in pBR322. Recombinant plasmids were linearized by digestion with 
restriction endonuclease Sail. (B) Heteroduplexes of the purified DNA inserts described under (A). (C) 
Schematic restriction endonuclease map of human c-/ms. DNA fragments homologous to v-/ms are 
represented as heavy bars. In the upper part of the figure a restriction map of the DNA sequences not 
found in the abnormal c-/f7is proto-oncogene is shown. The position of these sequences in the normal 
human c-/ms locus is indicated by dotted lines. The two BamHI restriction sites used in the molecular 
cloning of the 2 • 8 and 3 · 3 kbp DNA fragment are indicated by prominent marking lines. B. BamHI: Bg. 
BgUI: E. EcoRI; H. Hindlll: Hf. НіпП: P. PstI: S. Sau3A. 
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Based upon detailed Southern blot analysis of the DNA of the leukaemic blood cells it was 
concluded that these cells were homozygous for the abnormal c-/ms gene The observation 
that in the DNA of the patient s leukaemic blood cells the normal C-/IJIS allele was absent was 
of interest The possibility that highly similar or identical somatic mutations had occurred 
independently in both chromosomes is not very likely Furthermore a monosomy of 
chromosome 5 could be excluded based upon the chromosome analysis Further study 
revealed that the apparent homozygosity for the observed genetic change was inherited 
Southern blot analysis was performed with DNA isolated from skm fibroblasts of the patient 
and with DNA from each parent The same restriction fragment pattern as observed in the 
UNA of the patient s leukaemic blood cells was also observed in DNA isolated from his skin 
fibroblasts (data not shown) Furthermore each parent appeared to have both a normal and 
an abnormal с fins allele (Fig 1 lane C) (data DNA of father not shown) 
It has been suggested that the c-/ms encoded protein(s) may have a crucial role in 
mammalian development Relatively high levels of expression o(c-fms have been reported for 
h u m a n placenta Fxpression of c-/ms in h u m a n amnion and chorion cells appeared 
somewhat lower and that in a number of other organs including lymph nodes insignificant 
(Mueller et al 1983) In this respect the observation of congenital hypothyroidism in an 
individual homozygous for an inherited abnormal allele of the c-fms locus is of particular 
interest, a l though it may be accidental A possible correlation with the observed acute 
lymphoevtic leukaemia also remains questionable Further analysis is required to establish 
the direct effect of the deletion on the function of the c-/ms translational product(s) 
Identification of more individuals homozygous for this trait should be of value in determining 
the functional significance of the abnormal с /ms proto-oncogene in the h u m a n genetic pool 
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ADDENDUM 
To determine the distribution of the c-fms RFLP, DNA from cancer patients and 
healthy individuals was analysed by Southern blot hybridisation with a v-fms DNA probe. 
The genomic DNA from 31 unrelated healthy individuals and 27 cancer patients has 
been tested. The tumors tested were leukemias, Gravitz -, Wilms -, lung - and thyroid 
tumors. 
The results are summarized in tabel 1. 
Tabel. 1. Distribution of the fms alleles (n=normal, a=abnormal) 
Tumors Healthy 
heterozygotes na 5 (18,5%) 4 (13%) 
homozygotes nn 22 (81,5%) 27 (87%) 
homozygotes aa О (0%) 0 (0%) 
+ + 
total tested 27 31 
A French research group has tested 48 unrelated healthy individuals. It appeared 
that 23% were heterozygotes na, 75% homozygotes nn and 2% homozygotes aa. The 
children from couples na χ nn have also been tested Their results suggest a selective 
pressure in favor of heterozygotes (1). 
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Tbc organiutlon of the human c-fms pnrio-oncogene has been determined and compared with an abnormal 
allele. The human v-fms homologous genelk sequences are dispersed discontlnuously and collnearly with the 
viral oncogene over a DNA region of св. 32 kilobasc pairs. The abnormal c-fms locus contains a small deletion 
In lis 3' portion. DNA sequencing analysis Indicated that It was 426 base pairs In size and located in close 
proiimlty to a putative c-fms exon. 
Proto-oncogene s are thought io play an important role in 
cell differentiation and development (5, 17-19) They can be 
converted to oncogenes, and as such they have been impli­
cated in tumongenesis (3, 12, 13, 23, 27, 28) Molecular 
The proto-oncogene under investigation m the present 
study is c-fms, which is homologous to the viral oncogene 
v-fms of the McDonough strain of feline sarcoma vims 
(SM-FeSV) SM-FeSV, originally isolated from a naturally 
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+Ш 
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FIG 1 Restriction enzyme map of the normal and mutated human c-fms region In the upper pori ion of the figure, the SM-FeSV provirus 
is shown Open boxes represen! the long terminal repeats (LTR) Lhe solid bar represents the relative position of v-fms, and feline leukemia 
virus-specific seque псе ь are represented as a solid line Directly below the SM-FeSV genome DNA fragments used as molecular probes are 
indicated In the center of the figure, a schematic restriction enzyme map of the human с-[тл region and the map positions of human flam HI 
restrictюп endonuclease fragments (labeled a through Г, see also Fig 2) thai exhibit homology with ν /mj-specific molecular probes are 
shown Digestions wiih resi nel юп endonucleases £<r>RI and Htndlli ndrrow down Ihc ranges of homology further (solid bars) Solid lines 
below the rcsinciion enzyme map of the human c-fms region idennfy the relalive positions of lhe DNA inserts in cosmid clones 
CMLW-2M83-C17 4 and AL LW 1283-0122 In the lower part of lhe figure lhe restnclion enzyme map of lhe DNA insert of subclone pSVIO 
is indicated, and in lhe DMA insert of subclone pSV12 the size and the position of lhe deletion is given more precisely Both pS V10 and pSV12 
are recombinants of pBR322 B, BamHX. Bs. BstEU. E, ¿coRI, Η tfindlll, P, Pstl, S ¿аиЗА, Sc ¿ori, Sm. Smal, T. Taql 
analysis of proto-oncogenes may thus provide insight m the 
mechanisms involved in these processes 
* Corresponding author 
occumng fibrosarcoma of a domestic cat (14), is a recombi-
nant between feline leukemia virus and cellular genetic 
sequences ol cat origin (4, 6, 9) The primary SM-FeSV 
translational product was identified as a 170,000-molecular-
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FIG- 2. Comparison of the normal and a mutated form of the 
human v-fms cellular homolog by genomic blot analysis and molec-
ular cloning High-molecular-weight cellular DNA punned from 
human liver (patient 18783) (A) or leukemic blood cells of patient 
1283 (B) was digested with restriction endonuclease BamHi and 
analyzed by Southern blot analysis. As a molecular probe, a 
combination of subgenomic subclones of SM-FcSV. including a 
3 0-kbp SaclSacl. a 0 4-kbp SmalPstX. a 0 7-kbp Ps¡\-Psi\. a 
0.4-kbp Psil-Pstl. and a 1 45-kbp Pstl Psli DNA fragment repre-
senting the entire v-fms oncogene, as indicated m Fig 1, was used 
Hybridizing bands are labeled a through f and d* DNA of cosmid 
clone CMLW-25383-C17-3 (C) and cosmid clone ALLW 1283C122 
(D) was digested with restriction endonuclease BamHl. size frac-
tionated on an 0 8% agarose gel. and stained withcthidium bromide 
DNA fragments corresponding to hybridizing bands ш the genomic 
blots (A. B) are labeled a through f and d* accordingly (hybridiza­
tion data not shown) Molecular weights of DNA fragments were 
deduced from coelectrophoresed restriction endonuclease Hmdlll-
digested A DNA markers 
weight polyprotem. PITO^/"", consisting of the ammo-ter-
minal structural proteins pl5 ( pl2, and p30 encoded by the 
feline leukemia vims gag gene covalently linked to a non­
structural component encoded by the acquired feline cellular 
sequence (2, 21, 25) The function of the polyprotcin remains 
NOTES 423 
to be established, but it possesses a number of charactens-
tics in common with growth factor receptors (1). 
For detection of human v-fms homologous cellular genetic 
sequences, five probes (indicated in Fig. 1) were prepared 
from pCOI, which contains a 6 7 kilobase-pair (kbp) insert 
of SM-FeSV subcloned from a XgtWES.XB recombinant 
clone (4) High-molecular-weight DNAs isolated from a 
normal human liver (Fig 2, lane A) was digested with 
restriction endonuclease BamHl and analyzed by Southern 
blot hybridization (24) As shown, v-fms homologous human 
DNA restriction fragments of 9.7, 4.2, 4.0, 3.3, 2.0, 1.3, and 
0.8 kbp (labeled a through g in Fig. 2) were resolved. DNA 
fragments of 97. 2 0. 13, and 0 8 kbp showed rather weak 
hybridization under the conditions used. These results indi­
cate that all human v-fms homologous genetic sequences 
detectable by such genomic blot analysis are contained m 
seven Bamiil DNA fragments. 
The BamHl restriction fragment patterns observed in 
analysis of DNA samples of a number of individuals (four 
normal individuals and 12 cancer patients) were all identical. 
However, in the DNA isolated from a patient suffering from 
common-type acute lymphocytic leukemia and congenital 
hypothyroidism (patient 1283), a restriction fragment length 
polymorphism was observed- The 3.3-kbp BamHl fragment 
wasmissing, and a new 2 8-kbp DNA fragment (labeled d* m 
Fig. 2) was observed (Fig 2, lane B). In comparative 
analysis of the DNA of this patient and normal human liver 
DNA with restriction endonuclease EcoRl, a similar obser­
vation was made. The EcoKl restriction fragment pattern 
observed in normal human liver appeared to include DNA 
fragments of 16, 12, and 2.5 kbp (data not shown). The 
pattern obtained with DNA isolated from the leukocytes of 
patient 1283 lacked the 16- and 12-kbp DNA fragments and 
showed instead a 28-kbp DNA fragment. A similar observa­
tion was made with restriction endonuclease //indili (data 
not shown). These Southern blot analyses indicate the 
absence of a normal c-/mj allele in the leukemic blood cells 
of this particular patient. A detailed map of the human c-fms 
locus is required to define the observed restriction fragment 
length polymorphisms more precisely Therefore, we under­
took molecular cloning of both the normal and abnormal 
allele. By using the pJB8 cosmid vector system (11), ge­
nomic libraries were constructed (10, 11) with high-molccu-
lar-weight DNA isolated from purified leukocytes of patient 
1283 (abnormal c-/mj alleles) and chronic myelocytic leuke­
mia patient 25383 (normal c-/m5 alleles). These genomic 
libraries have been designated ALLW-1283 and CMLW-
25383, respectively Three cosmid clones containing v-/m5 
homologous genetic sequences have been isolated from the 
two libraries (8). Hybridization analysis with the complete 
provirus of feline leukemia virus as a probe revealed that 
none of the isolated cosmid clones exhibited any sequence 
homology (data not shown). Two of the three cosmid clones 
(CMLW-25383-C17-3 and ALLW-1283-C122) have been se­
lected for further analysis in this study. The third cosmid 
clone, isolated from cosmid library CMLW-25383. contained 
a 39-kbp DNA insert which was partially overlapping at the 
5' end with clone CMLW-25383-C17-3. EcoKl restriction 
endonuclease digestion revealed the DNA inserts of CMLW-
25383-C17-3 and ALLW-1283-C122 to be 36 and 45 kbp in 
size, respectively. 
In Fig. 2, DNA fragments detected in genomic blot 
analysis arc compared with those present in the two cosmid 
clones Analysis of cosmid clone CMLW-25383-C17-3 (Fig. 
2, lane C) upon digestion with restriction endonuclease 
BamHl and ethidium bromide staining revealed the presence 
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tgatgitcae a lu tggget ctttaggggc cttccctgac t tatct tact t t a t t t t c t t іго 
tatigeare« cltg*g**tc tcctagatac aigtttattt geglttaatg cctctclctg 1Й0 
ccactagaat gcaaactcca tggaggggca gggactttgt «ctgttcaac telgaateag 210 
cgltgcctga cacaaalags tgitcaaga« agtatgtgga tgggciaet* i tat icegcc 300 
ttaaa 
SD 
•agga agggaatlct gacctgtgct gcagcatgaa tgaaccttga agacattatg 36О 
ctgggtgaaa taaggcaatc teaatag·«» catgctgtgc gagtccactg aggtgcagtg 420 
cctagagcag tgcaattcac agagacagca gaatcatggt tegecagggg ctggaggagg 180 
gauggggag t tget t t t ta acaggaacag aatttcagtt ttgcaagstg aaaagagctc 5<Ό 
tggaaactgg ttgeacaagg ugaatgtaa tt tacttaat actactgaac catacactt« 600 
aaa*t»gtig aaatggtau tttcatgtat gttttatcac aattaaaata tatatatata 660 
tttggatggg aggttgggtg ggtggatgga tgggtagatg gatggacag· tgaacggatg Τ20 
gataagatct caa« 
ED 
ttccac cctccctoct ggctcaega* ttaccagatt atsagagat« 780 
tcagggccct cag>eettgt cttgtccaag gtcttcaata cacaaatagt gaaacaggee 8*0 
tggagaaggg aautcacac aacaauc«! agtcaagcag gaacatgetc teagtgetat 900 
gttcatgaga cgacctetct oageccagag caggecttgc cctgccttct cccaetgggo 960 
iccttgggac igcecaoacc ectgetottg ggggtcagaa acaagglcea ggaaclgcct 1020 
gccagccccg actgccacgt gcteccttcc tcttetycaaMagcccaagt accaggtceg 10ЙО 
etggaagatc atcgagagct atgagggcaa cagtcatact tteategace ccacgcagct 1140 
gecttaeaac gagaagtggg agtteccccg gaaoaacctg с а к і і і ц і я aaatnacagc 1200 
tcatcactcc acagcttcct atcacagggc cctgtggggg ttgeagggag 1250 
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c-fne tgg gag t tc cec egg вас aac ctg csg t t t g 
FIG 3 Nucleotide sequences of the human c-fms gene In (A) portions of the DNA inserts of subclones pSV12 and pSVIO are indicated 
Individual DNA fragments subcloncd in bacteriophage M13mp8 and mp9 (15) are indicated by arrows Solid arrows represent stretches that 
arc actually sequenced E, EcoRl, P, Pstl, S Sau3A, T, Taq[ In (B) the nucleotide sequence of 1230 bp ofcfms DNA isolated from patient 
25383 (normal c-fms gene) is presented m the same orientation as the v-fms oncogene The nucleotide sequence was determined by the 
dideoxy chain termination method (22) The length of the deletion is estimated to be 426 bp and the size of the putative c-fms exon is 127 
bp Deletion start points and end points are indicated by arrows (SD start of deletion, ED, end of deletion) Consensus splicing sequences 
adjacent to the exon are underlined In (C) the coding sequences of the putative c-fms exon are compared with the amino acid sequences 
encoded by the corresponding v-/ms homologous region, as published by Hampc et al (6) Positions of nucleotide substitutions are 
underlined 
of DNA fragments of 9 7, 7 5,4 2,4 0, 3 3, 3 0, 2 8, 2 0, 1 3. probably intervening and flanking sequences Similar com-
1 1, and 0 8 kbp in length Hybridization with DNA probes, paralive analysis of cosmid clone ALLW-12B3-C122 (Fig. 2, 
representing the entire v-fms oncogene, showed that all lane D) with genomic DNA of patient 1283 (Fig 2, lane B) 
BamHl DNA fragments detected in the genomic blot analy- revealed that this cosmid clone contained DNA fragment d* 
sis (Fig 2, lane A, bands a through g) were present m this By using restriction endonuclease B J Í E I I , BamHl. Clal, 
cosmid clone (data not shown) These results indicate that £coRI, Wmdlll, Sail, Xbal, Xhol, or combinations of 
the complete human v-fms cellular homolog as detected by these enzymes in a hybridization analysis with five subge-
genorme blot analysis is represented in this cosmid clone nomic v-fms probes, the localization of BamHl, EcoRl, and 
The DNA fragments that do not exhibit \-fms homology are HindlU within cosmid clone CMLW-25383-C17-3 was ob-
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tamed (Fig 1) Asean be seen in the figure, the human \-fms 
cellular homolog within this cos mid clone is dispersed over a 
DNA region of ca 32 kbp and is interspersed by at least four 
regions of nonhomology These data confirm results de­
scribed by Heisterkamp et al. (9) Furthermore, the human 
v-/mj homologous genetic sequences appeared to be distrib­
uted colmearly with the viral oncogene (data not shown) By 
a similar approach, a restriction enzyme map was generated 
of the abnormal allele (Fig 1), and it was established that the 
genetic change was a small deletion More detailed informa­
tion about the genetic organization of the region missing in 
the abnormal allele was obtained by DNA sequencing anal­
ysis (Fig 3) The size of the deletion is 426 base pairs (bp) 
and is located in close proximity to a 127-bp v-/mj homolo­
gous region flanked by consensus splicing acceptor and 
donor sequences (16) (Fig 3B) Companson of the sequence 
data of the human and viral homologous DNA regions 
revealed nine base substitutions (Fig 3C) They were all 
found in the third position of a codon, leaving the amino acid 
sequence intact (Fig 3C) 
The v-/mi oncogene, which has been derived from the 
feline c-fms locus (4, 9), was reported to be ca 3.0 kbp in 
size (6) That of the human c-fms coding sequences remains 
to be determined However, most of the 32-kbp c-fms region 
probably represents noncoding or intervening sequences, as 
can be concluded from the DNA sequence analysis indicat­
ing a human c-fmb region of 1,250 bp to contain only 127 
nucleotides of v-fms homologous coding sequences It should 
be emphasized that the complexity of the human c-fms 
coding sequences may not be accurately determined with 
only w-fms as a tool Not all coding proto-oncogene se­
quences are necessarily present in a viral oncogene, as was 
documented for the Gardner-Arnstem and the Snyder-
Theilen strains of feline sarcoma virus (7), different isolates 
of Abelson murine leukemia virus (29), and the Finkel-Biskis-
Jinkins murine osteosarcoma virus (26) In a similar way, 
v-fms may lack some feline c-/mi-specific genetic se­
quences. Furthermore, v-fms may have been subjected to 
diversion during or subsequently to its generation Species 
differences between humans and cats are less likely to be a 
major factor DNA sequence analysis of one z-fms exon 
revealed sequence homology with the feline v-fms sequence 
of 93% with no change in the ammo acid sequence These 
results are typical for the high degree of conservation of 
proto-oncogenes during the evolution Precise mapping of 
coding sequences in the human c-fms gene requires further 
mRNA and DNA sequence analysis 
It is not known whether the deletion affects the expression 
of the c-fms allele Neither could we establish whether the 
physical condition of the patient was a consequence of the 
presence of the abnormal c-fms allele 
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SUMMARY 
The notion that the acutely transforming retroviruses owe their tumorigenic 
properties to the transduction of particular cellular genes of their host (oncogenes) 
marks a new stage in the research on the molecular basis of tumongenesis Cloning 
of the proviruses gave us the tools in the form of DNA probes to search for the original 
homologous cellular genes (proto-oncogenes) in the complex eucaryotic genome 
Subsequently, these genes can be moleculariy cloned as a first step in the process of 
investigating their normal cellular function and their involvement in non-viral 
tumongenesis The research presented in this thesis is focused on two oncogenes, fes 
and fms 
Three well characterized, independent FeSV (feline sarcoma virus) isolates have 
captured genomic sequences of the same feline locus, c-fes These sequences are only 
partially overlapping Moreover, comparison of the different v-fes sequences with the 
homologous viral oncogene v-Cps of FSV (Fuijmami sarcoma virus) suggested that in all 
three FeSV isolates 5 fes sequences are missing Therefore, another not well studied, 
proviral genome of a FeSV , also containing v-fes sequences, was moleculariy cloned 
and structurally analyzed The virus proved to be closely related to ST-FeSV (Snyder-
Theilen feline sarcoma virus) The variant clone shows a frameshift pointmutation that 
extends the open reading frame with 46Θ bp This explains why the variant virus 
encodes a 104 kDa fusion polyprotem and the prototype ST-FeSV a 85 kd fusion 
polyprotem 
The proto-oncogenes c-fes and c-fms of the cat have been moleculariy cloned and 
the human c-frns as well Clones from cosmid libraries that contain parts of the fes 
and fms loci could be identified by using FeSV oncogene sequences as molecular 
probes Restriction enzyme mapping and Southern blot analysis revealed that the proto­
oncogene sequences are distributed discontmuously and colmearly with the viral 
transforming genes over long DNA regions Comparison of the DNA sequence of a 
putative (small) exon of human c-fms with the DNA sequence of v-frns (of feline origin) 
confirmed the striking conservation of the (proto-)oncogene at both the nucleic acid and 
ammoacid level 
To determine the location of mutations that are involved in the activation of the 
transforming potential of the fes gene a chimeric v-fes/c-fes gene was constructed It 
was demonstrated that the carboxyl half of the GA-FeSV (Gardner-Arnstem feline 
sarcoma virus) transforming protein can be functionally replaced by the corresponding 
carboxyl portion of the feline c-fes protein Fusion to viral gag sequences therefore 
seems to be the most important step in the activation of the fes gene 
Certain types of human cancer are strongly correlated with sub-chromosomal 
abnormalities Using Southern blot hybridization with FeSV fes and fms probes, human 
DNA isolated from cancer patients and from healthy individuals was screened for RFLPs 
(restriction fragment length polymorphism) associated with the genes mentioned A 
patient with congenital hypothyroidism and acute lymphocytic leukemia was found to 
be homozygous for a RFLP in the c-frns proto-oncogene With DNA from purified 
leukocytes of this patient a genomic cosmid library was constructed Analysis of a clone 
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that contained v-fms homologous sequences revealed that the RFLP was caused by a 
426 bp deletion located in the 3' portion of the gene, in close proximity to a putative 
exon Genomic DNA of 27 cancer patients and 31 healthy individuals was analysed 
84% did not show the polymorphism 16% appeared to be heterozygous This 
distribution was the same for cancer patients and healthy individuals 
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SAMENVATTING 
Met het besef dat de acuut-transformerende retrovirussen hun tumorgene 
eigenschappen te danken hebben aan de transductie van bepaalde genen van hun 
gastheer (oncogenen) ging het onderzoek naar de moleculaire basis van tumorgenese 
een nieuwe fase in Klonering van de provirale genomen van deze virussen gaf ons de 
gereedschappen, in de vorm van DNA probes, om de originele homologe cellulaire 
genen (proto-oncogenen) te identificeren in het complexe eukaryotische genoom Op 
hun beurt kunnen deze genen gekloneerd worden als een eerste stap in het onderzoek 
naar hun normale cellulaire functie en hun rol in met-virale tumorgenese Het onderzoek 
gepresenteerd in dit proefschrift beperkt zich tot de oncogenen fes en fms 
Drie goed gekarakteriseerde onafhankelijke katte-sarkoom virus-isolaten hebben in 
hun genoom sequenties opgenomen van hetzelfde katte locus, c-fes Deze sequenties 
zijn slechts gedeeltelijk overlappend Bovendien bleek uit een vergelijking van de 
verschillende v-fes sequenties met de sequentie van het homologe virale oncogen v-
fps, afkomstig van het FSV (Fuijmami sarkoom virus) uit de kip, dat waarschijnlijk in alle 
drie de katte-sarkoom virussen sequenties van het 5' deel van c-fes ontbreken Daarom 
werd een nog met nader geïdentificeerd katte-sarcoom virus-isolaat, dat ook v-fes 
sequenties bevat, gekloneerd en de structuur geanalyseerd Hieruit bleek dat het virus 
nauwe verwantschap vertoont met het Snyder-Theilen katte-sarkoom virus isolaat De 
variant kloon bevat een puntmutatie, die leidt tot een verschuiving in het leesraam wat 
resulteert in een verlenging van dit leesraam met 46Θ baseparen Dit verklaart waarom 
deze Snyder-Theilen virus variant voor een 104 kDa fusie-poly-eiwit codeert en het 
prototype Snyder-Theilen virus voor een 85 kDa fusie-poly-eiwit 
De c-fes en c-frns proto-oncogenen van de kat zijn gekloneerd alsmede het c-fms 
gen van de mens Klonen, afkomstig van cosmide-banken, die sequenties homoloog 
aan v-fes en v-frns bevatten, konden worden geïdentificeerd door virale oncogen 
sequenties, afkomstig van katte-sarcoom virussen, te gebruiken als DNA probes Een 
analyse met behulp van restrictie enzymen en Southern blots toonde aan dat de proto-
oncogen-sequenties discontinu en colmeair met de virale sequenties zijn verdeeld over 
grote DNA fragmenten Een vergelijking van de DNA sequentie van een verondersteld 
(klem) exon van het menselijke frns-locus met de DNA sequentie van v-/ms, dat van de 
kat afkomstig is, bevestigde de opvallende consen/ermg van deze (proto-)oncogen 
sequenties op het niveau van zowel het DNA als het eiwit 
Om de plaats te bepalen van mutaties, die zijn betrokken bij de activatie van het 
transformerende vermogen van het fes locus, werd een chimeer v-fes/c-fes gen 
geconstrueerd Aangetoond werd dat de carboxy-helft van het transformerende eiwit van 
het Gardner katte-sarkoom virus kan worden vervangen door een overeenkomstig 
carboxy-deel van het katte-c-fes zonder de transformerende activiteit aan te tasten Fusie 
met virale gag sequenties lijkt daarom de belangrijkste stap in de activatie van het fes 
gen 
Er bestaat bij de mens een duidelijk verband tussen bepaalde vormen van kanker 
en sub-chromosomale afwijkingen Met behulp van de hybridisatie van Southern blots 
met v-fes en v-frns probes, afkomstig van katte-sarkoom virussen, werd menselijk DNA, 
geïsoleerd uit tumorweefsel van kanker-patiënten en normaal weefsel van een 
willekeurige groep gezonde individuen, getest op de aanwezigheid van polymorfismen 
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in de lengte van DNA fragmenten (RFLP), die homoloog zijn met de genoemde 
oncogenen Een patient met congenitale hypothyroidie en acute lymphatische leukemie 
bleek homozygoot te zijn voor een RFLP in het c-fms proto-oncogen Met het DNA, 
geïsoleerd uit gezuiverde leukocyten van deze patient, werd een cosmide-bank gemaakt 
Analyse van een kloon, die sequenties homoloog aan v-fms bevatte, toonde aan dat 
dit RFLP werd veroorzaakt door een deletie van 426 baseparen gelegen in het 3' deel 
van het gen, vlak voor een verondersteld exon Het genomisch DNA van 27 kanker 
patiënten en 31 gezonde personen werd geanalyseerd Hiervan bleek 84% het 
polymorphisme met te vertonen terwijl 16% heterozygoot was In tumoren en gezond 
weefsel was de frequentie, waarmee het polymorphisme aanwezig was, dezelfde 
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